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Abstract  
 
     Molecular genetic analysis by our team and others revealed a frequent deletion 
of the 6q15 region in prostate cancer (PCa), suggesting the presence of one or more 
tumour suppressor gene(s) (TSG) within this region, whose inactivation may play a 
role in prostate carcinogenesis.  Previously we have shown that the cannabinoid 
receptor 1 (CNR1) gene, located at 6q15, was down-regulated in PCa cell lines and 
one clinical PCa sample at the mRNA level compared to normal tissue, suggesting 
CNR1 as a potential TSG in PCa. I, therefore, aimed to investigate whether CNR1 
may act as a TSG in prostate cancer.   
 
I sequenced the coding and 1 kbp promoter regions of this gene in five prostate 
cancer cell lines, 22RV1, LNCaP, DU145, PC3 and VCaP. No mutations were found, 
which is consistent with these cells having a potentially functional CNR1. A 6bp 
polymorphism sequence was found on the promoter region, with the shorter allele 
more frequently found in cancer samples. The 6 bp polymorphism causes the 
addition of another transcription factor binding sites for each transcription factors 
(TFII-1, STAT4, c-Ets-1, Elk-1), but no association of the polymorphism with prostate 
cancer risk was found. Further investigation will determine its impact on the CNR1 
gene translation and functionality in PCa. Mutation analysis was further performed 
using combined fluidigm amplification and next generation sequencing on 73 PCa 
clinical samples. No mutations in CNR1 coding and promoter regions were identified.  
 
CNR1 expression at mRNA levels was investigated in prostate cancer cell lines, 
22RV1, LNCaP, DU145, PC3 and VCaP cells. Using real-time PCR analysis, I found 
CNR1 was highly expressed at mRNA level in 22RV1, LNCaP, DU145, while lower 
levels of expression were detected in PC3 and VCaP cells compared to PNT1a 
immortalised prostate epithelial cells. The protein expression of CNR1 receptors was 
investigated in PCa cell lines using different commercial anti-CNR1 antibodies. The 
specificity of the CNR1 antibody (Ab23703) was confirmed using two approaches 
including Knocked-down of CNR1 protein in prostate cancer cell line 22RV1 and 
inhibition of CNR1 glycosylation protein in the prostate cancer cell line LNCaP. These 
data confirmed that ab23703 antibody proved to be specific for CNR1 receptors and 
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can be used for further functional studies to investigate the role of CNR1 in prostate. 
Using ab23703 antibody, the expression of CNR1 at the mRNA level generally 
correlated with the protein level in the prostate cancer cell line.  
 
To further investigate the role of CNR1 as a TSG in prostate cancer cells, I employed 
various functional assays including cell viability (MTS), migration (Transwell), scratch-
wound and colony formation assays. These studies showed that CNR1 knockdown in 
DU145 cell lines caused a significant increase in cell viability, cell migration and 
invasion. Furthermore, cell cycle analysis showed that CNR1 knockdown caused a 
decrease in G0/1 phases and an increase in G2/M phases of DU145 cells. These 
results suggest that CNR1 may be involved in the suppression of prostate cancer cell 
growth and invasion.    
 
Next, I investigated whether targeting CNR1 with cannabinoid agonists would have a 
potential for treating prostate cancer. Addition of the CNR1 agonist (HU210) to the 
prostate cancer cells 22RV1, LNCaP, DU145, and PC3 resulted in a significant 
decrease in cell viability in a dose-dependent manner as determined by MTS assays. 
The reduction in cell viability induced by the cannabinoid HU210 was significant (**P 
< 0.01) and was prevented by the CNR1 antagonist (R)-SLV-319 in all evaluated cell 
lines, demonstrating that HU210-induced cell killing is initiated through activation of 
the cannabinoid receptor and that CNR1 mediates anti-proliferative effects in 
response to agonists. I further demonstrated that HU210 reduces the viability of the 
(22RV1, LNCaP, DU145, PC3) cells through induction of apoptosis by Western blot 
analysis of caspase-3 and PARP proteins.  
 
My findings demonstrate that CNR1 may play an important role in proliferation, 
migration and invasion of prostate cancer cells. These results suggest that CNR1 may 
act as a tumour suppressor gene in prostate cancer cells. 
 
 
Table of contents  
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1 INTRODUCTION AND AIMS       
1.1 HUMAN PROSTATE CANCER 
 
In the adult, the prostate is a small acorn-shaped gland, with ductal –acinar 
histology, that lack discernible lobular organization. The prostate gland 
surrounds the urethra at the base of the bladder and functions by 
contributing secretory proteins to the seminal fluid. McNeal et al. defined 
three morphological regions within the human prostate: the peripheral 
zone, the transition zone and the central zone (Figure 1.1) (McNeal 1969).   
 
 
Figure 1.1 Diagram of the male prostate gland and the three distinct areas 
of the prostate. The peripheral zone, the central zone, and the transition zone.  
Adapted from http://radiologyreview.tumblr.com   
 
Prostatic adenocarcinomas arise from the lining of the gland, more often in 
the peripheral zone of the prostate. The normal prostatic epithelium is 
arranged in a double layer basal and luminal cells along with some rare 
embedded neuroendocrine cells (Figure 1.2). Matrix cells and stromal 
fibromuscular cells transmit signals to adjust the epithelium. The epithelium 
is separated from the stroma by membrane containing laminins (LM5, 
LM10) and collagens (COLIV, COLVII). Luminal cells express high level of 
androgen receptor, PSA and Keratins (K8 & K18) with no integrins 
expression. Basal cells express high level of p63, Bcl2, EGFR, Met and 
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keratins (K5 & K14) and integrins (α6β4, α3β1)(de Muga, Hernandez et al. 
2010). In addition, intermediate basal and luminal cells contains K5 and K18 
(van Leenders, Aalders et al. 2001). The tumours of prostate are 
characterized by progressive loss of the basal cells and loss of the markers 
LM5 and COLIV. (Figure 1.2) (Frank and Miranti 2013). In addition, the 
tumours also express integrins, α6β1 that promotes an abnormal growth 
and survival of prostate cancer. Moreover, tumour cells frequently co-
express basal and laminal keratins, K5 and K8 respectively. .  
 
             
Figure 1.2 Prostate epithelial gland structure. Normal prostate epithelium is 
composed of a double layer of basal cells, and luminal and a few rare 
neuroendocrine cells. The epithelium is separated from the underlying stroma 
by a basement membrane. Basal cells that interact specifically with the 
basement membrane. Basal cells do not express AR.  Adapted and modified 
from (Frank and Miranti 2013). 
 
Histopathological studies of tissue from prostate cancer led to the 
identification of a specific type of lesion that is thought to be the main 
precursor of human prostate cancer, known as prostatic intraepithelial 
neoplasia (PIN). PIN and most advanced high grade PIN (HGPIN) is found 
together with cancer. Early PIN lesions are not considered as a 
prerequisite for cancer. However, HGPIN is considered the precursor 
lesion of most intermediate and high grade adenocarcinomas that arise in 
the peripheral zone (DeMarzo, Nelson et al. 2003). More than 95 % of 
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prostate cancers are adenocarcinomas (cancer of epithelia originating in 
glandular tissue) arising from the epithelial cells of the prostate. Of these, 
70 % occur in the peripheral zone, 15-20 % in the centre, and 10-15 % in 
the transition zone. The cellular origins of prostate cancer are still 
controversial. It was reported that prostate cancer can arise from luminal 
cells (Goldstein, Huang et al. 2010) and based on the AR pathway activity, 
prostate cancer cells are more resemble the luminal cells than basel cells. 
However, the authors also reported that naïve basal cells could initiate 
acinar-type adenocarcinoma in response to oncogenic stimulation. In 
addition, other studies supported these findings including that basal cells 
from the BPH-1 prostate cell line can initiate prostate cancer after treating 
cells with estrogen and testosterone (Taylor, Toivanen et al. 2012). Other 
studies showed that using both mouse and human prostate tissue 
confirmed that transformed basal cells can develop malignant luminal 
progeny in vivo (Stoyanova, Cooper et al. 2013). These data suggest 
there are subfractions of basal cells within the tumour to ensure 
continuous production of malignant luminal-like cancer cells.  Most cancer 
cells are multifocal and simultaneously developed influenced in many 
regions of the prostate gland, which indicates that prostate cancer is 
probably the result of non-clonal expansion. 
 
 
1.2 PROSTATE CANCER EPIDEMIOLOGY AND RISK 
FACTORS 
 
Prostate cancer is the most common non-cutaneous malignancy in 
western men. There were 41,736 new cases of prostate cancer in the UK 
in 2011, making it the fourth most common cancer in the UK. The 
incidence of prostate cancer is strongly correlated with age; in the United 
Kingdom between 2010 and 2011, approximately 85 % of cases are 
diagnosed in men over 65, while only 1% of the cases were diagnosed in 
the group of less than 50 years (www.cancerresearchuk.org). The 
incidence of prostate cancer has increased dramatically, likely due to 
increased detection through the widespread use of prostate specific 
antigen (PSA) and longer life (UK).  
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Prostate cancer is recognized as one of the major medical problems facing 
the male population. In UK, 10,800 prostate cancer related deaths were 
recorded in 2012, almost three quarter of prostate cancer deaths occur in 
men aged 75 and over (UK). Mortality has declined by nearly 10% in UK 
according to Cancer research UK (http://info.cancerresearchuk.org) and 
could be due to improved treatment, including new drugs such as 
Abiraterone, enzalutamide and more effective radiotherapy, earlier 
diagnosis may also contribute (Simon M Collin and Rollo Moore 2008).     
 
Although the specific causes of initiation and progression of prostate 
cancer is not yet known, strong evidence suggests that both genetics and 
the environment play roles in the evolution of this disease. Several genetic 
studies suggested that hereditary factors might account for 5 - 10% of 
prostate cancers. The risk is increased in relatives of affected males. The 
risk of a man is twice as high if first-degree relatives, as a father or brother 
has prostate cancer, and the risk is greater (folds 5-11) if 2 or 3 first-degree 
relatives with prostate cancer (Turati, Negri et al. 2014). Therefore, men 
with a familiar prostate cancer should be screened earlier for this disease. 
Another risk factor for prostate cancer is increasing age. Men aged 75-79 
years have about 130 times the risk of men of 45-49 years. The older the 
man, the greater the risk and this link with the post mortem results in about 
80 % of men 80 years of age to have cancerous cells in their prostate.  
 
Ethnicity is another significant risk factor. In UK, black Caribbean and 
black African men have approximately two to three times the risk of being 
diagnosed or dying from prostate cancer than white men, while Asian men 
generally have a lower risk than the national average (Kheirandish and 
Chinegwundoh 2011) (UK). Studies have shown that migrants from low 
risk to high-risk countries are experiencing an increase in the incidence, 
which suggests that environmental factors and lifestyle are important in 
the etiology of prostate cancer (Sutcliffe and Colditz 2013).  
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Diet has been associated with prostate cancer. An increased intake of 
animal fat and possibly red meat has been associated with an increased 
risk of prostate cancer (Joshi, Corral et al. 2012). In contrast, vegetables, 
fruit, antioxidants, and plant oestrogens found in soybeans reduce the risk 
of prostate cancer by 30-60% (Hori, Butler et al. 2011, Key 2011, Micheal 
F Leitzmann 2012). High intake of cruciferous vegetables containing the 
chemoprotective isothiocyanate sulforaphane was correlated with a 
diminished risk of prostate cancer (Aragon-Ching 2011, Ben Liu 2011, 
Hori, Butler et al. 2011).  
 
Another potential risk factor is the hormone levels, in particular 
testosterone levels. A meta-analysis of previously published studies on 
hormonal predictors of prostate cancer concluded that men whose total 
testosterone level is in the highest quartile are 2.34 times more likely to 
develop prostate cancer (Shaneyfelt, Husein et al. 2000). However recent 
studies reported that prostate cancer is not related to exogenous and 
endogenous testosterone levels (Klap, Schmid et al. 2015, Boyle, Koechlin 
et al. 2016) 
 
1.3 PROSTATE CANCER DIAGNOSIS AND STAGING  
 
1.3.1 DIAGNOSIS 
 
Patients with prostate cancer show few early symptoms. Severe 
symptoms such as haematuria, urinary obstructive and bone pain are 
only present in advanced disease or cancer with metastases. Blood 
levels of PSA, and digital rectal examination (DRE), magnetic resonance 
imaging (MRI) and computed tomography (CT) scan are the most 
common combinations of diagnostic tools for prostate cancer detection 
(Heidenreich, Aus et al. 2009). PSA values are not only influenced by 
the presence of prostate cancer, but also by various factors such as age, 
race and inflammation (FitzGerald, Kumar et al. 2013). Therefore, upon 
detection of elevated PSA levels, a biopsy is recommended to confirm 
the presence of this malignancy. In the UK, patients with a family history 
of prostate cancer are advised to have a PSA test (UK).  
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Although PSA screening has become widely used, there is increasing 
controversy regarding the limitations of its sensitivity and specificity.  The 
association of PSA with age and other prostatic conditions, including 
benign prostatic hyperplasia (BPH), leads to a significant number of false-
positive cases. Therefore, a more specific test to discriminate the false 
positive in these patients has been developed, the prostate cancer gene 
3 (PCA3) molecular marker. PCA3-gene generates prostate-specific 
noncoding mRNA that is found overexpressed in 95% of prostate cancers 
(Groskopf, Aubin et al. 2006). PCA3 does not increase as a consequence 
of benign enlargement of the prostate or prostatitis (Groskopf, Aubin et al. 
2006). Gene expression profiling studies have confirmed that PCA3 is one 
of the most sensitive and specific prostate cancer biomarkers (Tomlins 
2014). Recently, a test detecting both PCA3 and the TMPRSS2:ERG 
fusion transcript in urine showed to have a higher sensitivity and result in 
fewer false-positives in prostate cancer diagnosis (Gregoire Robert 2012, 
Salami, Schmidt et al. 2013, Yang, Yu et al. 2016).  
 
A more sensitive technique, transrectal ultrasound (TRUS) biopsy is 
recommended when DRE or PSA tests detect an abnormality (Lee and 
Chia 2015, Teoh, Yuen et al. 2015). Although prostate cancer can spread 
to a wide variety of organs, it tends to metastasise to the bones. Thus, 
when prostate cancer is diagnosed, a bone scan is performed using CT or 
MRI (Tombal and Lecouvet 2012). 
 
 
 
1.3.2 PATHOLOGY GRADING SYSTEM 
 
Adenocarcinoma of the prostate accounts for most prostate cancers. For 
the grading of prostate adenocarcinomas a few systems are available. The 
most widely used and generally accepted system is that proposed by 
Gleason (Mellinger, Gleason et al. 1967, Gleason and Mellinger 1974, 
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Gleason and Mellinger 2002). The Gleason score distinguishes five 
different grades or patterns on a scale of 1 to 5, from well differentiated to 
poorly differentiated (Figure 1.3) (Gleason and Mellinger 1974, Gleason 
and Mellinger 2002). Because prostate cancer is usually very 
heterogeneous, with two or more grades in a given cancer, Gleason 
incorporates both a primary and a secondary grade into his system. The 
final score is the sum of the primary and the secondary grade, ranging 
from 2 (1+1) to 10 (5+5) (Green, Hanlon et al. 1998, Humphrey 2004). 
 
 
FIGURE 1.3 Gleason grade of prostate cancer. The Gleason score in 
five different sections: Grade 1 (well differentiated), uniform shaped 
glands, Grade 2 (well differentiated), some infiltration into the 
surrounding stroma, Grade 3 (moderately differentiated), most 
common grade with more variation in size, shape, and separation of 
the glands, Grade 4 (poorly differentiated), fusion of the glands 
forming a solid anastomosing network and Grade 5 (undifferentiated), 
characterised by a complete absence of gland formation with sheets 
or clusters of cells. Adapted from Dr Gleason’s simplified drawing of 
the five Gleason grades of prostate cancer (Gleason and Mellinge.Gt 
1974) 
 
1.3.3 TMA SYSTEM FOR TUMOUR STAGE 
 
The main goals in staging prostate cancer are to predict prognosis and to 
rationally select the therapy. Staging systems of prostatic carcinoma have 
been discussed intensively during the last few decades. In 1992 staging 
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concepts began to include the TNM scoring system. T (tumour) - 
measuring tumour size, N (nodes) - is the spread of cancer in the lymph 
nodes and M (metastasis) - explains spread of cancer to different distant 
tissues into the bloodstream. Furthermore, APC stages I-IV describes the 
aggressiveness of the disease, R cancer confined to the prostate 
designation and IV indicates a very aggressive and deadly form PC. (Table 
1.1) (Liang Cheng 2012). 
 
Table 1.1 The UICC 2002 TNM (Tumour Node Metastasis) 
classification is used for staging with several changes. 
Stage Tumour 
I T      Primary tumour 
TX    Primary tumour cannot be measured 
T0    No evidence of primary tumour 
T1    Clinically unclear tumour not evident by imaging 
I/IIa T1a  Tumour incidental histological finding in 5% or less of 
resected tissue  
         T1b  Tumour incidental histological finding in more than 5% 
of  resected tissue 
T1c  Tumour identified by needle biopsy (e.g elevated 
prostate-specific antigen level) 
III T3    Tumour extends through the prostatic capsule 
         T3a   Extracapsular extension (unilateral or bilateral) 
T3b  Tumour invades seminal vesicle(s) 
IV T4   Tumour is fixed or invades adjacent structures other 
than seminal vesicles: bladder neck, rectum and/or pelvic 
wall 
 N Regional lymph nodes 3 
           NX  Regional lymph nodes cannot be assessed 
           N0   No regional lymph node metastasis 
           N1   Regional lymph node metastasis 
 M Distant metastasis 4 
          MX   Distant metastasis cannot be assessed 
          M0    No distant metastasis 
          M1    Distant metastasis 
          M1a  Non-regional lymph node(s) 
          M1b  Bone(s) 
          M1c  Other site(s) 
 
 
      1.4 CLINICAL MANAGEMENT 
 
In general, for clinically localized prostate cancer in men in good condition, 
with a life expectancy of 10 years or more, the goal of treatment should be 
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the eradication of the disease. This can be achieved by radical surgery or 
radiation therapy (external or interstitial) (Wilt and Thompson 2006) (Silva 
2010). Active surveillance, or watchful waiting, is applied to men with a 
short-life expectancy or in those with a PSA test ≤ 10ng/ml, a Gleason 
score ≤ 6 and staged at T1c to T2a who decide not to undergo immediate 
surgery or radiation therapy (Damber and Aus 2008, Albertsen 2011). 
Tissue specimens from prostate biopsies are histologically analysed and 
provide information of the presence of prostate cancer cells and tumour 
aggressiveness (William K. Oh 2007.). Some of the tests have been 
commercially developed for prostate cancer but not approved by the USA 
FDA including Oncotype DX assay which is a multi-gene expression assay 
developed for FFPF diagnostic prostate needle biopsies as little as 1mm 
of prostate tumour. This assay measures expression of 12 cancer-related 
genes which are involved in four different biological pathways (AZGP1, 
KLK2, SRD5A2, RAM13C, TPX2, FLNC, GSN, TPM2, GSTM2, BGN, 
COL1A1, SFRP4) (Boström, Bjartell et al. 2015). This assay has been 
analytically and clinically validated as a predictor of aggressive prostate 
cancer. Another active surveillance test called the Decipher test 
(GenomeDx Bioscience), measure the expression level of 22 RNA 
biomarkers involved in multiple pathways that have been associated with 
aggressive prostate cancer (Ross, Feng et al. 2014).  It predicts the 
probability of metastasis after prostatectomy and provides an assessment 
of tumour aggressiveness.  
 
The best choice for locally advanced prostate cancer is the combination of 
radiation and hormonal therapy (Lars Budaus 2012). The main treatment 
for patients with lymph node or distant metastases is androgen-deprivation 
therapy (Kirby 2008, Minelli, Bellezza et al. 2009, Gupta-Elera, Garrett et 
al. 2012, Theodorescu 2010). However, most cases will experience the 
development of androgen-insensitive prostate cancer clonal expansion, 
also known as castration-resistant prostate cancer (CRPC). Unfortunately, 
there are no established treatment options for this type of prostate cancer, 
and palliative care is the most common choice for its management 
(Amaral, Macedo et al. 2012). So much remains to be done to develop 
treatment options for patients, since treatment of CRPC remains a major 
challenge. 
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Hormonal treatment is initially effective in most patients, using luteinizing 
hormone releasing hormone (LHRH) agonist leuprolide acetate (Prostap) 
or androgen-receptor antagonists as abarelix (Gomella 2009). But this 
effect is temporary, because virtually all patients inevitably develop 
disease progression (Mei Ka Fong 2012). Once the disease is progressive 
under hormonal therapy, so called hormone resistant prostate cancer, 
there is no curative second line of treatment available (Mei Ka Fong 2012).  
Patients with hormone refractory prostate cancer HRPC have limited 
treatment options beyond the addition of other antiandrogens.  
 
The current treatment of choice for castration-sensitive prostate cancer 
(CSPC) is androgen ablation therapy or androgen deprivation therapy. 
This treatment is intended to block the production of androgens, which, in 
turn, regresses the growth, and spread of prostate cancer. Some drugs 
approved by the FDA include Abiraterone, a CYP17 inhibitor that leads to 
the reduction of testosterone levels (Pezaro, Mukherji et al. 2012), and 
Enzalutamide, AR antagonist (Scher , Fizazi  et al. 2012). Initially, patients 
respond well to these treatments, but they do not achieve a complete cure, 
resulting in recurrence of prostate cancer and eventually death (Amaral, 
Macedo et al. 2012). The main challenge of hormone ablation therapy is 
that it does not target prostate cancer cells able to survive and proliferate 
in the absence of androgens (Katzenwadel and Wolf 2015). 
Despite using hormone therapy, men with metastatic PCa eventually 
develop castration-resistant prostate cancer (CRPC). This means that the 
cancer is able to grow and continue to spread. In these cases, other 
additional treatment is required to help in controlling the growth of the 
cancer (Hotte and Saad 2010). 
 
First-line chemotherapeutic treatment, Docetaxel and prednisolone are 
presently considered the standard of care for men with CRPC and 
radiologically proven metastatic disease (Petrylak , Tangen  et al. 2004, 
Tannock , de Wit  et al. 2004). This combination was recommended 
following the publication of two large randomised controlled trials that 
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compared it with the previously used standard of mitoxantrone and 
prednisolone. The survival rates have been shown to be significantly 
better with docetaxel and prednisolone, compared with mitoxantrone and 
prednisolone (Petrylak , Tangen  et al. 2004, Tannock , de Wit  et al. 
2004). In addition, patients treated with docetaxel showed a 
greater reduction in pain (35%) compared to men treated with 
mitoxantrone (22%) (Petrylak , Tangen  et al. 2004, Tannock , de Wit  et 
al. 2004). 
 
Second-line chemotherapeutic treatment, two trials, SPARC (Sternberg, 
Petrylak et al. 2009) and TROPIC (de Bono, Oudard et al. 2010) have 
assessed chemotherapeutic agents in patients with progressive disease 
after docetaxel. The results showed a significant and clinically relevant 
survival advantage with cabazitaxel therapy (de Bono, Oudard et al. 2010, 
Chopra and Rashid 2015, Perletti, Monti et al. 2015). Considering all these 
positive results, cabazitaxel was approved as a second-line chemotherapy 
drug in patients with CRPC and is available on the Pharmaceutical 
Benefits Scheme for Australian men (Chopra and Rashid 2015). 
Subsequently, additional trials were successful in prolonging survival in 
the post-docetaxel setting, including COU-301 and AFFIRM. The 
combination of abiraterone and prednisone (compared with placebo and 
prednisone) was shown to significantly prolong median overall survival. In 
view of these results, the US Food and Drug Administration (FDA) 
approved abiraterone. The COU-AA-301 trial of abiraterone in patients 
with mCRPC previously treated with docetaxel chemotherapy 
demonstrated improved overall survival (de Bono, Logothetis et al. 2011). 
These trials have evaluated whether, compared with prednisolone and 
placebo, prednisone and abiraterone acetate can improve survival. 
Abiraterone acetate is a potent and irreversible inhibitor of CYP17, which 
is a critical enzyme in androgen biosynthesis (Hotte and Saad 2010, 
Pezaro, Mukherji et al. 2012, Omlin, Pezaro et al. 2014). Enzalutamide is 
an androgen receptor signalling inhibitor (ARSI) that binds the androgen 
receptor ligand site and thereby inhibits nuclear translocation of the 
androgen receptor. The results of the AFFIRM study, comparing 
enzalutamide with placebo in patients previously treated with docetaxel, 
were recently published and showed a significant advantage in overall 
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survival in patients with mCRPC (Scher, Fizazi et al. 2012, Beer, 
Armstrong et al. 2014). 
 
Furthermore, several treatments are approved for mCRPC patients 
including sipuleucel-T, an FDA-approved immunotherapy. Recent 
additional trials using sipuleucel-T (an autologous cellular immunotherapy 
targeted to prostatic acid phosphatase) and randium-223 (a bone-seeking 
alpha particle emitter), demonstrated an improvement of survival in 
patients with asymptomatic mCRPC and symptomatic mCRPC patients 
with bone metastasis respectively (Kantoff, Higano et al. 2010, Parker, 
Nilsson et al. 2013, Graff and Chamberlain 2015, Nilsson 2016).  
  
The improvements of survival in patients with metastatic castration-
resistant prostate cancer have succeeded with the use of next-generation 
hormonal therapy, cytotoxic chemotherapy, immunotherapy and 
radiotherapy. A recent study (CHAARTED Trial) showed that the 
combination of androgen-depravation therapy (ADT) and docetaxel 
resulted in better cancer control than with ADT alone (Sweeney, Chen et 
al. 2015). In addition, it showed a significantly longer overall survival (44.0 
months) than that with ADT alone followed by docetaxel (57.6 months) in 
men with Castration-sensitive metastatic prostate cancer and a substantial 
reduction of the PSA level (Sweeny et al 2015). These findings were 
confirmed by another study (STAMPEDE Trial) presented by The 
American society of clinical oncology in 2015 (James, Spears et al. 2015) 
(James et al 2015).  
Currently, there is lack of proof for a specific sequence of therapy. All 
survival-prolonging treatments are effective options, taking into account 
the patient status and the availability of the drug. Further research is 
needed in managing patients and in determining the optimal sequencing 
of treatments over the disease course.   
 
1.5 GENETIC ALTERATIONS IN PROSTATE CANCER 
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1.5.1 GENOMIC ALTERATIONS IN PROSTATE 
CANCER 
 
Prostate cancer, like other types of cancer, is a result of the accumulation 
of both genetic and epigenetic alterations that can lead to loss of function 
of tumour suppressor genes (TSGs) or overexpression of oncogenes that 
transform normal glandular epithelium to pre-neoplastic lesions and then 
invasive carcinoma (Figure 1.4) (Vinall, Chen et al. 2012). With the 
development of new genetic and genomic technologies, extensive studies 
have concentrated on the identification of genetic alterations occurring in 
prostate cancer (Spurgers, Chari et al. 2006, Barbieri, Bangma et al. 
2013).  
 
 
Figure 1.4 Schematic diagram of molecular progression in prostate 
cancer. Stages of progression are correlated with loss of specific 
chromosome regions. Adapted and modified from (Vinall, Chen et al. 2012) 
 
Genetic alterations can be germline alterations or somatic alterations. 
Also, epigenetic mechanisms, including DNA methylation, contribute to 
prostate cancer. 
 
1.5.2 GERMLINE MUTATIONS AND 
POLYMORPHISMS IN PROSTATE CANCER 
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As age, race, and family history remain primary risk factors for the 
development of prostate cancer. It has been shown that prostate cancer 
is one of the most heritable cancers with epidemiological studies 
suggesting the role of genetics in prostate cancer development (Van den 
Broeck, Joniau et al. 2014) 
 
Although an increasing number of candidate genes for hereditary prostate 
cancer have been identified, from 5% to 10% of prostate cancer cases 
believed to be primarily caused by high-risk inherited genetic factors or 
prostate cancer susceptibility genes (Carter, Beaty et al. 1992, Lynch, 
Kosoko-Lasaki et al. 2016). 
 
Prostate cancer linkage studies have been used to localise rare and highly 
susceptibility genes. Genes including the RNase L (RNASEL) gene in 
hereditary prostate cancer 1 (HPC1) on chromosome 1q23-25 (Wei, Xu et 
al. 2012), the elaC homolog 2 (ELAC2) gene in hereditary prostate cancer 
2 (HPC2) on chromosome 17p11 (Xu, Tong et al. 2010), and the 
macrophage scavenger receptor 1 (MSR1) gene at 8p22 have been 
identified as prostate cancer susceptibility genes by linkage and 
mutational analyses (Maier, Vesovic et al. 2006). However, most gene 
linkages were not replicated across studies. The most promising candidate 
identified so far is BRCA2, which is associated with a 20-fold increased 
risk for breast cancer relative to the general population, and the evidence 
points to a more important role of this gene in prostate cancer at a younger 
age. However, this genetic linkage may explain only a small fraction of 
familial prostate cancer because germline mutations of BRCA2 are quite 
rare in prostate cancer patients (Akamatsu, Takata et al. 2012).  
 
The most common germline alterations described in prostate cancer are 
frame-shift mutation of the ribonuclease L-2, 5-oligoisoadenylate 
synthase-dependent gene (RNASEL/HPC1) located at 1q25.  Two 
mutations in RNASEL (Met1Ile and Glu265X) were reported to segregate 
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with prostate cancer. One of these, Glu265X, was also associated with 
prostate cancer risk in familial and sporadic prostate cancer in other 
studies (Wei, Xu et al. 2012). A recent study showed the association 
between RNASEL Asp541Glu and Arg462Gln polymorphisms and 
prostate cancer risk (Bingbing Wei 2012).  
 
Furthermore, a study used linkage analysis in combination with targeted 
massively parallel sequencing to identify a recurrent mutation in HOXB13 
that is associated with early-onset and hereditary prostate cancer (Ewing, 
Ray et al. 2012). This novel rare mutation (G135E) of the HOXB13 gene 
was also found to be associated with increased prostate cancer risk in 
Chinese men (Lin, Qu et al. 2012). Recent study showed that Danish men 
who carry the HOXB13 G84E mutation are more likely to develop 
aggressive prostate cancer (Storebjerg, Høyer et al. 2016). That finding 
provides further evidence that HOXB13 plays an important role in prostate 
cancer etiology.   
 
The testes, the adrenal glands and the prostate itself secrete androgens. 
The main androgen hormone is testosterone, which can be converted by 
5-α-reductase to dihydrotestosterone (DHT) in prostate cells. Androgen 
production is regulated by endocrine stimulation from the hypothalamus 
via the pituitary gland. Gonadotrophin releasing hormone (GnRH) is 
normally released in pulses from the hypothalamus, stimulating pulsatile 
release of follicle-stimulating hormone (FSH) and luteinising hormone 
(LH), the latter stimulating production of testosterone by the Leydig cells 
in the testes (Figure 1.5).  
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Figure 1.5 Androgen and AR action. The genome organization of the 
human androgen receptor gene and the functional domain structure of the 
androgen receptor protein.  (A) Androgen and AR signaling in prostate 
cells. Testosterone is transported to the prostate and converted to 
dihydrotestosterone (DHT) by 5-α-reductase. DHT binds to the ligand-
binding pocket and promotes the separation of heat-shock proteins (HSPs) 
from the AR. The AR then transfer to the nucleus, binds to the androgen 
response element (ARE) in the promoter region of target genes such as 
prostate-specific antigen (PSA) and TMPRSS2. The AR binds the basal 
transcription machinery proteins including TATA-box-binding protein 
(TBP), transcription factor IIF (TFIIF), other coactivators and cAMP-
response element-binding protein (CREB)-binding protein (CBP), at the 
promoter region, SHBG: serum sex hormone-binding globulin. (B) The 
androgen receptor gene located on the long arm of the X-chromosome 
(locus: Xq11-q12). Adapted from (Tan, Li et al. 2015) 
 
The androgen receptor (AR) gene, a member of the steroid and thyroid 
hormone receptor gene superfamily, is a transcription factor that mediates 
testosterone and dihydrotestosterone (DHT) activities by initiation of 
transcription of androgen-responsive genes. The AR gene is located on 
the X chromosome at the locus Xq11-Xq12. It contains eight exons 
interrupted by introns of varying lengths (0.7–2.6 kb) with two highly 
polymorphic trinucleotide repeat segments, (CAG) n and (GGN) n, that 
reside in the transactivation domain of AR (Tan, Li et al. 2015). 
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Several studies have reported an association between prostate cancer 
susceptibility of the polymorphic CAG repeats in the AR gene, which 
codes for a polyglutamine (PolyQ) tract in the N-terminal domain (exon 1) 
of the AR protein (Gu, Dong et al. 2012). The role of the variation in the 
CAG repeats (rs4045402) length in prostate cancer risk has been 
investigated in many studies. A meta-analysis of 19 studies including 
Caucasian, African-American and Asian subjects predicted an increased 
risk of prostate cancer in men with shorter (≤21) CAG repeats.  In addition, 
a Swedish study suggests that men with shorter AR CAG lengths (e.g., 
≤22 repeats) are at a greater risk of developing prostate cancer.  Other 
studies found no association between the AR CAG repeat length and 
prostate cancer risk. Although evidence that mutations in the AR 
predispose men to prostate cancer is undisputed, AR NTD CAG repeats 
length association with prostate cancer risk thus remains controversial 
(Tan, Li et al. 2015). Other genes with different polymorphisms which may 
influence the risk of prostate cancer are CYP11A1 (Yamada, Nakayama 
et al. 2012), CYP17 (Song, Tao et al. 2016), TA dinucleotide repeat in 
SRD5A2 (Choi, Kim et al. 2015), HSD3B1 (Wu, Huang et al. 2015), 
GSTM1 (Wang, Li et al. 2015), GSTP1 & GSTT1 (Gong, Dong et al. 2012), 
MYC (Li, Liu et al. 2015), vitamin D receptor (VDR) levels (Jingwi, Abbas 
et al. 2015). 
 
There has been an increasing focus on the role of single nucleotide 
polymorphisms (SNPs) in the development and progression of prostate 
cancer but also on their role in diagnostics and risk prediction. SNPs are 
the most common polymorphisms in the genomes of many species. The 
definition of a SNP is a variation of the DNA sequence at a frequency 
larger than 1% of the allele of a population (Van den Broeck, Joniau et al. 
2014).   
 
Genome-wide association studies (GWAS) provide stronger power to 
detect small to modest effects on disease risk. In the last decade, GWAS 
have successfully identified roughly 100 loci associated with prostate 
cancer risk (Gudmundsson, Sulem et al. 2007, Yeager, Orr et al. 2007, 
Thomas, Jacobs et al. 2008, Eeles, Kote-Jarai et al. 2009, Takata, 
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Akamatsu et al. 2010, Haiman, Chen et al. 2011, Kote-Jarai, Olama et al. 
2011, Schumacher, Berndt et al. 2011, Boyd, Mao et al. 2012, Xu, Mo et 
al. 2012, Amin Al Olama, Kote-Jarai et al. 2013, Eeles, Olama et al. 2013, 
Al Olama, Kote-Jarai et al. 2014) and 33% of familial risk is associated 
with known SNPs (Al Olama, Kote-Jarai et al. 2014).  
 
The great majority of GWA studies of prostate cancer have been mainly 
performed on European population (Amundadottir, Sulem et al. 2006, 
Eeles, Olama et al. 2013, Yang, Yu et al. 2016).  However, in the last few 
years, a number of meta-analysis of GWAS data and the replication 
studies have showed certain loci contribute to prostate cancer in multiple 
ethnic populations such variants at 11q12 (rs1938781), 10q26 
(rs2252004) and 3p11.2 (rs2055109) in Japanese populations (Akamatsu, 
Takata et al. 2012), loci at 9q31.2 (rs817826) and 19q13.4 (rs103294) in 
Chinese populations (Xu, Mo et al. 2012), at loci at 8q24 (rs114798100 
and rs111906923) in African ancestry (Han, Rand et al. 2016). Recently, 
Marzec et al have shown that four loci (rs12567052, rs10235505, 
rs7463708 and rs1456315) on 8q24 contribute to prostate cancer risk in 
both European and Chinese populations (Marzec, Mao et al. 2016).  
 
Numerous studies have been reported the association of SNPs in 8q24 
region and prostate cancer.  To date there are about 64 variants of 8q24 
SNPs investigated for the association with prostate cancer risk, and only 
20 of those are confirmed to be prostate cancer risk SNPs (Amundadottir, 
Sulem et al. 2006, Gudmundsson, Sulem et al. 2007, Gudmundsson, 
Sulem et al. 2007, Haiman, Patterson et al. 2007, Witte 2007, Yeager, Orr 
et al. 2007, Yeager, Chatterjee et al. 2009, Li, Liu et al. 2015, Ren, Zhang 
et al. 2015, Bishop, Han et al. 2016, Han, Rand et al. 2016, Marzec, Mao 
et al. 2016).  For example, it was confirmed that SNPs in three 8q24 
regions (rs1447295, rs1690979 and rs6983267) were significantly 
associated with prostate cancer risk in Caucasian families (Salinas, Kwon 
et al. 2008). Most recently, Marzec et al have found that mainly four loci 
on 8q24 contribute to prostate cancer risk in a large population of Chinese 
men, which is different in the European population (Marzec, Mao et al. 
2016).  Other studies showed similar results among Caucasians, Asians 
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and African-Americans (li, Liu et al. 2015). Moreover, a meta-analysis for 
rs6983267 polymorphism in prostate cancer was performed, and data 
showed that rs6983267 is significantly associated with prostate cancer risk 
in both European and Asian descent (Zhu, Zhang et al. 2015).  
 
Several other studies showed that SNPs is associated with prostate 
cancer aggressiveness.  Williams et al, identified SNPs in three genes 
associated with poor clinical outcomes in TCGA (Provisional) and 
GSE21032 prostate cancer gene expression datasets (CXCL14, ITGAX, 
and LPCAT2) were all associated with aggressive prostate cancer 
including the following SNPs, rs2237061, rs10515473 and rs4463175 in 
CXCL14 gene, were found to be associated with Gleason score at 
prostatectomy (Williams, Lee et al. 2014).  In addition, Berndt et al, 
identified two loci specific for aggressive prostate cancer, rs78943174 at 
3q26.31, and rs35148638 at 5q14.3, which are associated with Gleason 
score, a pathological measure of prostate cancer aggressiveness. These 
SNP are located near genes involved in vascular disease, cell migration 
and metastasis, which make them interesting loci for further study (Berndt, 
Wang et al. 2015). Furthermore, The NCI-SPORE Genetics Working 
Group provided further support using clinicopathologic information and 
genotype data for 36 SNPs. They showed that a prostate cancer-risk SNP 
rs2735839 near the KLK3 gene on chromosome 19q13 might be 
associated with aggressive and high-grade prostate cancer (Helfand, 
Roehl et al. 2015). All in all, these findings may improve the understanding 
of prostate cancer susceptibility and provide clues for further functional 
studies.  
 
1.5.3 SOMATIC GENOMIC ALTERATIONS IN 
PROSTATE CANCER  
 
It has been clear for many years that somatic alterations of the genome 
occur at a high frequency in the majority of cells isolated from most 
common forms of cancer.  
 35 
Prostate cancer cells usually contain a large number of somatic genome 
alterations, such as, deletions, point mutations amplifications and 
translocations that contribute to the cancer phenotype. For example, 
inactivation or loss of a tumour suppressor gene by mutation or deletion, 
results in the loss of the tumour suppressor function, resulting in the 
uncontrolled proliferation of cells (Dong 2001).    
 
Several methods such as conventional G-banding, fluorescence in situ 
hybridization (FISH), comparative genomic hybridization (CGH) and loss 
of heterozygosity (LOH) have all been performed to study chromosomal 
abnormalities in prostate cancer. Various chromosomal abnormalities 
have been described in prostate cancer. The most commonly reported are 
gains of 2p, 3q, 7q, 8q, 9q, 17q, 20q, and Xq, deletions of 2q, 5q, 6q, 8p, 
10q, 12p, 13q, 16q, 17p, 17q, 18q, 21q, and 22q, hyperdiploidy, and 
aneusomy of chromosomes 7 and 17 (Gu and Brothman 2011, Williams, 
Greer et al. 2014).  
 
Recent studies using next-generation sequencing (NGS) have provided a 
catalogue of such changes at much higher resolution than has previously 
been possible. Besides small sequence changes (such as point mutations, 
and small insertions or deletions of nucleotides), NGS studies highlight the 
abundance of chromosomal aberrations in cancer genomes. These 
chromosomal aberrations include different forms of abnormalities, such as 
chromosomal rearrangements (e.g. large insertions or deletions, 
rearrangement between chromosomes, chromosome fragmentation) and 
regions of amplification, as well as numerical aberrations associated with 
the gain or loss of whole chromosomes (or aneuploidy)(Ashok 2014).  
With the development of NGS technology, prostate cancer is being deeply 
exposed in terms of diagnosis and prognosis at the level of its genetic 
basis.  New prospectus of personalised treatment is arising due to the 
latest developments in NGS tools, which can identify genomic mutations 
and their downstream effects on gene expression (Yadav, Li et al. 2015). 
NGS tools can reveal genetic alterations at the level of the whole genome 
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(Whole genome sequencing; WGS), exome (Whole-exome sequencing; 
WES) and transcriptome (RNA-Seq). Information can then be combined 
with clinicopathological and radiological data leading to an accurate 
diagnosis of cancer aggressiveness (Yadav, Li et al. 2015). 
 
Genomic alterations such as insertions, deletions, rearrangement of 
repetitive elements, copy number variations, microbial infections, active 
retrotransposons, chromosomal translocations and inversions can be 
inclusively provided by WGS. In addition, WGS can be a sufficient 
advancement in providing a patient-specific reference of genomic 
alterations to track tumour progression, treatment efficiency and 
mechanisms of drug resistance (Yadav, Li et al. 2015). On the other hand, 
accurate detection of mutations by WGS demands great amounts of DNA, 
as, opposite to exome sequencing, WGS does not involve a DNA 
amplification step, in addition to costly expenditures. Whereas WGS is 
considered a useful tool in diagnostics (Majewski, Schwartzentruber et al. 
2011, Rabbani, Tekin et al. 2014), since it analyses approximately 2% of 
genomic DNA referred to the exome with high sensitivity. However, WES 
is insufficient in recognizing copy number variations and other mutations 
that are included in the whole genome. 
 
Several of WES-based studies have identified genes that are recurrently 
mutated, such as, Barbieri et al. 2012 have sequenced the exome of 112 
prostate tumour and normal tissue pair and identified genes that are 
recurrently mutated in prostate cancer including SPOP, MED12 and 
FOXA1 genes, using whole-exome sequencing (Barbieri, Baca et al. 
2012). In addition, the SPOP gene lacked EST family gene 
rearrangement, which may anchor a district subtype of EST fusion-
negative prostate cancer (Barbieri, Baca et al. 2012, Baca, Prandi et al. 
2013, Barbieri, Bangma et al. 2013).  Furthermore, Grasso et al, 2012 
sequenced the exome of 50 CRPC tissues and identified the recurrent 
alterations in genes knows to be associated with prostate cancer including 
TP53, AR, ZFHX2 and PTAN (Grasso, Wu et al. 2012). Recently, 
Robinson et al have used whole-exome and transcriptome sequencing on 
150 mCRPC tissue tumour biopsies.  And found abnormalities in AR, EST, 
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TP53 and PTEN genes.  Moreover, aberrations were found in high 
frequencies in BRCA2, BRCA1 genes compared to the normal those in 
the primary prostate cancers (Robinson, Van Allen et al. 2015). Other 
studies identified copy number alterations involving MYC, RB1, PTEN, 
and CHD1 (Berger, Lawrence et al. 2011, Pflueger, Terry et al. 2011, Gao, 
Vela et al. 2014).  
 
The complexity of prostate cancer, both diagnostic and clinical 
management is based on its multifocal origins within the prostate body. 
Several studies have shown that independent clonal multiple tumour foci 
occur. These different tumour foci, in turn, can advance at different rates 
depending on the nature of the genetic alterations that confer different 
degrees of biological aggressiveness (Taylor, Schultz et al. 2010, 
Lindberg, Klevebring et al. 2013, Cooper, Eeles et al. 2015). A research 
team recently found that a prostate tissue that appears normal might not 
be that normal after all (Cooper, Eeles et al. 2015).  They performed the 
whole genome DNA sequencing technology to read the complete DNA 
code inside the cells present in all the biopsies that were taken from the 
prostates of three men. They found that the so-called normal prostate 
cells, that surrounded the tumour cells, harboured genetic alterations in 
their DNA that might develop into cancer. 48 % of the so called normal 
prostate samples carried genetic mutations and genetic errors, strongly 
supporting the idea to work on the whole prostate rather than focusing on 
one single area.  
 
 
WGS-based studies have also identified genes that involved in prostate 
cancer including recent studies have uncovered biallelic loss of BRCA2 
gene in sequenced CRPC samples (Cheng, Pritchard et al. 2015, Decker, 
Karyadi et al. 2016). This discovery is potentially important prognostic and 
biomarkers for treatment response to DNA-damaging therapy, 
chemotherapies and in aggressive prostate cancer.  
 
NGS applications have also been used to screen prostate cancer for 
multiple gene alterations in men routinely diagnosed with this disease. 
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Beltran et al. (Beltran, Yelensky et al. 2013) performed targeted 
sequencing using advanced prostate tumour FFPE samples (50 ng DNA). 
They observed that over 44% of CRPCs harboured genomic alterations 
involving the AR gene. Other recurrent mutations included TMPRSS2-
ERG fusion, PTEN loss, TP53 mutation, RB loss, MYC gain and PIK3CA 
mutation, BRCA2 loss and ataxia telangiectasia mutated gene (ATM) 
mutations. Recently, a study was performed using small amounts of DNA 
(30 ng) dissected from transrectal ultra-guided (TRUS) or transperineal 
needle biopsy specimens. It showed that this amount of DNA was 
sufficient to generate mutation data using NGS technologies.  The results 
were consistent with other studies observed in prostate cancer (Beltran, 
Yelensky et al. 2013, Iacono, Buttigliero et al. 2016) including TMPRSS2-
ERG fusion, TP53, ATM, and SPOP (Manson-Bahr, Ball et al. 2015). This 
technique provides a more robust method that may be used to assess 
gene mutations in men underdoing diagnosis for prostate cancer.   
NGS applications are further used to pinpoint alterations at the level of 
gene expression and detect new splice variants and SNPs. Identification 
and quantification of allele-specific expression, non-human transcripts, 
deregulated gene fusions are also enabled by the use of RNA-Seq tools 
although it is a challenging process due to RNA fragility and many 
preparatory steps that demand matching process to the reference genome 
(Fang and Cui 2011, Han, Vickers et al. 2015).  In addition, identification 
of methylated CpG islands are also of great interest to target down-
regulated genes in both normal and cancerous cells by NGS using a 
technique known as reduced representation bisulfite sequencing (RRBS) 
(Smith IM et al 2010)(Delpu, Cordelier et al. 2013). 
 
1.5.3.1 Gene fusions in Prostate cancer 
 
Gene fusions are important in the development of many haematological 
malignancies and sarcomas but are rare in most other tumour types 
(Parker and Zhang 2013). Fusion genes may involve the regulatory 
elements of one gene (often tissue-specific) aberrantly apposed to a 
proto-oncogene, for example, immunoglobulin and T-cell receptor 
regulatory regions fused to the MYC oncogene in B and T cell 
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malignancies, respectively. Alternatively, coding regions of two genes are 
juxtaposed, resulting in a chimeric protein with a new or altered activity, 
for example, the BCR–ABL1 gene fusion in chronic myeloid leukaemia 
(CML) and a subset of acute lymphocytic leukaemia (Kumar-Sinha, 
Tomlins et al. 2008). The BCR–ABL1 gene fusion on the Philadelphia 
chromosome (aberrant chromosome 22), discovered by Nowell and 
Hungerford in 1961, results from a translocation of the proto-oncogene 
ABL1 from chromosome 9 to the BCR gene on chromosome 22. BCR–
ABL1 is a diagnostic marker for CML. Detection of BCR–ABL1 fusion 
transcript in peripheral blood is used to confirm CML diagnosis, and to 
monitor cytogenetic remission and residual disease (Kumar-Sinha, 
Tomlins et al. 2008) 
 
In 2005, Petrovics et al (Petrovics G 2005) reported frequent 
overexpression of the ETS transcription factor ERG mRNA in clinical 
prostate cancer (62% of 114 prostate cancer samples). Later that year, 
Tomlins et al (Tomlins SA 2005) showed that ERG overexpression in 
prostate cancer was caused by a recurrent gene fusion of the TMPRSS2 
gene to the ERG and ETV1 genes. The microarray-expression profiles 
studies revealed strong outlier profiles for two ETS family transcription 
factors genes, ERG and ETV1 (Tomlins SA 2005) 
 
Since the discovery of TMPRSS2:ERG and TMPRSS2:ETV1 fusions, 
subsequent studies have identified additional transcripts from the fusion of 
TMPRSS2 and the ETS variants ETV4, ETV5 and ELK4. These 
transcription factor gene family members have been identified as common 
events in prostate cancer and highlight the importance of fusion genes in 
the development and progression of epithelial cancers. TMPRSS2:ERG 
gene fusion, which accounts for approximately 85% of all the ETS fusion 
samples, has been reported in more than 50% of early- and mid-stage 
localised and hormone refractory metastatic prostate cancers (Mosquera, 
Perner et al. 2008) 
 
Recently published data in our group showed that TMPRSS2: ERG occurs 
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less frequently in Chinese prostate cancer samples than in western 
prostate cancer samples. We found a significant reduction in the frequency 
of certain somatic genomic changes that are commonly found in western 
prostate cancers, including the 21q22.2-22.3 deletions, which involve the 
TMPRSS2:ERG fusion gene, and 10q deletion, which causes PTEN 
inactivation (Mao, Yu et al. 2010, Xue, Mao et al. 2012). Low 
TMPRSS2:ERG frequency has been found in other Asian populations 
(Chen, Ren et al. 2014, Kelly, Kong et al. 2015). 
 
1.5.4 EPIGENETIC CHANGES IN HUMAN PROSTATE 
CANCER 
 
Epigenetic is the study of heritable changes in gene expression that are 
not explained by changes in DNA sequences. Three important 
mechanisms lead to epigenetic events: DNA methylation, histone 
modification, and RNA-associated silencing. DNA methylation and histone 
modification play an essential role in many molecular and cellular 
alterations associated with the development and progression of prostate 
cancer (Kim and Yu 2012). 
 
Aberrant epigenetic events such as DNA hypermethylation, DNA 
hypomethylation and histone acetylation have been observed in prostate 
cancer (Vasiljević, Wu et al. 2011, Kim and Yu 2012). The most common 
epigenetic change in prostate cancer is hypermethylation of glutathione-
S-transferase proteins (GSTPs) occurring in approximately 70% of PIN 
lesions and in the majority (>90%) of prostate carcinomas but not in normal 
prostate tissue and benign prostatic hyperplasia. Abnormal gene 
methylation has been associated with poor clinical outcomes in patients 
with prostate cancer and it may serve as a potentially useful tool for 
disease diagnosis and prognosis (Carmen Jero´nimo 2011).  A recent 
report showed that the DNA promoter hypomethylation of CD147 may be 
one of the regulatory mechanisms involved in the cancer-related 
overexpression of CD147 and may play a crucial role in the 
tumourigenesis of prostate cancer (Liang, Mo et al. 2015). 
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Another common epigenetic change in prostate cancer is RASSF1A, 
located at 3p21.3, which encodes a protein similar to the RAS effector 
proteins. In prostate cancer, RASSF1A gene silencing is observed in over 
70% of cases (Nelson, De Marzo et al. 2009). Silencing of the RASSF1A 
promoter through methylation is associated with advanced grade prostatic 
tumours, suggesting a correlation between loss of RASSF1A expression 
and tumour prognosis (Karishma S Amin 2012). Moreover, large numbers 
of PIN samples show RASSF1A promoter hypermethylation (Li L 2004).  
Table 1.2 summarises other genes affected by epigenetic changes in 
prostate cancer. 
 
      Table 1.2 List of genes affected by epigenetic changes in prostate. 
Epigenetic 
aberration 
 
Gene Function 
DNA hypermethylation  
 
AR, ESR1, ESR2,  
CCND2, CDKN2A  
APC, RASSF1, CDH1,  
CDH13, CDH1, CD44 
GSTP1, MGMT 
Hormone signalling 
Cell cycle control 
Tumour invasion 
Cell Adhesion 
Repair of DNA 
damage 
DNA hypomethylation  CAGE, HPSE, PLAU  
Histone methylation  GSTP1, PSA  
      Adapted from (Albany, Alva et al. 2011). 
1.5.5 TUMOUR SUPPRESSOR GENES INVOLVED IN 
PROSTRATE CANCER 
 
The growth of cells has to be controlled by many external and intrinsic 
signals to maintain a steady state (homeostasis). Failure of growth 
inhibition is one of the fundamental alterations in the process of 
carcinogenesis. The proteins that prevent the cell proliferation are the 
products of tumour suppressor genes (TSG) (Vogelstein, Papadopoulos 
et al. 2013).  TSGs refer to genes whose loss of function results in the 
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promotion of malignancy. They normally function as negative regulators of 
growth or other functions that may affect invasive and metastatic potential, 
such as cell adhesion and regulation of protein activity (Hanahan and 
Weinberg 2011, Logtenberg and Boonstra 2013).  
 
According to Knudson’s “two-hit” theory of TSG inactivation, the first hit is 
usually a point mutation or submicroscopic deletion in the first allele, 
followed by the second hit that affects the second allele (Knudson 2001). 
The second hit may result from different genetic mechanisms, such as the 
loss of the whole chromosome by mitotic non-disjunction, chromosomal 
translocation followed by the loss of a part of the chromosome harboring 
the TSG, mitotic recombination and subsequent selection, or deletion of 
the segment that harbors the TSG (Devilee, Cleton-Jansen et al. 2001). 
Consequently, in these examples, the second hit generates the loss of 
heterozygosity (LOH) in a chromosomal segment spanning the TSG, 
which can be used as a tool for mapping TSGs by using polymorphic loci 
in the region (Figure 1.6). 
 
 
Figure 1.6 Knudson’s two-hit hypothesis for tumourigenesis involving a 
tumour suppressor gene (TSG).  
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In prostate cancer, the series of genetic events underlying tumourigenesis 
is still poorly defined but inactivation of multiple tumour suppressor genes 
appears to be a common genetic alteration (Barbieri, Bangma et al. 2013). 
 
One of the most common chromosomal deletions is the loss of 8p region, 
which harbours the gene NKX3.1 (Eeles, Kote-Jarai et al. 2009, Gu and 
Brothman 2011). The 8p deletion was found in the HGPIN stage of 
prostate cancer which is considered to be a premalignant stage of prostate 
cancer (Dong 2006).  About 40% of prostate carcinomas involved the loss 
of 8p according to CGH studies. At least two minimally deleted regions, 
8p21 and 8p22, have been identified, suggesting that several tumour 
suppressor genes may be located at 8p (Abate-Shen, Shen et al. 2008).   
 
Another frequently deleted chromosomal region in prostate cancer is the 
10q23 where the well-known tumour suppressor gene PTEN is located.  
Early studies using the loss of heterozygosity analyses estimated that 35–
58% of 10q deletions in advanced prostate cancers include PTEN 
(Yoshimoto, Ludkovski et al. 2012). Studies revealed that PTEN loss also 
frequently occurs in HGPIN (Yoshimoto, Cutz et al. 2006, Luchman, 
Benediktsson et al. 2008), suggesting that PTEN mutation is an early 
event in prostate carcinogenesis and may have an important role in cancer 
initiation (Mao, Yu et al. 2010, Boyd, Mao et al. 2012).   
 
The loss of 13q has been associated with high-grade or metastatic 
tumours where the RB1 gene is located. The loss of RB1 gene on 13q14.2 
is reported in approximately one-third of localized prostate cancers 
(Williams, Greer et al. 2014).  
 
Deletion of 6q is not only frequently found in prostate cancer but also has 
been implicated in breast, ovarian, urothelial melanoma-cell leukemia, 
pancreatic and small cell lung cancers. Most of these studies showed 
multiple regions of loss at 6q (Verhagen, Hermans et al. 2002, Lane, 
Strefford et al. 2007, Mao, Yu et al. 2010, Shan, Ambroisine et al. 2010, 
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Wu, Shi et al. 2012). Deletion of 6q14–q22 is one of the most common in 
many cancers including prostate cancer. SNORD50A gene located at 
6q14 was found to have a 2-bp deletion in 10% of a sporadic prostate 
cancer (Dong, Rodriguez et al. 2008). This gene was found 
transcriptionally downregulated in prostate cancer cells.   
 
Although 6q15 deletion has been widely recognised as a frequent event in 
prostate cancer (Liu, Chang et al. 2007), the target TSG(s) located in this 
region are yet to be identified. Liu et al. (Liu, Chang et al. 2007) applied 
SNP array analysis on 55 matched prostate cancer and non-malignant 
tissue samples and identified a minimum overlapped deletion region 
between 90,3493 and 91,310 Kb (817 Kb), which was shared by 20 
tumours. Five genes (MAP3K, CASP8A2, CX62, MDN1 and BACH2) were 
located in this small region. Further analysis of MAP3K7 revealed the 
correlation of its down regulation with high-grade prostate cancer (Liu, 
Chang et al. 2007). Carmer et al described MAP3K7 as a prostate cancer 
putative TSG that encodes TGF-β activated kinase-1 (Tak1), which has 
an important role in proliferation and invasion. They showed that Tak1 
expression was progressively lost with increasing Gleason grade, both 
within each and across all cancers (Wu, Shi et al. 2012).   
 
Cannabinoid receptor 1 (CNR1) is one of the two-cannabinoid receptors 
responsible for the psychoactive effect of marijuana. CNR1 is located at 
the 6q15-deleted region. Several reports have demonstrated that CNR1 
expression was silenced in human cancer including colorectal (Bedoya, 
Rubio et al. 2009) and esophageal (Bedoya, Meneu et al. 2009). However, 
noetailed analysis of this gene had previously been reported regarding the 
role in prostate tumourigenesis.  
 
 
 
Table 1.3 Deleted chromosomal regions and genes in prostate cancer  
Location Gene Function Status in prostate cancer References 
1p36 EPHB2 Tumour suppressor gene encoding a 
receptor tyrosine kinase 
Frameshift mutations (Huusko, Ponciano-
Jackson et al. 2004) 
6q14-15 SNORD50A Guide RNAa in the site specific ribose 
methylation of preribosomal RNA 
Deletion (Dong, Rodriguez et al. 
2008) 
6q15 MAP3K7/TAK1 Putative tumour suppressor gene encodes 
TGF-b activated kinase-1 (Tak1), role in 
proliferation and invasion 
Deletion (Liu, Chang et al. 2007) 
7q36 EZH2 Histone methyltransferase involved in 
maintaining the transcriptional -Repressive 
state 
Deletions, missense /frameshift 
mutations 
(Carmen Jero´nimo 2011) 
8p NKX3.1 Tumour suppressor regulating proliferation 
Of glandular epithelium  
Chromosome deletion (Bethel, Faith et al. 2006) 
10p15 KLF6 Zing finger transcription factor associated 
with cell proliferation.  
LOH and mutation (Narla, Heath et al. 2001) 
10q21 ANXA7 Ca2+-activated GTPase Chromosomal loss (Srivastava, Torosyan et al. 
2007) 
10p23 PTEN Tumour suppressor by negatively regulating 
AKT/PKB signalling pathway 
Deletion/ frameshift mutations (Li, Yen et al. 1997) 
12p12-13 CDKN1B 
(p27/Kip) 
Inhibit cyclin-dependent kinases and block 
cell proliferation. 
Deletion (Dong 2001) 
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Location Gene Function Status in prostate cancer References 
13q21 KLF5 Transcription factor associated with cell 
proliferation, differentiation and 
carcinogenesis  
Hemizygous deletion 
 
(Chen, Bhalala et al. 2003) 
16q22 ATBF1 Control cell proliferations, up 
regulation of p53 
Deletion/ 
frameshift mutations 
(Sun, Frierson et al. 2005) 
17p13 P53 
 
Tumour suppressor gene involved in the 
induction of cell cycle arrest, apoptosis, DNA 
repair 
Single point mutations (Taylor, Schultz et al. 2010) 
22q12 CHEK2 Regulate p53 in the DNA-damage-
signalling pathway. 
Truncation/ frameshift mutations, 
Deletion 
(Dong, Wang et al. 2003) 
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1.5.5.1 Tumour suppressor gene therapy for cancer 
 
Because tumour suppressor genes are often mutated, deleted or 
epigenetically silenced in cancer cells, effective anticancer therapies that 
target tumour suppressor genes must restore the normal functions of 
tumour suppressor genes. Identifications of oncogenes and tumour 
suppressors have played a pivotal role in enhancing our understanding of 
the unique biology of cancer, as well as aiding in the development of new 
cancer therapies. Therefore, gene therapies have been developed for 
cancers, where the loss of tumour suppressor functions is compensated 
via ectopic expression of wild-type genes. Alternatively, numerous 
inhibitors have been identified to either disrupt interactions between 
tumour suppressor genes and their negative regulators, or induce 
synthetic lethality, although the effectiveness of these inhibitors needs to 
be validated with solid clinical data. A tremendous amount of financial 
resources and manpower have been invested to understand the 
malignant nature of cancer in hopes of finding a cure. 
 
Drug treatment for cancer depends on the notion that mutations that give 
rise to the development of cancer also bring about a weakness that can 
be exploited therapeutically (Weinstein et al. 2013). These genetic 
alterations consist of gain-of-function mutations in which genes are 
amplified, translocated, or mutated, and loss-of-function mutations in 
which gene function is compromised by missense mutation or deletion. 
The former group of mutations has been the subject of intense focus by 
the pharmaceutical industry for the development of targeted cancer drugs. 
These efforts have resulted in a number of cancer drugs that target 
activated driver oncogenes, such as HER2, BCR-ABL, EGFR, and 
BRAF (Pagliarini et al. 2015). These drugs target signaling proteins that 
are aberrantly activated as a direct consequence of an oncogenic 
mutation, and hence their inhibition is detrimental to the cancers 
(Weinstein 2002).  
 
From a drug discovery perspective, the loss-of-function mutations are 
much harder to tackle, and the same is true for a number of activated 
oncogenes that have proven to be more or less undruggable, such as the 
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MYC transcription factor and the RAS proteins. Synthetic lethality 
provides the possibility of drugging undruggable targets indirectly 
(Prahallad & Bernards 2015). 
 
Synthetic lethality refers to a genetic principle in which the combination of 
two genetic disorders is fatal, while in each individual this is not the case. 
Such redundancies in signaling ensure that cells often survive when a 
single gene is inhibited because another gene can compensate for it 
functionally. However, the inhibition of these compensatory genes can 
induce cell death, in particular, when the first gene is mutated but does 
not affect the growth of cells lacking that mutation. When the inhibition of 
a signaling pathway leads to the biochemical activation of a second 
pathway that mediates survival, the simultaneous inhibition of both 
pathways can cause cell death due to synthetic lethal interaction (Blomen 
et al. 2015).  
 
There are two important aspects to synthetic lethality in the context of 
cancer drug development. Firstly, the genes that are synthetic lethal with 
oncogenic driver mutations are not necessarily mutated in cancer. Thus, 
the exploitation of synthetic lethal interactions in cancer cells can 
significantly expand the number of oncology drug targets. Secondly, the 
effects of drugs that have no (or limited) clinical activity as single agents 
could be greatly be effective when used in combination with a second drug 
that is synthetic lethal with the first drug. For example, inherited loss-of-
function mutations in BRCA1 and BRCA2 genes predispose to tumour of, 
primarily, the breast and ovaries.  Because BRCA gene products have a 
role in homologous recombination (HR) during repair of double strand 
DNA breaks, it was hybothesized that inhibiting additional DNA repair 
system could be synthetic lethal with the loss of BRCA gene function 
(Farmer et al. 2005).  
 
Certainly, inhibitors of the PARP enzyme which has roles in excision 
repair, were found to be strongly synthetic lethal with mutations in BRCA1 
and BRCA2 genes.   Following encouraging clinical studies in 2009 by 
Fong et al., the use of the PARP inhibitor olaparib was approved for 
treating BRCA-mutated ovarian cancer in late 2014.  However, quite a few 
clinical trials are ongoing that take advantage of synthetic lethal 
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interactions between BRAF and EGFR inhibitors identified in the 
laboratory including National Trial numbers 01719380, 01750918, and 
01791309. There are also multiple trials based on the synthetic lethal 
interaction between MEK inhibitors and panHER inhibitors in KRAS-
mutant cancers, including National Clinical Trial numbers 02039336, 
02230553, and 02450656 (Bernards 2012).  
 
Another example where the function of the p53 tumor suppressor protein 
is lost in almost all cancers, either through mutation of the TP53 gene or 
by alterations in components that control p53 activity. Given the role of 
p53 in response to cellular stress, DNA damage, and DNA repair, the loss 
of p53 creates vulnerabilities that can be explored as targets in the context 
of synthetic lethality. Synthetic lethal interactions have been found 
between p53 and ATM/CHK2 (inhibitor/kinases respectively) pathway to 
maintain the genomic integrity and DNA damage response (Fedier et al. 
2003).  
 
Similar to TP53, the RB1 pathway is inactivated in most of the human 
cancers, either through mutations of the RB1 gene or by alterations in the 
pathways that control pRB activation including the loss of expression 
(encoding p16), overexpression or amplification of D-type cyclins. , a 
number of synthetic lethal interactions have been found between RB1and 
.   
 
Hence, once we understand the sequence by which new vulnerabilities 
arise in cancer, we may be able to treat cancer sequentially with therapies 
that are at least as effective as, or even more effective than the first-line 
therapy. 
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1.6 CANNABINOID RECEPTOR 1 GENE (CNR1) AS A 
POTENTIAL TSG IN PROSTATE CANCER 
 
1.6.1 THE HISTORY OF CANNABINOID DISCOVERY: 
 
Human beings have used cannabis for thousands of years. The first 
archeological discovery is from China around 4000 BC. In 2737 BC, Shen 
Nung, the Emperor of China, was the first known to describe the properties 
and therapeutic potential of cannabis (Ware, Doyle et al. 2003).  From the 
hemp plant Cannabis sativa more than 400 different chemicals can be 
extracted, and more than 80 are grouped under the name cannabinoids or 
phytocannabinoids. The main psychoactive compound is ∆9-
tetrahydrocannabinol (THC). In 1964 the chemical structure of THC was 
reported, and in 1988, the first demonstration of cannabinoid binding sites 
in the rat brain was published (Gaoni and Mechoulam 1964, Devane, 
Dysarz et al. 1988). After the discovery of the binding sites, Matsuda and 
coworkers published the DNA encoding a G protein-coupled receptor, 
which was activated by the cannabinoids and thereby called cannabinoid 
receptor type 1 (CNR1) (Matsuda, Lolait et al. 1990). Later, a second G-
protein coupled cannabinoid receptor, cannabinoid receptor type 2 
(CNR2), was cloned (Munro, Thomas et al. 1993). In addition, other 
receptors, including the transient receptor potential cation channel 
subfamily V member 1 (TRPV1) and certain orphan G protein- coupled 
receptors, GPR55, GPR119 and GPR18, have been proposed to act as 
endocannabinoid receptors (Pertwee, Howlett et al. 2010). 
 
There are three types of cannabinoids (Figure 1.7), plant-derived 
cannabinoids such as THC, synthetic cannabinoids such as WIN-55-212-
2, JWH-13 and methanandamide (MET) and endogenous cannabinoids 
also known as endocannabinoids such as anandamide (ANA) and 2-
Arachidonoylglycerol (2-AG) that are produced in the human bodies. The 
cloning of the receptors led to the identification of the endogenous ligands, 
called endocannabinoids. The first to be discovered was AEA (Devane, 
Hanus et al. 1992) and thereafter 2-AG (Mechoulam, Ben-Shabat et al. 
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1995). Other substances have been proposed to be endocannabinoids, 
such as 2- arachidonyl-glycerol ether (noladin ether) (Hanus, Abu-Lafi et 
al. 2001), and virodhamine (Porter, Sauer et al. 2002) but these have not 
yet been formally accepted as endocannabinoids. These derivatives have 
drawn renewed attention because of their diverse pharmacologic activities 
such as growth inhibition, anti-inflammatory effects, tumour regression, 
targeting angiogenesis and cell migration (Sarfaraz, Afaq et al. 2006, 
Alexander, Smith et al. 2009, Díaz-Laviada 2011, Guindon and Hohmann 
2011, Velasco, Sanchez et al. 2012).  
 
  
Figure 1.7 The chemical structure of some cannabinoids. There 
are three types of cannabinoids, the phytocannabinoids that are 
derived from marijuana, synthetic cannabinoids and the endogenous 
cannabinoids. Adapted and modified from The Endocannabinoid 
system (Javid, Phillips et al. 2016). 
 
The endocannabinoid system is a neuromodulatory system comprised by 
endogenous ligands (N-anachidonoylethonalamine, AEA, anandaminde, 
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and 2-arachidonoylglycerol, 2-AG), which are lipid molecules that 
generated in the cell membrane from phospholipid precursors (Figure 1.8). 
These endocannabinoids are synthesized on demand at the site of action 
in response to specific signals, such as an increase intracellular calcium 
or activation of phospholipase C-β by Gq/11 metatropic receptors 
(Basavarajappa, Yalamanchili et al. 2008). Degradation of the 
endocannabinoids occurs locally by fatty-acid amide hydrolase (FAAH) 
and monoacylglycerol lipase (MAGL) (Hermanson and Marnett 2011) 
(Marnett et al 2011). It has been reported that the uptake of 
endocannabinoids from the extracellular space occurs by facilitated 
diffusion mediated by selective transporter (Fowler 2013).    
 
 
Figure 1.8 Endocannabinoids are long chain polyunsaturated fatty acid.  
Anandamide and 2-arachidonoyl glycerol (2-AG) are produced from the 
phospholipids through pathways that use NAPE-PLD (N-
acylphosphatidylethanolamine-selective phospholipase D) and DAG 
(Diacylglycerol) lipase synthesis enzymes.  They rapidly metabolized and 
hydrolyzed by FAAH (Fatty Acid Amide Hydrolase) and MAGL (Monoacyl lipase) 
enzymes.  Adapted from (Di Marzo, Melck et al.). 
 
The specific cannabinoid receptors are expressed in numerous cell types 
in the body and modulate many biological functions. In the central nerve 
system (CNS) the endocannabinoid system participates in the control of 
motor coordination, memory, learning, appetite and pain. Most neural 
functions controlled by endocannabinoid signalling depend on the neural 
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CNR1). This receptor is the main mediator of the inhibition of 
neurotransmission by retrograde signalling mediated by 
endocannabinoids (Hermanson and Marnett 2011). 
 
1.6.2 CANNABINOID RECEPTOR 1 
 
Cannabinoid receptor type 1 (CNR1), also named CB1, is a member of 
the G protein-coupled receptor superfamily possessing seven 
transmembrane domains with 68% amino acid homology within the 
transmembrane domains (Munro, Thomas et al. 1993). It is highly 
expressed in brain regions such as hippocampus, basal ganglia, and 
cerebellum (Demuth and Molleman 2006) and also expressed in 
peripheral tissues including eye, spleen, leucocytes and uterus, prostate 
(Bifulco, Laezza et al. 2006), and skeletal muscle (Eckardt, Sell et al. 
2009). Further studies have shown that CNR1 is mainly expressed 
presynaptically on axon terminals (Katona et al., 2001). The distribution of 
the cannabinoid receptors appears well conserved between many 
vertebrate species. 
 
The human CNR1 gene (hCNR1, CB1) is located on chromosome 6 locus 
q15 (Onaivi, Leonard et al. 2002) Figure 1.9A.  Exon 4 contains the entire 
protein coding regions of human CNR1, while the three non-coding exons, 
named exon 1, 2, and 3 are located 5’ to the protein-coding region and are 
separated by three introns (introns 1, 2, and 3) (Zhang, Ishiguro et al. 
2004). Alternative splicing of the 5’-UTR of the hCNR1 gene results in the 
formation of six hCNR1 transcripts with variable 5’ UTR, termed variants 
1, 2, 3, 4, 5 and 6 (Figure 1.9B). Each of these variants has a unique 5'- 
UTR, transcription initiation site and distribution pattern in the human brain 
and peripheral tissues (Miller and Devi 2011).  
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Figure 1.9 (A) The CNR1 genomic location: locus according to 
Ensemble. (B) Schematic diagram of the human CNR1 gene and 
mRNA variants. Six splice variants of the 5’UTR of hCNR1 (hCB1) gene 
have been identified. Blue Boxes indicate exons, while interconnecting 
blue lines indicate introns. The coding region is located in exon 4, while the 
non-coding regions are exon 1,2 and 3. Adapted and modified from 
(Zhang, Ishiguro et al. 2004, Laprairie, Kelly et al. 2012)  
 
The translation of the hCNR1 starts at the first ATG located at the 5’ end 
of un-spliced exon 4 and produces a polypeptide chain of 472 amino acids. 
This chain forms an exceptionally long extracellular N-terminal tail of 116 
amino acids connected to seven transmembrane domains and ended by 
an intracellular carboxyl terminus (The National Centre for Biotechnology 
Information, NCBI;(Zhang, Ishiguro et al. 2004) (Figure 1.10). Alternative 
splicing of hCNR1 within the coding region has been identified, hCNR1a 
(411 amino acids; (Shire, Carillon et al. 1995, Ryberg, Vu et al. 2005). 
Subsequently, the second hCNR1 splice variant mRNA, hCNR1b (439 
amino acids) has been identified (Shire, Carillon et al. 1995, Ryberg, Vu 
et al. 2005). The hCNR1a transcript lacks an internal segment of 167 base 
pairs within the sequence encoding the N-terminal tail of the receptor. 
Translation of the hCNR1a starts at the second ATG located at the 5’ end 
of exon 4. The resulting receptor is shorter than hCNR1 by 61 amino acids 
at its N-terminus. In addition, the first 28 amino acids of the N-terminus are 
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totally different to hCNR1, while the remaining 27 amino acids are similar 
to the hCNR1. hCNR1a also lacks two out of three glycosylation sites and 
resulted in a more hydrophobic receptor. hCNR1b transcript is missing an 
internal segment of 99 base pairs resulting in a protein lacking 33 amino 
acids at the N-terminus tail. However, unlike hCNR1a, translation of 
hCNR1b starts at the first ATG located in exon 4 as hCNR1(Shire, Carillon 
et al. 1995, Zhang, Ishiguro et al. 2004, Ryberg, Vu et al. 2005) (Figure 
1.10& 1.11).  
 
The existence of these isomers on hCNR1 has raised questions 
concerning their functional variation.  One of the reports characterized the 
hCNR1a splice variant and found that the binding of THC and WIN5521-2 
agonists was slightly higher than binding to hCNR1 or hCNR1b, when the 
isoforms were stably expressed in Chinese hamster Ovary (CHO) cells 
(Rinaldi-Carmona, Calandra et al. 1996). Activation of hCNR1a by CNR1 
agonists was able to inhibit cAMP and increase MAP kinase 
phosphorylation compare to the full-length hCNR1.  In contrast, it has been 
reported that hCNR1a and hCNR1b mRNAs are translated and expressed 
as functional receptors in vivo. They found that hCNR1; hCNR1a were 
expressed at a similar level. However, hCNR1b were expressed at 2.5-
fold higher level than hCNR1 in HEK293 cells (Ryberg, Vu et al. 2005). In 
addition, they found that all the hCNR1 were expressed to a similar degree 
at the membrane in HEK293 cells however, hCNR1a and hCNR1b 
displayed less affinity when they treated with the endogenous cannabinoid 
ligands (anandamide) (Ryberg, Vu et al. 2005). A more recent study 
published by Straiker’s team, that hCNR1 variants were all robustly 
expressed in cultured hippocampal neurons (Straiker, Wager-Miller et al. 
2012). Given difference in general studies, further investigation is required 
to understand the signalling properties of the hCNR1 variants.    
 
 56 
 
Figure 1.10 Amino acids sequence alignment of the human CNR1 and its 
splice variants CNR1a (CB1a) and CNR1b (CB1b), Modified from Kofalvi 
2008. N-terminus of the hCNR1 consists of 116 amino acids, indicated in bold. 
The hCNR1a uses a different initiation coding leading to a frameshift from the 
reading frame of hCNR1, with only 55 amino acids N-terminal tail that differs 
from hCNR1 in the first 28 amino acids (highlighted in gray). The hCNR1b 
lacks an internal segment of 33 amino acids in a N-terminal tail. Glycosylation 
sites are indicated in red, - represent missing nucleotides. Adapted and 
modified from Laprairie, Kelly et al. 2012. 
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Figure 1.11 Schematic illustration of the amino acid sequences 
of hCNR1 (hCB1), hCNR1b (hCB1b) and hCNR1a (hCB1a). adapted 
and modified from Cayman chemical company 
(https://www.caymanchem.com/Home). 
 
1.6.3 CANNABINOID RECEPTORS SIGNALING 
PATHWAYS 
 
The majority of CNR receptors are coupled to G proteins, mostly of the Gi/o 
type. As a consequence of this special coupling, activation of cannabinoid 
receptors, CNR1 and CNR2 primarily leads to the inhibition of adenylyl 
cyclase and reductions in cyclic AMP accumulation in most tissues and 
models. The major mediators of CNR1 are the G proteins of the Gi/o family 
(Turu and Hunyady 2010), which inhibit adenylyl cyclases in most tissues 
and cells, and regulate ion channels, including calcium and potassium ion 
channels (Demuth and Molleman 2006, Basavarajappa, Yalamanchili et 
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al. 2008, Guindon and Hohmann 2011, Straiker, Wager-Miller et al. 2012).  
 
CNRs produce a number of different intracellular signaling responses that 
are dependent upon the cell type and situation investigated. One of the 
signaling pathways is Retrograde signaling in the brain. In glutamatergic 
synapses, the release of glutamate results in activation of postsynaptic 
ionotropic glutamate and the endocannabinoid system is not engaged. 
However, excessive glutamate signaling leads to activation of 
metabotropic receptors that are localized postsynaptically. Activation of 
these receptors leads to the synthesis of endocannabinoids, which then 
diffuse back across the synapse and bind to CNR1 receptors on 
presynaptic terminals of neurons, where they inhibit release of glutamate. 
This is achieved as a result of the inhibition of voltage-activated Ca2+ 
channels, and activation of inwardly rectifying K+ channel (Castillo, Younts 
et al. 2012). GABAergic neurons are also modulated by 
endocannabinoids, and retrograde endocannabinoid signaling has been 
demonstrated to be involved in electrophysiological processes such as 
depolarization-induced suppression of excitation, depolarization-induced 
suppression of inhibition, and long-term potentiation. In most cases, the 
use of selective inhibitors of endocannabinoid inhibition and/or knockout 
mouse models have indicated that 2-AG is the main endocannabinoid 
involved in these processes (Castillo, Younts et al. 2012) 
 
Furthermore, cannabinoid receptors have also been shown to modulate 
other several signalling pathways that are more directly involved in the 
control of cell proliferation and survival, including extracellular signal-
regulated kinase (ERK) (Bouaboula et al., 1995), c-Jun N-terminal kinase 
(JNK) and p38 mitogen-activated protein kinase (MAPK) (Liu et al., 2000; 
Rueda et al., 2000), phosphatidylinositol 3-kinase (PI3K)/Akt (Go´mez del 
Pulgar et al., 2000), focal adhesion kinase (Derkinderen et al., 1996), and 
maybe the ceramide pathway (Guzma´n et al., 2001) (Figure 1.12). 
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Figure 1.12 Signalling pathways coupled to the CNR1 (CB1). 
Cannabinoids bind to specific receptors. The Gi/o-protein-coupled CNR1 
(CB1) receptor signals to several different cellular pathways, including the 
adenylyl cyclase (AC), cAMP and protein kinase A (PKA) pathway; MAPK 
cascades (ERK, p38 MAPK); the Akt pathway; and a pathway for de 
novo synthesis of ceramide.  
 
1.6.4 CANNABINOID RECEPTOR 1 AND PROSTATE 
CANCER 
 
In a healthy prostate, CNR1 is expressed in two regions- the 
parasympathetic nerves where it modulates contraction of the prostate 
duct and in the epithelial cells of the prostate duct, where it regulate 
prostate secretion (Díaz-Laviada 2011). Other reports described the 
immunolocalization of CNR1 is primarily found within the epithelial lining 
of the prostatic duct, epithelial grandular and neuroendocrine cells with 
little or no staining of the stroma (Ruiz-Llorente, Sanchez et al. 2003, 
Chung, Hammarsten et al. 2009, Czifra, Varga et al. 2009). These findings 
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indicate that CNR1 is highly expressed in the prostate epithelium.  CNR1 
have been localised in the human prostate as well as in the biopsy from 
patients with BPH and prostate cancer 
 
There is evidence indicating that cannabinoid receptors (CNR1 and 
CNR2) could be an important target for the treatment of prostate cancer 
(Idris 2012, Van Dross, Soliman et al. 2013). Several studies have now 
evaluated the expression of CNR1 in different prostate cancer tissue/cell 
lines (Snchez, Snchez et al. 2003, Sarfaraz, Afaq et al. 2005, Sarfaraz, 
Afaq et al. 2006, Olea-Herrero, Vara et al. 2009, Sharma, Hudson et al. 
2014). Previous exon array analysis in our group showed that the 
cannabinoid receptor 1 (CNR1) gene, located in 6q15, was downregulated 
in all prostate cancer cell lines and clinical prostate cancer samples at the 
mRNA level compared to normal tissue (Shan 2010). Our group finding 
was supported by other reports published such as the expression of CNR1 
was down-regulated in human colorectal cancer (CRC) due to methylation 
of its promoter (Wang, Wang et al. 2008); mutation in the coding exon of 
CNR1 receptors was detected in oesophegal and colorectal cancers 
(Bedoya, Meneu et al. 2009, Bedoya, Rubio et al. 2009, Larrinaga, Begoaa 
et al. 2010, Meneu-Diaz, Bedoya et al. 2011); and CNR1 receptor was 
found to be down-regulated in Clear Cell Renal cell carcinoma using RT--
PCR and western blot (Larrinaga, Begoaa et al. 2010).   
 
Nevertheless, different observation also supported that, CNR1 was 
upregulated in prostatic adenocarcinoma tissues, and several cell lines 
including PC-3, DU-145, LNCaP, CWR22Rv1 and CA-HPV-10, CNR1 and 
CNR2 expression levels were higher, as compared with normal prostate 
epithelial cells (Sarfaraz, Afaq et al. 2005, Chung, Hammarsten et al. 
2009, Czifra, Varga et al. 2009, Brown, Cascio et al. 2010, Sharma, 
Hudson et al. 2014). These observations agreed with my findings where 
CNR1 was upregulated in prostate cancer cell lines including DU145, 
LNCaP, and 22RV1. Furthermore, an extensive study of 399 human 
prostate cancer samples revealed the expression level of CNR1 was 
considerably higher in prostate cancer tissues than in normal prostate 
tissues (Chung, Hammarsten et al. 2009). Other cancer types including 
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hepatocellular carcinoma (Xu, Liu et al. 2006) and pancreatic ductal 
adenocarcinoma showed an increased level of CNR1 expression in 
human pancreatic tumour cell lines as well as in biopsies of human 
pancreatic tumours, whereas in samples obtained from normal pancreatic 
tissue, mRNA levels for these receptors were very low or could not be 
detected (Carracedo, Gironella et al. 2006) 
 
Relatively large amount of data have accumulated during the last decade 
about the role of CNR1 receptors in tumour generation and progression. 
In many cases, these reports showed that levels of CNR1 are increased 
in cancers including prostate cancer, a situation that frequently correlates 
with tumour aggressiveness (Malfitano, Ciaglia et al. 2011) 
 
In prostate cancer, it was found that patients with a tumour with higher 
CNR1 expression had a significantly higher proportion of Gleason scores 
8–10, and metastases at diagnosis (Chung, Hammarsten et al. 2009). For 
269 cases, tumour CNR1 was measured for patients who only received 
palliative therapy at the end stages of the disease, allowing the influence 
of CNR1 upon the disease outcome to be determined. CNR1 in non-
malignant tissue was not associated with disease outcome. A tumour 
CNR1 score ⩾ 2 was associated with a significantly lower disease-specific 
survival indicating that a high tumour CNR1 score is associated with 
prostate cancer severity of the disease and poor prognosis (Chung, 
Hammarsten et al. 2009). In other types of cancer, Fowler et al, reported 
that the level of CNR1 receptor expression in colorectal cancer is 
associated with the tumour grade in a manner dependent upon the degree 
of CpG hypermethylation. They found that the high CNR1 is indicative of 
a poorer prognosis in stage II microsatellite stable tumour patients 
(Gustafsson, Palmqvist et al. 2011).  Furthermore, CNR1 receptor levels 
are also increased and correlate with disease severity in human epithelial 
ovarian tumours (Messalli, Grauso et al. 2014) and have been proposed 
to be a factor of bad prognosis following surgery in stage VI colorectal 
cancer  (Jung, Kang et al. 2013, Velasco, Hernández-Tiedra et al. 2015).  
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Despite the above-discussed conflicting data relative to the role of CNR1 
receptors in tumour progression, during the last two decades many reports 
have shown that in experimental models of different types of cancer, 
cannabinoid receptor agonists exerted antitumor effects. 
 
In prostate cancer, the treatment with cannabinoid receptor agonists, 
including R (+)-Methanandamide (MET) and WIN-55, 212-2, resulted in 
inhibition of cell growth in LNCaP and PC3 cells, and this was associated 
with inhibition of AKT and activation of ERK (Snchez, Snchez et al. 2003, 
Sarfaraz, Afaq et al. 2005, Sarfaraz, Afaq et al. 2006, Olea-Herrero, Vara 
et al. 2009). Data also showed that treatment of LNCaP prostate cancer 
cells with WIN-55, 212-2 (CNR1/2 agonist) results in a significant dose- 
and time-dependent decrease in cell viability and increased apoptosis with 
an arrest of the cells in the G0-G1 phase of the cell cycle; induction of p53 
and p27/KIP1 genes; down-regulation of cyclins D1, D2, E; decrease in 
the expression of cdk-2, -4, and -6 (Sarfaraz, Afaq et al. 2006). Also, 
cannabinoid receptor inhibition of  cell proliferation and invasion has also 
been associated with induction of p27kip and inhibition of cell cycle 
regulatory molecules, CDKs, and inhibition of VEGF expression in 
androgen-dependent cancer cells has been also reported (Bifulco, Laezza 
et al. 2006).  
 
The anti-proliferative and apoptotic effects of the endogenous cannabinoid 
ANA in LNCaP, DU145, and PC3 were also reported been mediated 
through down-regulation of epidermal growth factor receptor (EGFR) and 
accumulation of ceramide (Mimeault, Pommery et al. 2003).  Interestingly, 
the ANA analogue (R)- methanandamide was shown to have a mitogenic 
effect on LNCaP cells at very low doses (Snchez, Snchez et al. 2003).  
Apart from the inhibition of cell growth, the ligand of CNR1, endogenous 
2-arachidonoylglycerol (2-AG), has also been reported to inhibit invasion 
of prostate cancer cells (Ramer and Hinz 2008).  
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Several studies have evaluated the antitumor effect of CNR1 receptors in 
different cancers tissue/cell lines. For instance, in breast cancer, 
Anandamide (AEA) is important lipid ligands regulating cell proliferation, 
differentiation and apoptosis. It was reported that anandamide inhibits 
basal and nerve growth factor (NGF) induced proliferation of MCF-7 and 
EFM-19 cells in culture through CNR1 receptor and Δ9-THC inhibits 
17beta-estradiol-induced proliferation of MCF7 and MCF7-AR1 
cells (Melck, Petrocellis et al. 2000). Cell death by apoptosis is the result 
of cell cycle arrest. The analogue of anandamide, Met-F-AEA reduces 
MDA-MB-231 proliferation by arresting cells in the S phase of the cell cycle 
(Grimaldi, Pisanti et al. 2006). Furthermore, treating NSCLC cell lines 
(A549 and SW-1573) with CNR1/CNR2- agonists Win55, 212-2 
significantly attenuated the growth of cells. Also observed a significant 
reduction in focal adhesion complex, which plays an important role in 
migration, upon treatment with Win55, 212-2. In addition, CNR1 agonists 
Win55, 212-2, significantly inhibited in vivo tumour growth and lung 
metastasis (∼50%). These effects were receptor mediated, as pre-
treatment with CNR1/CNR2 antagonists abrogated CNR1/CNR2 agonist–
mediated effects on tumour growth and metastasis (Preet, Qamri et al. 
2011).  
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1.7 PREVIOUS WORK IN OUR TEAM AND RATIONALE 
FOR MY THESIS PROJECT 
 
In a previous study by Shan 2010, FISH analysis was performed on 68 
prostate cancer samples and six morphologically non-malignant prostate 
samples (Shan 2010). Thirteen of 28 (out of 68) prostate cancer samples 
(46%) were assessed as 6q15-deletion positive. The genes 
downregulated in the deletion region were examined using our Exon Array  
(Affymetrix Exon 1.0 ST) data of six prostate cancer cell lines (LNCaP, 
PC3, 22RV1, DU145, VCaP and MDA PCa 2b), one clinical prostate 
cancer sample (p127) and two BPH samples (p143 and p2) as a control. 
CNR1 on 6q15 was down-regulated in the six prostate cancer cell lines 
and one clinical prostate cancer sample. qRT-PCR analysis was applied 
to validate the down-regulation of this gene. Relative expression of CNR1 
gene measured by qRT-PCR was consistent with the Exon Array data, 
showing down-regulation in all prostate cancer cell lines and the clinical 
sample (p127) compared to the BPH samples. Followed by qRT-PCR 
validation of CNR1 gene in enlarged clinical prostate cancer samples 
(BPH and tumour samples), CNR1 was still found down-regulated in these 
samples. However, detection of the CNR1 protein failed. Although the 
antibody (Ab23703, Abcam) was demonstrated to be specific for 
immunohistochemistry IHC using BPH as a positive control, in western blot 
analysis using the same antibody was inconclusive.  
 
In contrast, several studies have shown that the CNR1 was highly 
expressed in prostate cancer cell lines at protein levels using western blot 
analysis (Sarfaraz, Afaq et al. 2005, Czifra, Varga et al. 2009).  Although 
it is possible that the differences generated between the studies were 
caused by different cell linages or cell culture conditions, such as different 
media and growth factors, the misrecognition of a nonspecific band at the 
expected size of the CNR1 protein might have been the main reasons for 
these conflicting results. The conflict between a potential tumour 
suppressor role and reported high expression of CNR1 may by due to the 
difficulty in accurate detection of CNR1 protein expression caused by the 
uncertainty of a specific and reliable antibody. Moreover, as CNR1 is 
 65 
located at 6q15, one of the most frequently deleted regions in prostate 
cancer; DNA mutation or methylation may reduce the receptor activity. 
Also, deregulation in downstream signalling pathways in some of the 
patient samples may have caused the reduction of receptor activity.   
In light of this and the previous findings in our laboratory, an investigation 
was taken into the hypothesis that CNR1 is a prostate cancer tumour 
suppressor.   
 
 
 
 66 
1.8 AIMS OF THIS THESIS 
 
I aimed to investigate whether CNR1 could act as a TSG in prostate cancer 
by characterising its status in prostate cancer cell lines and clinical 
samples and investigating its functional roles. 
The objectives of this project were: 
• Investigate the expression of CNR1 in prostate cancer cell lines 
(22RV1, LNCaP, DU145, PC3, and VCaP) and immortalised 
prostate epithelial cell lines (PNT1a and PNT2) at mRNA and 
protein levels 
• Evaluate the antibodies to select the most reliable one for further 
determination of CNR1 expression levels, using different 
approaches for CNR1 knockdown by siRNA silencing and 
glycosylation inhibitors 
• Identify any mutations in the CNR1 gene using Next Generation 
Sequencing analysis and if genomic polymorphism in the gene 
associated with prostate cancer risk. Analyse the function of CNR1 
by overexpression and knockdown of this gene in relevant  
prostate (cancer) cell lines using MTS assay, colony formation 
assay and migration and invasion assays 
• Determine the therapeutic potential of cannabinoid analogues 
such as HU210 in treating prostate cancer and using CNR1 protein 
expression as a biomarker   
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2 MATERIAL AND METHODS  
   
2.1 CELL LINES 
 
Five prostate cancer cell lines, including 22RV1, LNCaP, DU145, PC3 and 
VCaP (obtained from ATCC), two SV40-immortalized prostate epithelial 
cell lines PNT1a and PNT2, (obtained from Norman Maitland and Colin 
Cooper, respectively), and normal prostate epithelial cells PrEC (obtained 
from Lonza), were selected for this study. All cells were tested and 
authenticated in August 2010, using the ABI AmpF/STR identifier kit. Table 
4 describes the cell type, PSA and AR status of each cell line.  
 
Table 2.1 Human prostate cell lines 
Cell line Cell type PSA status AR status 
22RV1 Human prostate carcinoma 
epithelial 
pos wt/mt active 
LNCaP Human prostate carcinoma pos mt active 
DU145 Human prostate carcinoma neg neg 
PC3 Human prostate carcinoma neg neg 
PNT1a Immortalized prostate epithelia wt wt 
PNT2 Immortalized prostate epithelia wt wt 
PrEC Normal prostate epithelia wt wt 
AR, and PSA expression status: pos: positive; neg: negative; wt: wild type; mt: 
mutant.  
 
 
 
  2.2 CELL CULTURE 
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All cells were stored in liquid nitrogen in 10% Dimethyl Sulfoxide (DMSO) 
(Sigma-Aldrich), 20% Foetal Calf Serum (FCS) (Life Technology), and 
70% RPMI (Cancer Research UK) or Dulbecco’s DMEM media (Cancer 
Research UK). All cell lines were cultured in RPMI or DMEM media 
supplemented with 10% FCS and 1% Penicillin/Streptomycin (100 
units/ml). Cells were then pelleted by centrifugation at 1200 rpm for 5 min, 
the supernatant was discarded and the cell pellet was re-suspended in 5 
mL of culture medium. Cell suspensions were maintained in T75 culture 
flasks and incubated at 37°C in humidified atmosphere with 5% CO2.   
 
The cells were grown in tissue culture flasks and the media renewed every 
72 h of incubation. When cells were 80% confluent, they were sub-cultured 
by adding 1x Trypsin-Ethylenediaminetetraacetic Acid (Trypsin-EDTA) 
into the flask without the culture medium and incubating at 37°C for 5 min. 
Next, 5 ml RPMI/10%FCS media was added to the flasks to deactivate the 
trypsin. Cell suspensions were then collected in 50ml tubes and 
centrifuged at 1200 rpm for 5 min. The supernatants were decanted and 
the cell pellet was re-suspended in pre-warmed fresh 10% FCS media, 
transferred to new flasks and incubated at 37°C with 5% CO2 for further 
culture.  
 
2.3 TISSUES AND BLOOD SAMPLES   
  
2.3.1 Formalin-fixed paraffin embedded     (FFPE) 
clinical samples 
 
73 prostate cancer samples were collected from Bart the London hospital 
by the Orchid tissue bank.  All samples were formalin fixed and paraffin 
embedded after removed from the patients. The collection of these 
specimens was approved by the Local Ethical Committee.  
 
2.3.2 Blood samples from prostate cancer patients  
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13 blood samples from prostate cancer patients were collected from Bart 
the London hospital.  96 blood samples taken from Chinese non-cancer 
prostate patients and 107 blood samples taken from Chinese prostate 
cancer patients.  The blood samples from prostate cancer patients were 
obtained from shanghai hospital. Each sample was frozen and stored at -
80C until analysis was done.  The collection of these specimens was 
approved by Local Ethical Committee  
 
2.4  CNR1 AGONIST (HU210) AND ANTAGONIST R-
SLV- TREATMENT 
 
CNR1 agonist HU210 was purchased from Tocris Bioscience, UK. CNR1 
antagonist (R)-SLV-319 was purchased from Cayman Chemicals, UK. Both, 
HU210 and (R)-SLV-319 were dissolved in DMSO at a stock concentration 
of 100 mM, aliquot and stored at -20°C until further use. For each 
experiment, required concentrations were freshly prepared by diluting the 
100 mM stocks with an antibiotic/FBS-free medium.  
Cells (1x104) were pre-seeded in 6-well plates and incubated in penicillin-
free, 10% FBS RPMI media under standard conditions. After 24 h 
incubation, cells were treated with different concentrations of HU210, (R)-
SLV-319 or DMSO. 
 
        2.5 TUNICAMYCIN TREATMENT 
 
Tunicamycin was purchased from Sigma-Aldrich. It was dissolved in 
DMSO at a stock concentration of 10 mg/ml, and diluted to the required 
final concentration with the antibiotic/FBS-free medium. It was stored at 
4°C. Tunicamycin was used as a vehicle for different time points. 
LNCaP cells were pre-seeded in 6-well plates and incubated penicillin-free 
10% FBS under standard conditions. After 24 h incubation, cells were 
treated with 5 μM tunicamycin or DMSO for the inhibition of glycosylation 
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of CNR1 protein  
 
       2.6 RNA EXPRESSION ANALYSIS 
 
2.6.1 TOTAL RNA EXTRACTION FROM CELL LINES 
 
RNA was extracted using the Trizol (Invitrogen) according to the 
manufacturer’s protocol. Briefly, 70% confluent cells were washed twice 
with PBS. Then, 1 ml of Trizol reagent was added to the cells and the 
homogenate was kept at room temperature for 1 min to ensure a complete 
dissociation of nucleoprotein complexes. Homogenate was transferred to 
a 1.5 ml tube and 200 µl of chloroform was added with vigorous shaking 
for 15 s. After incubating the mixture at room temperature for 5 min, the 
tube was spun at 12000 rpm for 15 min at 4°C. For RNA precipitation, the 
aqueous phase (upper phase) was transferred into a new 1.5 ml tube, 
mixed with 500 µl of isopropanol and incubated at room temperature for 
10 min. The mixture was centrifuged at 12000 rpm for 15 min at 4°C, and 
the supernatant was decanted. To wash the RNA pellet, 500 ml of 75% 
ethanol were added to the pellet and the tube was centrifuge at 7500 rpm 
for 5 min at 4°C. The ethanol was carefully removed and the RNA pellet 
was air-dried for 30 min at room temperature, resuspended in 15-30 μl 
DEPC-treated water, incubated at 55°C for 10 min and cooled on ice 
immediately before storage at -80°C.  Extracted RNA was quantified by 
using Nanodrop (Thermo Scientific) and quality determined by running 1% 
Agarose gel.  
  
 
 
 
2.6.2    REMOVAL OF GENOMIC DNA FROM RNA 
SAMPLES 
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In order to remove any residual genomic DNA from the cell extracted RNA, 
DNase I (Ambion, Applied Biosystem) treatment was applied following the 
manufacturer’s protocol. Briefly, 1 µl (2U) of DNase I was added for each 
10 µg of RNA (in a 50 µl total volume solution with DEPC-treated water 
and DNase buffer). After incubation at 37 °C for 30 minutes, RNA was 
purified using standard phenol/chloroform extraction to inactivate the 
DNase I. Briefly, 100 µl of 1:1 phenol/chloroform was added to the sample, 
vortexed for 15 sec and centrifuged at 12000 rpm for 3 min. The top 
aqueous phase was transferred into a 1.5 mL fresh tube containing a 
mixture of 100 µl isopropanol and 5 µl 4M NaCl to precipitate RNA. To 
improve the RNA quality, RNA was precipitated by adding 250 µl of 100% 
ethanol and 10 µl of 3M NaOAc (pH 5.2, Invitrogen) to the samples. After 
24 h incubation at -20°C, RNA samples were centrifuged at 12000 for 5 
min at 4°C. The precipitated RNA was washed with 70% ethanol and air-
dried at room temperature for 30 min. Finally, RNA was re-dissolved in 
DEPC-treated water and stored at -20°C until further use.  
 
The yield of total RNA was determined by measuring the 
spectrophotometric absorption (optical density; OD) at 260 nm. The 
absorbance of RNA samples at 260 nm and 280 nm, diluted in sterile 
distilled water, was used to evaluate protein contamination (A260/A280 OD 
ratio). The A260/A280 OD ratio was determined and used to assess the 
purity of the sample (OD ratio = 1.8-2). 
 
2.6.3 SYNTHESIS OF COMPLEMENTARY DNA (CDNA) 
 
The synthesis of cDNA was performed using M-MLV RT RNase H minus 
point mutant (Promega, UK). Briefly, 1 µg of total RNA was mixed with 1µl 
of 50 µM random hexamers and incubated at 70°C for 5 min.  After cooling 
on ice, the sample was mixed with 6 µl of 5x synthesis buffer (Promega), 
10 µl of dNTP (2.5mM each) and 2 µl M-MLV RT RNase H minus point 
mutant (200 U/µl). The reaction was then incubated at 42°C for 1 h 
followed by 95°C for 5 min. Finally, the cDNA samples were stored at -
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20°C. A negative control (without DNA template) was always included to 
evaluate accidental reagent contamination. 
 
2.6.4  CDNA CONFIRMATION USING Β-ACTIN CONTROL 
POLYMERASE CHAIN REACTION (PCR)  
 
Following the cDNA synthesis, a standard PCR using β-actin primers 
(Sigma) (Table 5). β-actin is a commonly used endogenous gene for PCR-
based techniques and western blotting. Simply, β-actin was used as a 
positive control to determine the cDNA synthesised by checking for the 
presence or absence of PCR product and to ensure equal amounts of total 
cDNA in each sample. For each sample, the PCR reaction was performed 
in 25 μl volumes. A mixture of 1 μl of cDNA, 2.5 μl 10X PCR buffer 
(Invitrogen), 0.5 μl of dNTPs (10 mM), 0.75 μl of MgCl2 (50 mM, 
Invitrogen), 1 μl of each β-actin primer (10 μM each, Sigma), 0.2 μl of Taq 
DNA polymerase (5 U/μl, Invitrogen) and 17.05 μl of DEPC-treated water 
was used. The PCR was carried out under the following conditions: 95 ºC-
1 min; 95 ºC-30 s, 62 ºC-30 s and 68 ºC-90 s for 35 cycles; 72 ºC for an 
additional 1 min after the final cycle. PCR products were analysed on a 
1.5% agarose /Ethidium Bromide gel and bands of 250 bp were expected.  
Table 2.2 Standard PCR using β-actin primers 
Forward sequence  5’-GCGGGAAATCGTGCGTGCGTGACATT-3’ 
Reverse sequence  5’-GATGGAGTTGAAGGTAGTTTCGTG-3’ 
 
2.6.5 QUANTITATIVE REVERSE TRANSCRIPTION-PCR 
(QRT-PCR)  
 
CNR1 gene expression was analysed using TaqMan qRT-PCR. TaqMan 
assays require a probe with a reporter and a quencher dye attached in 
addition to a pair of primers of the gene of interest. The probes are 
designed to bind to the sequence amplified by the primers and then the 
probe is cleaved by the Taq DNA polymerase during each cycle of the 
PCR reaction. Degradation of the probe releases the fluorophore from it 
 73 
and breaks the close proximity to the quencher, thus relieving the 
quenching effect and allowing fluorescence of the fluorophore. Hence, 
fluorescence detected in the quantitative PCR thermal cycler is directly 
proportional to the fluorophore released and the amount of DNA template 
present in the PCR. This method was used as only the amplification of a 
specific target is detected; therefore the amount of CNR1 DNA in each 
condition could be specifically quantified.   
 
TaqMan gene expression probes (Table 2.3) were commercially obtained 
from Applied Biosystems, and qRT-PCR reactions were performed using 
an ABI 7500 Real-Time PCR system (Applied Biosystems) keeping the 
default settings for baselines and thresholds. Housekeeping gene GAPDH 
was used as an endogenous control. PCR reactions (25 µl) were prepared 
in triplicate on a 96-well plate.  The reaction mix is listed in (Table 2.4) and 
the cycling conditions in (Table 2.5). In addition to the samples, a no-
template control was included to look at DNA contamination of the 
samples and negative reverse transcriptase control was included to 
control for potential genomic DNA contamination in the RNA extraction.   
 
Table 2.3  TaqMan specific probe/primer mix           
Transcript Assay ID Interrogated 
sequence (Refseq) 
Exon Boundary 
CNR1 Hs00275634_m1 NM_016083.4* 1-2 
GAPDH Hs99999905_m1  3-3 
*Homo sapiens cannabinoid receptor 1 (brain) (CNR1), transcript variant 1, 
mRNA 
 
Table 2.4 TaqMan qRT-PCR reaction mixtures 
Components Volumes (µl) 
2x Universal PCR Master Mix 12.50 
20x ABI probe/primer mix 1.25 
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Table 2.5 QRT-PCR standard programs 
Step Temperature (°C) Time 
Initial denaturation 50 2 min 
Denaturation 95 10 min 
40 cycle   
Denaturation 95 15 sec 
Annealing 60 1 min 
 
Each probe reading generated an expression curve from which the cycle 
threshold (Ct) values were extracted and Ct mean was calculated from 
each triplicate. Each target mRNA was normalised against the 
endogenous control, GAPDH, by subtracting the Ct value of GAPDH from 
the Ct value of the target probe (∆Ct). To compare results against a control 
sample, the ∆Ct for the control sample was subtracted from the ∆Ct for the 
target sample (∆∆Ct). The fold change was compared with control was 
calculated by 2-∆∆Ct. 
cDNA 2.00 
Water 9.25 
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2.7 PROTEIN EXPRESSION  
 
2.7.1 TOTAL PROTEIN EXTRACTION OF CELL 
LYSATES 
 
Media supplemented with 10% FBS was removed before cultured cells 
were washed with PBS buffer solution. 1 ml of lysis buffer (1% Triton X-
100 (Sigma), phosphatase inhibitor and 1x protease inhibitor cocktail 
(Roche) in PBS) was applied to each well of a 6-well plate. Cells were 
scraped and pelleted in 4°C centrifuge at 2000 rpm for 2 min.  The 
supernatant was stored at -80°C. 
 
2.7.2 PROTEIN ASSAY 
 
The method used to determine the protein concentration of the cell lysates 
was Bio-Rad's protein assay, which is based on the Bradford dye-binding 
procedure (Bradford 1976), and involves a colorimetric assay for 
measuring total protein concentration. Protein standards were prepared 
using Bovine Serum Albumin (BSA) (Sigma).  
 
A standard curve of protein concentration was produced in duplicates 
using serial dilutions 0.1, 0.2, 0.3, 0.4, 0.5 and 1µg/µl. Protein was 
quantified by adding the whole cell extract (1:5) in DEPC-treated water, 
then 10 µl of the diluted samples was added into each well, then 190 µl of 
1x BioRad solution  (BioRad reagent (5x) diluted in H2O) was added to the 
samples and to the bovine serum albumin protein standard. The 96-well 
plate was incubated at room temperature for 5 min and analysed using 
Opsys MR 96-well microplate reader with absorbance 595 nm. A standard 
∆Ct = ∆Ct target - ∆Ct GAPDH 
∆∆Ct = (∆Ct target - ∆Ct GAPDH)sample – (∆Ct target - ∆Ct GAPDH)control 
Expression fold change = 2-∆∆Ct 
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curve of absorbance versus concentration was constructed for the 
different concentrations of BSA and the protein concentration in each 
sample was calculated using the standard curve graph. Samples were 
stored at -80°C until further use. 
 
2.7.3 SODIUM DODECYL SULPHATE- 
POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-
PAGE) AND WESTERN BLOTTING 
 
Protein samples (30-50µg) were subsequently incubated with 4X sample 
buffer, reducing buffer at 95°C for 5 min.  Proteins of the whole cell lysate 
were separated on an SDS-PAGE (10-12%) by electrophoresis according 
to the apparent molecular weight for 120 min at 120 V. 20 µl of a molecular 
weight Rainbow marker was run in parallel to the samples in order to 
predict the size of the protein bands. The gel was transferred onto PVDF 
membrane using the Bio-Rad mini-PROTEIN Tetra gel electrophoresis 
system (BioRad Laboratories Ltd) for 100 min at 200A.   
 
The membrane was re-activated with methanol and washed again in 0.2% 
TBS-tween before blocking for 24 h with 5% BSA or non-fat 5% milk (5% 
Marvel 0.2% Tween-20 in TBS) at 4°C. The membrane was washed in 
TBS-T three times for 10 min followed by incubation with the appropriate 
primary antibodies diluted in 5% BSA in TBS-T for 24 h at 4°C with 
agitation. The primary antibodies and dilutions used are shown in (Table 
2.6).  After the primary antibody incubations, the membranes were washed 
in TBS-T three times for 10 min each and incubated with horseradish 
peroxidase-conjugated secondary antibody for 45 min at room 
temperature on a plate shaker. Unbound antibody was removed by 
washing with TBS-T and the remaining immunecomplexes visualized 
using the enhanced chemiluminecence (ELC) western blotting detection 
system (Amersham Biosystem). Signal was visualized with RX Fuji X-Ray 
Film developed in a Curix 60 Developer. For loading control all blots were 
blocked with 5% BSA and re-probed with mouse anti-actin antibody using 
the same protocol described above. 
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Table 2.6 Antibodies and conditions 
Protein Source Species Western blot 
hCNR1-CB1,  Abcam ab23703 Rabbit 1:100 
hCNR1-CB1,  Santa Cruz, N-15 
 sc-10066 
Goat 1:500 
CNR1-L13 
 
Prof Elphick 
pAb, 2824.3 
Rabbit 1:500 
Pro-Caspase-3 Cell signalling Rabbit 1:1000 
PARP and Cleaved 
(Asp214) PARP  
Cell signalling Rabbit 1:1000 
 
2.8  IMMUNOFLUORESCENCE (IF) 
 
Sterilised glass coverslips were placed in 12-well plates.  8x105 cells were 
seeded on these coverslips, in 500 µl RPMI containing 10% FCS, and left 
to settle at 37°C for 24 h. Unbound cells were removed by washing with 
PBS and the remaining cells fixed at room temperature for 30 min using 
4% formaldehyde. After two washes in PBS (5 min/each), the coverslips 
were treated with blocking solution (50% Donkey serum+ 0.1% soparin 
+PBS) for 30 min at room temperature. After two washes (5 min/each), the 
coverslips were incubated overnight with primary antibody at 4°C on a 
rotor. Afterward, coverslips were washed in PBS and incubated with the 
secondary antibody fluorescein-conjugated anti-rabbit IgG for 1 h at room 
temperature. After two washes in PBS (5 min/each), the coverslips were 
incubated with DAPI for 10 min at room temperature and then washed with 
PBS-T. The coverslips were mounted with fixation solution and observed 
by fluorescence microscopy. 
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       2.9 FUNCTIONAL ASSAY 
 
A pool of four siRNA was chosen based on highly conserved CNR1 
sequence (SMARTpool; Dharmacon Research) (Table 2.7). This 
combination was chosen in order to knock-down all CNR1 isomers. 
BLAST searches were performed to verify the CNR1 specificity. siRNA 
were diluted in the manufacturer’s buffer (as recommended in Table 2.8). 
10 nmoles of CNR1 siRNA and non-targeting siRNA (NT siRNA) were 
dissolved in 1X siRNA buffer, which was diluted from 5X siRNA buffer 
(Dharmacon) in DEPC water, to a final concentration of 20 µM. The 
dissolved siRNA was incubated at room temperature for 30 min with 
rotation. The siRNA solution was stored in 50 μl aliquots at -20°C prior to 
use.  
 
Table 2.7 siRNA target sequences 
siRNA target Name Sequences 
CNR1  
 
 
siGENOME SMARTpool 1 
siGENOME SMARTpool 2 
siGENOME SMARTpool 3 
siGENOME SMARTpool 4 
CGGCAGUGAAGAACCGAUA 
CUGGAUGAGUAGCGCUAUA 
GCGAGAAACUGCAAUCUGU 
GGACAUAGAGUGUUUCAUG 
 
 
Table 2.8 Recommended siRNA re-suspension volumes and 
concentrations 
siRNA Amount 
(nMol) 
siRNA Buffer to be added  
(mL) 
Final siRNA 
concentration (µM) 
10 0.50 20 
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20 1.00 20 
50 1.00 20 
100 1.00 100 
 
2.9.1 TRANSFECTION WITH LIPOFECTAMINE 2000 
REAGENT 
 
One day before transfection, 5x105 22RV1 cells in 2 ml of growth media 
without antibiotics were plated in 6-well plates so that cells reached 90-
95% confluence at the time of transfection. For each transfection, 
complexes were prepared as follows: 4 μl of DNA was diluted in 250 μl of 
serum-free/antibiotic-free growth media; 10 μl of Lipofectamine™ 2000 
(Invitrogen) was diluted in 250 μl of serum-free/antibiotic-free growth 
media. After incubation at room temperature for 5 min, the diluted DNA 
was combined with diluted Lipofectamine™ 2000 followed by incubation 
at room temperature for 20 min. 250 μl of complexes were added to each 
well. Cells were incubated at 37°C in a CO2 incubator for 24-48 h prior to 
testing for transgene expression. 
 
2.9.2 REVERSE TRANSFECTION OF SIRNA USING 
OLIGOFECTAMINE 
 
Knock-down studies were performed using DharmaFECT1 transfection 
reagents (Invitrogen) following the manufacturer’s recommendations. In 
reverse siRNA transfection, siRNA, Oligofectamine reagents and cells 
were added to the wells at essentially the same time. 2.5x105 cells in 
antibiotic/FBS-free were seeded in 6-well plates. For each well, 10 µl of 20 
µM siRNA was diluted in 90 µl of 1X siRNA buffer plus 100 µl of 
antibiotic/FBS-free media, and 4 µl of Oligofectamine were diluted in 196 
µl of antibiotic/FBS-free media. Both dilutions were incubated at room 
temperature for 10 min. Then, Oligofectamine mix was added to the siRNA 
and further incubated at room temperature for 25 min. Finally, cells with 
1.6 ml of antibiotic-free media and 400 μl of siRNA mixture were added to 
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each well. Cells were harvested after 24, 48 and 72 h for RNA and protein 
quantification. 
 
2.9.3 DOUBLE TRANSFECTION OF SIRNA USING 
OLIGOFECTAMINE REAGENT 
 
Cells (3x105) were seeded per well in 6-well plates. Cells were cultured 
overnight in RPIM media supplemented with 10% FBS without antibiotics. 
5μl of each CNR1 siRNA or non-targeting (NT) siRNA were diluted in 180 
μl DMEM. 5 μl of Oligofectamine (Invitrogen) was diluted in 20 μl of DMEM 
followed by incubation at room temperature for 10 minutes. 25 μl 25 μl of 
the Oligofectamine mix was added to the CNR1 or NT siRNA mix and 
incubated at room temperature for 25 min. 210 μl of transfection mixtures 
were mixed with 790 μl of antibiotic/FBS-free DMEM. Cells in each well 
were then washed with PBS, and 1 ml of the transfection mixture with 
DMEM was added to each well. After 4 h, 500 μl of DMEM media, 
supplemented with 30% FBS, were added to each well.  After 48 h post 
transfection, adherent cells were re-transfected with siRNA at the same 
concentration. Cells were incubated under standard conditions and 
harvested after 24, 48 and 72 h for protein and mRNA analysis. 
 
2.9.4 MTS ASSAY 
 
90 μl of suspended cells (1x104cells/well) in RPMI supplemented with 
10% FCS were seeded in 96-well plates and incubated overnight under 
standard conditions. Next day, cell media was replaced with 100 μl of 
FCS-free media in each well. After suitable cell treatment, viability was 
assessed 1-day post-treatment (1 day after seeding) using the MTS 
viability assay following manufacturer’s instructions (Promega, WI, USA). 
The tetrazolium salt MTS (3-(4,5-dimethylthiazol-2-yl)-5(3-
carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium) is 
converted by mitochondrial dehydrogenases in metabolically active cells 
to a soluble formazan compound, which absorbs light at 490 nm. The 
 81 
product of the reaction is directly proportional to the relative number of 
live cells. After incubation at 37°C for 4-7 h, the plates were read using a 
microplate reader (Opsys MR, Dynex Technologies) at a wavelength of 
495 nm. Values were corrected against the blank wells containing media 
without cells and expressed as percentage cell death compared to 
untreated control cells. Sigmoidal dose-response curves were generated 
by non-linear regression analysis using GraphPad Prism version 4.0c for 
Macintosh (GraphPad Software, San Diego California, USA) to 
determine the effective concentration killing 50% of cells (EC50)-values 
for each agent or combination of agents in each cell line. 
 
2.9.5 WOUND SCRATCH ASSAY 
 
1x106 cells were seeded in 6-well plates and cultured in PRMI containing 
10% FCS until a monolayer had formed. After suitable treatment, one 
single scratch was then made in the monolayer of each well using a 200 
μl pipette tip. The media was removed and fresh RPMI media added. 
Images were taken of the scratch after 0 and 16 h using an Olympus light 
microscope at 40X magnification. The size of the wound was calculated in 
ImageJ software by analyzing the number of pixels the wound size 
contains, compared to the total area. Wound size represented as a 
percentage of the total area.   
 
2.9.6 COLONY FORMATION ASSAY  
 
Between 1000 and 500 of 22RV1 cells were seeded per well in a 6-well 
plate in RPMI media supplemented with 10% FCS and 1% penicillin. Cells 
were cultured for 7 days after suitable treatment. Culture media was 
changed every three days. The culture media was removed and colonies 
were washed twice with PBS. Colonies from each well were stained by 
adding 3 ml of 1% crystal violet (0.5 g dissolved in 500 ml of methanol) to 
the wells and incubating at room temperature for 20 min. Crystal violet was 
then aspirated and stained colonies were washed three times with distilled 
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water. The plate with colonies was left to air dry. Analysis took place by 
counting the number of colonies in each treated well. Experiments were 
carried out in triplicate. 
2.9.7 TRANSWELL MIGRATION ASSAY 
 
Insert, containing a filter 8 μm pores were used for the transwell migration 
assay.  Insert were placed in 24-well plates containing 750 μl of RPMI with 
10% FCS which was used as a chemoattractant. 2.5x104 cells suspended 
in 250 µl of serum-free media were added to each insert and incubated for 
6-9 h or overnight under standard conditions. Next day, the media was 
removed from both upper and lower compartment (from the insert and the 
well). Cells were then scraped from the top surface of the insert with a 
cotton pad. The insert was washed with PBS twice followed by fixation 
with 500 ml of 4% formaldehyde for 20 min at room temperature. After 
washing the 4% formaldehyde with PBS twice, the insert was dipped in 
500 μl hematoxylin for 1 h at room temperature. The membrane was cut 
from the insert carefully and placed it into a slide. Finally, 5 μl of DAPI was 
added on the coverslip, which was then replaced on the slide. Cells were 
then counted under the 40x microscope. Each experiment was performed 
in triplicate.   
 
2.9.8 MATRIGEL INVASION ASSAY  
 
Invasion assays were performed using Corning® Matrigel® Basement 
Membrane Matrix (10 ml). On day one, 24-well plates were coated with 
diluted Matrigel (5 mg/ml to mg/ml) in a serum-free cold RPMI. Next, 100 
μl of the diluted matrigel was added into the upper chamber of 24-well 
transwell and incubate at 37°C overnight. After 24 h incubation of the 
Matrigel, 750 μl RPMI media, supplemented with 10% FBS, was added 
to the lower chamber as a chemo-attractant. 2.5x105 cells suspended in 
200 μl of serum-free media were added to the upper chamber. Cells were 
then treated with siRNA for 48 h incubation at 37°C, cells that had 
invaded through the pores onto the lower surface of the filters were fixed 
with 100% methanol for 30 s. Next, the membrane was washed with 
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distilled H2O whereas the non-invaded cells at the top of the Matrigel 
membrane were removed. Cells present on the bottom of the membrane 
represented the invading cells. The membranes were stained with 1% 
crystal violate (Sigma-Aldrich) and the total number of invading cells was 
counted under an Olympus CX41 microscope at 40x magnification. Each 
experiment was repeated in triplicate. 
 
       2.10 FLOW CYTOMETRY  
 
2.10.1 CELL-CYCLE DISTRIBUTION AND SUB-
G1 REGION ANALYSIS 
 
The cell cycle analysis was performed in LNCaP, 22RV1, DU145 and PC3 
by flow cytometry. The cells (1.2 × 104 cells/well) were seeded in 6-well 
plates and were treated with 25, 10, 30 and 25 µM of HU210 or DMSO 
respectively for 24 h. Then, cells were harvested by trypsinization and 
centrifugation. The cell pellets were resuspended and fixed in 70% ice-
cold ethanol/PBS, pelleted and resuspended in buffer containing 50 µg/ml 
RNase A and 50 µg/ml propidium iodide (PI). Then, cells were incubated 
in the dark for 15 min on ice and then analysed by FACScan benchtop 
cytometer. The cell cycle phases, sub-G1 (apoptosis), G1, S, and G2/M, 
were measured by fluorescence emission at 617 nm (FL-2) after treating 
with RNase A and staining with PI. Each experiment was repeated in 
triplicate. 
Flow cytometry acquisition was performed on an FACSCalibur flow 
cytometer (Becton Dickinson Immunocytometry Systems, CA, USA) with 
CellQuest Pro software version 4.0.2 (Becton Dickinson Bioscience, CA, 
USA). A gate was drawn around the viable cells. Ten thousand gated events 
were analyzed per sample. The data obtained were further analyzed with 
FlowJo 9.1 software (Tree Star, ORE, USA) by plotting selected cells into a 
histogram displaying PI intensity which correlates with DNA content 
calculated by using Watson Pragmatic integration. 
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        2.11 GENOMIC ALTERATIONS ANALYSIS 
 
2.11.1 TRADITIONAL SANGER SEQUENCING-
DIRECT SEQUENCING 
 
The sequence of the human CNR1 gene (88879767-88848583) was 
retrieved from the public databases by BLAST search 
((http://www.ensembl.org/Homo_sapiens/Gene/Sequence?g=ENSG0000
0118432;r=6:88849583-88876078). The genomic DNA sequence was 
found in http://www.ensembl.org, enabling us to construct the primers 
covering 1Kb upstream from exon 1 (upstream promoter), 1Kb upstream 
from exon 3 (second promoter) and the coding region of the human CNR1 
gene with the expected size ~590 - 600 bp for each PCR products (Figure 
2.9). Four prostate cancer cell lines (22RV1, LNCaP, DU145 and PC3) as 
well as one immortalized epithelial prostate cell line (PNT1a), were 
screened for alteration in CNR1 by direct sequencing the coding region 
and the two promoter regions. 
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Figure 2.9 Schematic representations of genomic DNA of the gene CNR1, 
and the position of the primers. Arrows indicate the position of the promoters. 
 
All primers applied were ordered from Sigma.  PCR reactions with 
genomic DNA template were performed as described in section 2.2.1.4. 
Primer sequences, PCR thermos-cycle program are shown in (Table 2.9) 
and (Table 2.10). Direct DNA sequencing was performed in Genome 
Centre (QMUL). 
 
Table 2.9 The primers for Strong, weak promoter and coding regions 
for CNR1 sequencing  
No. PCR 
Primers 
Sequence Conditions 
annealing 
Tm 
Expected 
size 
Genome 
position 
1 CNR1p1.1R 
CNR1p1.1F 
5' CGTAGCCCCAAACTTTGCT 3' 
5' CCTACGGAGCCCAACTGTTT 3' 
61°C 637bp 2928-
3565 
2 CNR1p1.1F 
CNR1p1.1R 
5' GGAGGAGGAGGAAGAGGAGA 3  
5' GCGGAAAAGAAGTGGAGAAG 3' 
61°C 612bp 3453-
4065 
3 CNR1p2.1F 
CNR1p2.1R 
5' ACGGAGTCTCGCTCTGTCG 3'   5 
GCCTGACACAAAAGTAAGTCTTCA3' 
64°C 639bp 17838-
18477 
4 CNR1p2.1F 
CNR1p2.1R 
5' AAGGCAATGAGCATTCTTGAG 3' 
5'GGTGCTATTATCCCCATTTTCA 3' 
64°C 601bp 18325-
18926 
5 CNR1p2.1F 
CNR1p2.1R 
5' GGGTGCAGTGCTTGCTCTA 3'   
5' ACCAGCCTCCTACTGATGGA 3' 
64°C 630bp 18834-
19464 
6 CNR1e4.1F 
CNR1e4.1R 
5' TCCAAGAGTAGGGGTCATGTG 3' 5' 
TCATTTGAGCCCACGTACAG 3' 
64°C 595bp 24259-
24854 
7 CNR1e4.2F 
CNR1e4.2R 
5' GTCGATCCTAGATGGCCTTG 3' 5' 
CCCACCCAGTTTGAACAGAA 3' 
64°C 579bp 24780-
25359 
8 CNR1e4.3F 
CNR1e4.3R 
5' GCCTTCCTACCACTTCATCG 3' 5' 
CCAGCAGATGATCAACACCA 3' 
64°C 618bp 25224-
25842 
9 CNR1e4.4F 
CNR1e4.4R 
5' GGATGGGAAGGTACAGGTGA 3'  64°C 641bp 25743-
2684 
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5' CCCTGGAGAATGGAGTTTGA 3' 
 
 
 
 
 
Table 2.10 PCR program for CNR1 gene 
No. Step Temperature (C°) Time 
1 Initial 
denaturation 
95°C 5mins 
2 Denaturation 95°C 30sec 
3 Annealing 61°C strong promoter 
64°C coding region  
64°C weak promoter 
45sec 
4 Elongation 72°C 1min 
5 Go to 2 - 35 cycles 
6 Final elongation 72°C 10mins 
7 Stop 4°C Forever 
 
 
2.11.2 DNA MICROSATELLITE ANALYSIS  
 
Specific primers were designed for microsatellite analysis. The forward 
PCR primer was labeled with fluorescent dye (FAM) (Table 2.11). 
Genomic DNA was PCR-amplified. For this, 100 ng/μl of genomic DNA 
was mixed with 1 μl of each primer; 10 mM of 1μl dNTP, 5μl PCR buffer 
containing 15 mM MgCl2, 0.4 μl of Taq polymerase and distilled water in 
total volume of 50 μl. PCR thermos-cycle started with a denaturation step 
of 3 min at 95ºC and continued with 35 cycles, containing; a 30 sec 
denaturation segment at 95ºC, a 45 sec annealing segment at 61ºC, and 
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a 30 sec elongation segment at 72ºC. The final elongation step was 
extended to 10 min in order to allow all the products to be fully extended.  
 
Two different prostate samples groups have been analysed using 
microsatellite analysis. 13 UK prostate cancer samples were analysed for 
polymorphism at the CNR1 promoter region in the Genome Centre 
(QMUL). The other group is from China (Genomic DNA from 96 blood 
samples taken from Chinese non-cancer prostate patients and the other 
group from 104 gDNA blood samples taken from Chinese prostate cancer 
patients). The samples were analysed in China for polymorphisms in the 
CNR1 promoter region.   
 
Table 2.11 primers for Strong promoter region for microsatellite 
instability analysis 
PCR Primer Sequence Expected 
Size 
CNR1p1-Forward 
CNR1p1-Reverse 
5’ FAM–CCACGGGAGCGGCCTTGC- 
5’ –GCGCATCGCCAACACCTTCC- 
150 bp 
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2.11.2 NEXT-GENERATION SEUENCING-NGS  
 
The genomic regions containing all exons of CNR1 and upstream promoter 
region were amplified using Fluidigm Access Array using primers designed by 
the company (Fluidigm, Cambridge, UK). PCR product of each primer pair was 
assessed by Agilent Bioanalyser and further processed for next generation 
sequencing on an Illumina MiSeq system (Illumina, San Diego, CA). 
Sequencing data were aligned with Bowtie 2 (Langmead and Salzberg 2012) 
and variants were called with VarScan 2 (Koboldt, Zhang et al. 2012) using 
Genome Reference Consortium human build 37 (GRCh37). A mutation was 
recorded only when the mutant allele frequency is 10 or more. 
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      3       CHAPTER THREE  RESULTS 
CHARACTERISATION OF CNR1 STATUS IN   
PROSTATE CANCER 
 
3.1 GENETIC CHANGES OF CNR1 
 
Molecular genetic analysis by our team and others revealed a frequent 
deletion in the 6q15 region in prostate cancer and the downregulation of a 
number of genes at this region (Verhagen, Hermans et al. 2002, Liu, Chang 
et al. 2007, Shan, Ambroisine et al. 2010, Boyd, Mao et al. 2012). Our SNP 
array data showed that 6q15 was deleted in 53% of prostate cancer 
samples. In addition, 6q15 was deleted in up to 46% of prostate cancer 
samples, as detected by FISH analysis (Shan 2010), further supporting that 
the deletions in 6q15 are frequent events and that CNR1 is a candidate TSG 
at this region in prostate cancer.  
 
3.1.1 LACK OF MUTATIONS OF CNR1 GENE 
IN PROSTATE CANCER 
 
To investigate the potential of CNR1 inactivation through mutation in 
prostate cancer, and to characterise CNR1 status in the prostate cancer cell 
lines for further functional studies, I sequenced the CNR1 gene in the 
prostate cancer cell lines, using the traditional Sanger method with 
overlapping PCR primers as described in (Section 2.8). I determined the 
CNR1 sequences in the human prostate cancer cell lines 22RV1, LNCaP, 
DU145, PC3 and VCaP, and one immortalized prostate epithelial cell line, 
PNT1a. The sequencing data of CNR1 showed a clear indiviual sharp and 
evenly spaced peaks. Moreover, the lack of baseline noise in the sequences 
as shown in the DNA sequencing chromograph indicates good quality 
sequencing data with clean nucleotide peaks (Figure 3.1A).   
 
My results showed no mutations in CNR1 coding and promoter regions of 
the prostate cancer cell lines 22RV1, LNCaP, DU145 and VCaP and PC3.  
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However, a polymorphism of DNA sequence with or without a 6bp 
(CCTTCC) was found in the promoter of CNR1 gene (Figure 3.1B). Most of 
the cancer cell lines have the six bases,compared to  the common CNR1 
sequence and the PNT1a immortalised prostate epithelial cells without the 
six bases at the position 3250-3256 bp in the analysed prostate cancer cell 
lines (Figure 3.2).    
 
  
Figure 3.1A DNA sequencing chromatograph of CNR1 from 
prostate cancer cell line 22RV1. The sequence lacks of baseline 
noise as shown in the DNA sequencing chromograph, indicating a 
clean nucleotide peak. No mutaion was found in CNR1 coding and 
promoter regions.  
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Figure 3.1B The genomic DNA sequence of CNR1 gene  
(http://www.ensembl.org), The construction of the primers covering 1Kb 
upstream from exon 1 (upstream promoter). The 6bp polymorphism sequence 
is present in human genome (black bold letters). 
 
 
 
Figure 3.2 Multiple sequence alignment using ClustalW comparing the 
sequenced genomic DNA of prostate cancer cell lines with the CNR1 
database sequence in the upstream promoter region. The 6bp polymorphism 
sequence is present in human genome. 
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Gene mutation is another mechanism leading to the inactivation of TSGs. 
To further investigate the CNR1 inactivation, a screen 
for mutations in CNR1 was performed on human prostate cancer samples, 
using more advanced techniques than traditional Sanger sequencing, 
which can be a laborious task particularly when performed on a large 
genomic region with a large cohort of samples.  Fluidigm genomic 
amplification technology was used therefore in a combination with the next 
generation sequencing (NGS). Prostate cancer clinical samples were 
analysed using this method aiming at detecting any mutations in a gene of 
interest. The experiment was designed by Dr Lara Boyd and Dr Yong-Jie 
Lu in our team and performed by Dr Lara Boyd and the Genome centre 
(QMUL). The data analysis was performed by Mr Jacek Marzec (Centre for 
Molecular Oncology). The upstream promoter and coding region of CNR1 
we amplified by Fluidigm Access Array in 73 prostate cancer samples, and 
five prostate cancer cell lines (PC3, 22RV1, DU145, VCaP and LNCaP) and 
two immortalized prostate epithelial cell lines PNT1a and PNT2-C2, and 
analysed using next-generation sequencing. >100X depth was generated 
for all CNR1 exon regions and the promoter. The data demonstrate that a 
somatic mutation in CNR1 is a rare event in prostate cancer.  
Taken together, these results demonstrate that there are no mutations in 
CNR1 coding and promoter regions. Polymorphism of 6bp sequence in the 
promoter region will be further investigated in the following section.    
 
3.1.2 THE POLYMORPHISM IN CNR1 
PROMOTER REGIONS IN PROSTATE 
CANCER- MICROSATELITE ANALYSIS 
 
In the previous section  3.1, a polymorphism of 6bp was found in the 
promoter of CNR1 gene by analysing the prostate cancer cell lines 22RV1, 
LNCaP, DU145 and VCaP and PC3. In silico analysis, using Ensemble, I 
identified this polymorphism (variant rs147446147) to be located within the 
upstream promoter region of the CNR1 gene (Figure 3.1B).  
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All the cell lines only contain the longer allele type (154bp), the recently 
reported variant rs147446147 (with 6bp polymorphism), except in PC3 cells 
where both the shorter (147bp) and longer (154bp) alleles are present as 
compare to PNT1a (Figure 3.2).   
Then I  analysed  genomic DNA of 13 blood samples taken from UK prostate 
cancer patients for the polymorphism. We found six out of 13 blood samples 
contain the longer allele sequence 154 bp (homozygous) in the promoter 
region of CNR1 gene (Figure 3.3). 
 
 
Figure 3.3 Multiple sequence alignment using ClustalW comparing the 
sequenced genomic DNA of blood sample taken from prostate cancer 
patients with the CNR1 database sequence in the upstream promoter 
region. The 6bp polymorphism sequence is present in human genome with 
Homo-A2 (homozygous allele-2) 6bp longer and Hetero-A1 (heterozygous 
allele-1) 6bp shorter. 
 
I further investigated the presence of the 6bp polymorphism and its potential 
effect on transcription factor binding sites, in case it may influence CNR1 
gene expression by altering transcription factor binding to the promoter 
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region. A TF regulates transcription of its target gene by specifically binding 
to the transcription factor-binding site (TFBS) in the gene promoter region. I 
found potential TFBs for five TFs; TFII-1, STAT4, c-Ets-1, Elk-1 and GR-
alpha overlap with the polymorphism 6bp sequence (Table 3.1).  This 
overlapping causes the addition of another TFBS for each TF (Figure 3.4). 
As illustrated in Figure 3.4, the sequence in the promoter region with and 
without the 6bp polymorphism. It appears that the insertion results in 
additional TFBS for each TF. Also detected changes of the TFBS position of 
TFII-I and GR-alpha after the insertion of 6bp polymorphism sequences. 
 
Table 3.1 Potentially predicted transcription factor binding 
sites at RS147446147 region using Promo (version 8.3 of 
transfac). 
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Figure 3.4 Potential TFBS based on human CNR1 upstream sequence are 
marked by blue boxes: TFII-1, STAT4, c-Ets, GR-alpha and Elk-1. It appears 
that for each TFBS that I identified, there are two TFBS located in the upstream 
promoter regions of CNR1. However, with the 6bp polymorphism sequence, it 
causes the addition of another TFBS. The alignment shows the position of the 
TFBS in different positions of the promoter regions.  
 
Consequently, I further investigated if there is a difference of the frequency 
of these polymorphism alleles between prostate cancer and non-cancer 
control groups in the Chinese population, where blood samples were 
available. 96 Chinese non-cancer and 97 Chinese cancer blood samples 
were subjected to microsatellite analysis using sequencing gel and we 
found that the longer allele sequence was around 154 bp  (homozygous), 
which correlates to the polymorphism with the 6bp is more common in 
cancer samples compared to non-cancer samples (Table 3.2). In Chinese 
cancer samples, 67 (69.79%) samples with longer allele sequence while 
in the non-cancer samples, 58 (60.42%) with longer allele sequence. 
These results suggest that the longer allele sequence is more common 
than the shorter one in the Chinese population.  
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Table 3.2 Microsatellite analysis results of rs147446147 for 
Chinese non-cancer and cancer prostate blood samples 
Sample Homozygous 
(147) no 
insertion 
Homozygous 
(154) with 
insertion 
Heterozygous 
(147/154) 
Total 
Non-cancer 
China 
4 (4.1%) 58 (60.42 %) 34 (35.42 %) 96 
Cancer China 4 (4.1%) 67 (69.79 %) 26 (27.08 %) 97 
 
 
I further investigated whether there is any association between allelic-
specific and prostate cancer risk. A Fisher exact test was carried out to 
test the allele-specific association with prostate cancer risk (Table 3.3). 
Using the two-tailed test, the P-value equals 0.307 and consequently the 
association between cancer and the homozygous longer allele is not 
statistically significant. Our finding showed that the longer allele (154 bp) 
is not associated with prostate cancer risk in Chinese population. 
Therefore, this CNR1 promoter polymorphism is not involved in prostate 
cancer development at least in the Chinese population. 
 
Table 3.3 Statistical analysis of difference in rs147446147 alleles 
between Chinese non-cancer and cancer samples using 
microsatellite analysis. 
Samples 147bp allele 154 bp allele P Value* 
Non-cancer 42 150  
Cancer 34 160 0.307 
Total 76 310  
     *A Fisher exact test-two-tailed. 
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3.2 GENE EXPRESSION  OF CNR1 IN 
PROSTATE CANCER  
 
I determined the expression of CNR1 transcripts by qRT-PCR for the 
prostate cell lines used in this study. I observed that the cell line DU145 
presented the highest level of CNR1 transcript expression. Slightly higher 
expression levels were also observed in 22RV1 and LNCaP cells compared 
to the PNT1a and PNT2 immortalised prostate epithelial cells. PC3 and 
VCaP cells had very low levels CNR1 expression (Figure 3.5).  
 
 
Figure 3.5 CNR1 mRNA expression in prostate cancer cell 
lines. CNR1 mRNA expression in all prostate cancer cell lines 
and two immortalized epithelial cells lines as assessed by RT-
qPCR analysis. Expression of CNR1 measured by RT-qPCR 
relative to the expression of the housekeeping gene GAPDH.   
Endogenous CNR1 levels were normalised with respect to the 
CNR1 level in PNT1a.  Values are determined from two 
independent experiment performed in triplicate. 
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3.3 EXPRESSION OF CNR1 RECEPTOR IN 
PROSTATE CANCER CELLS AT PROTEIN 
LEVEL 
 
3.3.1 ANTIBODY SELECTION  
 
  Having determined CNR1 expression in 22RV1, LNCaP and DU145, 
PC3 and immortalised epithelial cells at mRNA level (section 3.2.1), I 
aimed to determine protein expression by western blot analysis of whole 
cell lysates from the prostate cancer cell lines. The specificity of an 
antibody is crucial for examining protein expression in cells. Therefore the 
antibodies against CNR1 products were carefully selected and antibody-
working conditions were optimised prior to use in further studies. First I 
evaluated a number of CNR1 antibodies to identify a specific antibody, as 
a recent study reported a series of commercial CNR1 antibodies which 
were non-specific for western blot and IHC (Grimsey, Goodfellow et al. 
2008). I therefore reviewed the literature and tested all the CNR1 
antibodies available at the time, including the following commercially 
available CNR1 antibodies: C-terminal antibodies from Abcam (ab23703) 
and Merck (209550), one N-terminal antibodies produced by Santa Cruz 
as well as one antiserum (L13) developed by Prof. Elphick (QMUL), by 
western blotting using human brain tissue, where CNR1 is highly 
expressed (Egertova and Elphick 2000), as a positive control. 
 
Cell extracts from the prostate cancer cell lines 22RV1, LNCaP, DU145, 
PC3, VCaP, the two immortalized prostate epithelial cell lines PNT1a and 
PNT2, and a human brain lysate as a positive control, were blotted for 
CNR1. Western blot analysis with the antibody from Abcam (ab23703) 
exhibited multiple bands including two prominent bands ~63 kDa and ~49 
kDa in most cell types, considered to reflect the presence of two different 
states of the protein which may correspond to CNR1 and CNR1b protein 
respectively (Egertova and Elphick 2000) (Figure 3.6). The Abcam 
antibody revealed an immunoreactive band for most prostate cancer cell 
lines at 49 kDa which was slightly larger in size compared to the brain 
lysate (<49kDa) (shown in Figure 3.6). The immunoreactive band at 63 
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kDa was detected in most cell types including the positive control (brain 
lysate). In addition, there are strong bands with molecular weights at ~35 
kDa that cannot be ignored since the positive control also showed a strong 
and specific band at 35 kDa.  
 
 
Figure 3.6 Western blot of CNR1 for human CNR1 receptor proteins 
expressed in prostate cancer cell lines. Western blot of proteins extracted 
from prostate cancer cell lines using Abcam (ab23703) antibody directed 
against CNR1. β-actin was used as loading control. 40 μg protein was loaded 
per lane and blotted for CNR1. One blot representative of three independent 
experiments. 
 
 
Figure 3.7 Western blot of CNR1 for human CNR1 receptor 
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proteins expressed in prostate cancer cell lines. cell lysates were 
prepared for separation on polyacrylamide gels. 40μg protein was 
loaded per lane and blotted for CNR1, using (L13) Antibody directed 
against CNR1. β-actin was used as loading control. One blot 
representative of three independent experiments.    
 
Antibody L13 (Prof Elphick, QMUL) also showed a CNR1 specific banding 
pattern at ~63 kDa and ~49 kDa (Figure 3.7). Multiple bands were 
obtained using CNR1 antibody from Merck (209550). Optimization of the 
Merck (209550) antibody did not improve detection of the predicted CNR1 
protein (Figure 3.8). Also, multiple bands were obtained between the 
molecular weights ~45 kDa and ~35 kDa with the Santa Cruz (sc-10066) 
antibody, but little at 63 and 49 kDa (Figure 3.9).  
 
 
Figure 3.8 Western blot of CNR1 for human CNR1 receptor 
proteins expressed in prostate cancer cell lines. Cell lysates 
were prepared for separation on polyacrylamide gels. 40μg protein 
was loaded per lane and blotted for CNR1 using Merck (209550) 
antibody directed against CNR1. β-actin was used as loading 
control. One blot representative of three independent experiments.    
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Figure 3.9 Western blot of CNR1 for human CNR1 receptor 
proteins expressed in prostate cancer cell lines. cell lysates were 
prepared for separation on polyacrylamide gels. 40μg protein was 
loaded per lane and blotted for CNR1 using Santa Cruz antibody 
directed against CNR1. β-actin was used as loading control. One 
blot representative of three independent experiments.   
 
The results demonstrated the lack of CNR1 specificity of Merck  (209550) 
and Santa Cruz (sc-10066) antibodies. However, Abcam (ab23703), and 
L13 antibodies had the potential to detect the endogenously expressed 
CNR1 receptors in prostate cancer cell lines. Therefore, the Abcam 
(ab23703), and L13 antibodies were employed for further optimisation.  
 
3.3.2 INHIBITION OF CNR1 
GLYCOSYLATION PROTEIN IN LNCAP 
CELLS 
 
Both antibodies ab23703 and L13 (Prof. Elphick, QMUL) detected CNR1 
signals by western blot analysis corresponding to ~63 kDa and 49 kDa 
(Figure 6 & 7). It has been reported that N-glycosylation contributes to the 
molecular weight of the protein species and inhibition of glycosylation can 
shift the bands detected by western blot (Andersson, D'Antona et al. 2003). 
To further evaluate which of the two antibodies are better for CNR1 
detection, LNCaP cells were treated in the absence or presence of N-
glycosylation inhibitor tunicamycin for 72h. Tunicamycin inhibits N-
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glycosylation by blocking the transfer of N-acetylglucosamine-1-phosphate 
(GlcNAc-1-P) from UDP-GlcNAc to dolichol-P, thereby decreasing the 
formation of dolichol-PP-GlcNAc and inhibits glycosylation. Western blot 
analysis with Abcam anti-CNR1 and L13 antibody was performed on whole 
cell lysates collected from untreated and tunicamycin-treated cells (Figure 
3.10).    
 
Using the Abcam antibody, treatment with (2 μg/ml) tunicamycin for 72 h, 
resulted in a decrease in the bands at ~63 kDa and 49 kDa with a molecular 
shift to about ~40 kDa in LNCaP cell extract. However,  this ~40 kDa band 
was not detected by the L13 antibody. Instead, the L13 antibody detected a 
new band in addition to the 63 kDa and 49 kDa bands, at about ~90 kDa in 
LNCaP cell extract. Surprisingly, the 49 kDa band disappeared completely 
which indicated that 49 kDa band might represent another glycosylated 
CNR1 protein. These data showed the specificity of the Abcam antibody 
that was therefore employed in all further western blotting. 
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Figure 3.10 CNR1 is highly glycosylated in LNCaP cells.  LNCaP cells were treated with 
tunicamycin for 72 h. Lysates were prepared from untreated LNCaP cells (UT), control cells treated 
with DMSO (-), and LNCaP cells treated with 2 μg/ml tunicamycin (TM) for 72h in 10% serum media 
at 37°C.  Total cell lysates (50µg/lane) were then processed and immunoblotted with Abcam rabbit 
polyclonal antibody and L13 antibody to detect CNR1. The membranes were re-probed with ß-actin 
to control for loading. The arrows indicate the glycosylated and shifted form of CNR1. Similar findings 
were observed in two independent experiments. 
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3.3.3 DETERMINING CNR1 KNOCKDOWN IN 
LNCAP CELLS AND FURTHER 
CONFIRMING THE SPECIFICITY OF THE 
ANTIBODY  
 
3.3.3.1 Knockdown of CNR1 in LNCaP using double 
transfection of siRNA   
 
In the previous section 3.3.2, I determined that the anti-CNR1 antibody 
from Abcam detects the expression of CNR1 and CNR1b. To further 
confirm the specificity of the Abcam antibody, I used gene silencing via 
siRNA. CNR1 was knocked down by a specific siRNA in the prostate 
cancer cell line LNCaP.  
A double siRNA transfection method was performed in the LNCaP cells, 
where CNR1 mRNA is expressed. After 48 h post transfection, using the 
double transfection protocol, a 90% reduction in CNR1 mRNA was 
observed in cells transfected with the CNR1-targeting siRNA compared 
to non-targeting siRNA transfected cells (Figure 3.11).  
 
 
Figure 3.11 Relative expression of CNR1 mRNA in LNCaP cells 
using double transfection method. Initial siRNA transfection of 
pre-seeded LNCaP cells, followed by re-transfection after 48h. Cells 
were transfected twice (Double transfection with 100nM siRNA 
complexes and Oligofectamine reagent). The expression level of 
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CNR1-targeting siRNA in LNCaP cells (Si) was measured by RT-
qPCR relative to the expression of the housekeeping gene GAPDH 
and normalized to the non-targeting siRNA transfected LNCaP cells.  
mRNA expression represents one experiment.  
 
The effect of knockdown of CNR1 on protein expression in LNCaP cells 
was determined using western blot analysis. A significant difference in the 
relative density of the two isoforms in cells double-treated with CNR1-
targeting siRNA in comparison to non-targeting transfected cells was 
found (Figure 3.12). Therefore, these results demonstrate that the double-
transfection method effectively knocked down both forms of CNR1 
receptors in LNCaP cells and further confirmed the specificity of the 
Abcam antibody. Interestingly, other bands showed reduction after siRNA 
transfection as well. The possible explanation for this reduction in protein 
density is that it may be the product of CNR1 receptors that have been 
subjected to proteolysis or during protein extraction.  
 
          
Figure 3.12 Knockdown of CNR1 in LNCaP cells using double transfection 
method. Using Abcam antibody 1:100 dilution, LNCaP cells were seeded in 6 
well plates for 24 h prior to transfection. The cells were then transfected with 
oligofectamine and CNR1-targeting siRNA /non-targeting reagents. Cells were 
re-transfected with 100 nM siRNA complexes 48 h after the first transfection. 
Western blot analysis of CNR1 expression in untreated LNCaP cell (UT), LNCaP 
cells transfected with non-targeting siRNA (NT), LNCaP cells transfected with 
CNR1-targeting siRNA (si). Total cell lysates 40µg/lane). β-actin was used as a 
loading control with expected size at 43 kDa. The values above the figures 
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represent the relative density of the bands normalised to Actin. One blot 
representative of three independent experiments.  
 
3.3.3.2 Knockdown of CNR1 in LNCaP using reverse 
transfection of siRNA   
 
To reduce the exposure time of cells to the transfection reagents, 
transfection of CNR1 siRNA was performed on LNCaP cells in 
suspension. After 24 h, 90% of the volume of the media containing 
transfection complexes was replaced with fresh media to reduce the 
concentration of complexes and minimize toxicity to cells. The relative 
expression of CNR1 decreased with up to 80% after 24 h of the 
transfection in comparison to non-targeting siRNA transfected cells 
(Figure 3.13).  
 
 
Figure 3.13 Relative expression of CNR1 mRNA in LNCaP 
cells using reverse transfection method. The expression 
level of CNR1-targeting siRNA in LNCaP cells (si) was 
measured by qRT-PCR relative to the expression of the 
housekeeping gene GAPDH and normalized to the non-
targeting siRNA transfected LNCaP cells (NT) after 24 h, 48 
h, and 72 h post transfection. mRNA expression is 
representative of one experiment.  
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Protein expression of CNR1 in LNCaP cells transfected with CNR1-
targeting siRNA and non-targeting was examined using western blot 
analysis 72 h post-siRNA transfection. Most of  the CNR1 protein 
expression was knocked down in CNR1-targeting siRNA transfected 
LNCaP cells in comparison to non-targeting siRNA transfected cells 
(Figure 3.14). These results also demonstrate that the reverse transfection 
method effectively knocked down both forms of CNR1 receptors in LNCaP 
cells.   
  
 
Figure 3.14 Knockdown of CNR1 in LNCaP cells using reverse transfection 
of siRNA after 72h post transfection.  Using Abcam antibody (1:100 dilution, 
LNCaP cells, oligofectamine and siCNR1 reagent were incubated all at the same 
time.  Western blot analysis of CNR1 expression in untreated LNCaP cells (UT), 
CNR1 expression in LNCaP cells transfected with non-targeting siRNA (NT), 
CNR1 expression in LNCaP cells transfected with CNR1-targeting siRNA (si). 
Total cell lysates 40µg/lane). β-actin was used as a loading control with 
expected size at 43 kDa.  The values above the figures represent the relative 
density of the bands normalised to Actin.  One blot representative of three 
independent experiments.  
 
My data demonstrate that both transfection methods did knock down 
CNR1 expression at both mRNA and protein levels and further confirmed 
the specificity of the Abcam antibody.  
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3.3.4 KNOCKDOWN OF CNR1 IN 22RV1 
CELLS TRANSFECTED WITH CNR1 
CONFIRMED THE SPECIFICITY OF THE 
ABCAM ANTIBODY  
 
To further confirm the specificity of the antibody, I used 22RV1 cells that 
overexpressed CNR1, previously generated in our team (Shan 2010).  The 
CNR1 overexpressing cells were previously generated in our laboratory 
using a pcDNA3.1 (+) plasmid containing the CNR1 coding region. 
Several clones had been selected by culturing cells in the presence of 
geneticin G418 (1mg/ml). 
 
The expression levels of CNR1 mRNA were examined using TaqMan 
qRT-PCR analysis to measure the increases in CNR1 expression in 6 
clones compared to the control 22Rv cells transfected with empty vector. 
It showed that CNR1 mRNA levels were 120 and 113 fold higher in clone 
1, and 5  respectively, in comparison to the control cells (Figure 3.15). The 
overexpression of CNR1 in the stably transfected 22RV1  clone 1 was 
selected for continued examination of  Abcam antibody by knocking down 
CNR1 in these cells using the siRNA reagents.   
 
Figure 3.15 Overexpression CNR1 at the mRNA level in stably 
transfected 22RV1 clones using TaqMan qRT-PCR analysis. The 
expression of CNR1 RNA levels in CNR1 stably transfected 22RV1 
clones were measured by TaqMan RT-qPCR, relative to the expression 
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of the housekeeping gene GAPDH and normalized to the pcDNA3.1 (+) 
transfected 22RV1 cells as a control. mRNA expression is 
representative of one experiment.  
 
3.3.4.1 Knockdown of CNR1 in stably transfected 
22RV1 clone 1 cells at mRNA levels 
 
CNR1-targeting siRNA and non-targeting siRNA were transfected 
respectively into Clone 1 of the CNR1 stably transfected 22RV1cells. The 
decreases in CNR1 mRNA levels were measured by TaqMan-based gene 
expression detection (TaqMan probe: CNR1 Hs00275634_m1) and the 
RT-qPCR reactions were performed using ABI 7900 Real-Time PCR 
system. The housekeeping gene (GAPDH) was used as an endogenous 
control. The expression level of CNR1-targeting siRNA in stably 
transfected 22RV1 cells (SI) was measured by RT-qPCR normalised to 
the expression of the housekeeping gene GAPDH and relatively to the 
non-targeting siRNA transfected 22RV1 (NT) cells after 24 h, 48h and 72h 
transfection. The results showed that the relative expression of CNR1 
gene was silenced by up to 75% at 24 h post-transfection in CNR1-
targeting siRNA transfected 22RV1 cells in comparison to non-targeting 
siRNA transfected cells (Figure 3.16).   
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Figure 3.16 Relative expression of CNR1 in CNR1-stably 
transfected 22RV1 cells clone 1 with and without CNR1 
knockdown. mRNA expression is representative of one experiment.   
 
3.3.4.2 Knockdown of CNR1 in 22RV1 cells was 
determined by  immunofluorescent imaging 
 
 
 To further confirm expression and knockdown of CNR1 at the protein 
level, the Abcam ab23703 antibody was used in the immunofluorescent 
imagining of 22RV1 cells clone 1 with and without CNR1 siRNA 
transfection.  
 
The efficiency of the CNR1 knockdown at protein level was examined by 
immunofluorescence after 24 h siRNA transfection. In my study, the 
siCNR1 treatment substantially reduced the expression of CNR1 protein 
in 22RV1 cells as compared with non-targeting siRNA transfected cells 
(Figure 3.17). Importantly, the protein expression of CNR1 was found to 
be downregulated in these cells after 24 h of treatment. It was also clear 
that CNR1 was located to the cell membrane and the cytoplasm (green 
signal) in the 22RV1 cells clone 1 as expected (Figure 3.17). These 
results confirm that rabbit polyclonal anti-CNR1 Abcam antibody ab23703 
is capable of detecting CNR1 protein in 22RV1 cells. 
 
Overall, my results in this section showed that the expression of CNR1 
at the mRNA level correlated with the protein levels in prostate cancer 
cell lines. Furthermore, the Abcam antibody proved to be specific for 
CNR1 receptors and can be used for further functional studies to 
investigate the role of CNR1 in prostate cancer.    
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Figure 3.17 Detection of CNR1 receptors under expression using 
confocal fluorescence microscopy. Images showing immunofluorescent 
localisation of CNR1 immunoreactivity in stably transfected 22RV1 cells. Cells 
treated with (A) secondary antibody, (B) primary antibody, (C) Cells 
transfected with non-targeting reagent-siRNA, (D) Cells transfected with the 
siCNR1 reagent for 24 h and stained with antibody Alexa Fluor 488 conjugate.  
CNR1 receptors exhibit membrane and cytoplasmic distribution. Nuclei were 
stained with 4,6-diamidino-2-phenylindole (DAPI) blue and CNR1 receptors 
(green) at 1000x magnification. Similar findings were observed in two 
independent experiments.   
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3.4 DISCUSSION 
 
3.4.1 CHARACTERISATION OF CNR1 
STATUS IN PROSTATE CANCER 
 
Molecular genetic analysis by our team and others revealed a frequent 
deletion in the 6q15 region in prostate cancer and the downregulation of a 
number of genes at this region, including CNR1 (Verhagen, Hermans et 
al. 2002, Liu, Chang et al. 2007, Shan, Ambroisine et al. 2010, Boyd, Mao 
et al. 2012). I aimed to further investigate the potential of CNR1 as a TSG 
in prostate cancer and characterise CNR1 status in available prostate 
cancer cell lines for further functional studies. 
Tumourigenesis frequently occur when DNA sequences of genes 
encoding proto-oncogenes or tumour suppressor genes (TSGs) are 
altered. Alterations in proto-oncogenes may affect their function, resulting 
in constitutive activation and promotion of cell division (Bishop 1987), while 
any defects including deletion or mutations in TSGs also contribute to 
cancer formation.  First, I sequenced the coding region and 1kbp strong 
regions of the CNR1 gene in five prostate cancer cell lines, 22RV1, 
LNCaP, DU145 and PC3 and a non-malignant immortalized epithelial 
prostate cell line, PNT1a. No mutations were detected in the coding or the 
promoter regions of CNR1. To further investigate any mutations in CNR1 
in prostate cancer patients, a large number of clinical samples was 
analysed using a Fluidigm genomic amplification technology in 
combination with the next generation sequencing.  However, after 
comparing the sequences of the tumours with paired normal clinical 
samples, there was no evidence of somatic mutations in the CNR1 gene. 
It has been reported that a high frequency of GàA mutation in the CNR1 
gene was detected in eosophageal cancer (Bedoya, Meneu et al. 2009). 
Of the 139 tissues from the 29 eosophageal cancer patients, homozygous 
G/G was found in 15 and heterozygous G/A were detected in 85 samples. 
The patients with an A/A type had a reduced survival time in comparison 
to a G/G type. In addition, a study in colorectal cancer has shown that 
patients, who had genotype G/A or A/A, had a shorter overall survival time 
than G/G wild- type patients (Bedoya, Rubio et al. 2009). These studies 
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suggest that this point mutation inactivated CNR1 in cancers (Bedoya, 
Rubio et al. 2009, Meneu-Diaz, Bedoya et al. 2011). In prostate cancer, 
somatic mutations in the CNR1 gene appear not to be a main mechanism 
of inactivation.  
 
There is an increasing focus on the role of polymorphisms in prostate 
cancer development and progression. In my study, I detected the 6bp 
polymorphisms in CNR1 promoter region. Transcription factors (TFs) 
control the transcription of its target gene by binding to the transcription 
factor-binding sites (TFB) in the promoter region (Spitz and Furlong 2012). 
Identifying polymorphisms in the promoter would be a strong indication of 
disruption of transcription if they overlap with transcription factor binding 
sites. Using transcription factor binding site prediction tools (TRANSFEC), 
I found that the 6bp polymorphism causes the addition of the following 
transcription factors: c-Ets-1, Elk-1, GR-alpha, STAT4, and TFII-1. The 
promoter region controls and regulates mRNA transcription, making it the 
most important regulatory region. In my study, I found that the addition of 
6pb polymorphisms generally correlated with CNR1 expression in prostate 
cancer cell lines. All the prostate cancer cell lines only contain the longer 
allele type (154bp), except PC3 cells where both the shorter (147bp) and 
longer (154bp) alleles are present. Interestingly, PC3 cells have much 
lower CNR1 expression compared to the other cancer cell lines. However, 
the effects of the polymorphism in the CNR1 promoter would have to be 
confirmed, for example by using a luciferase promoter-reporter assay in 
prostate cancer cells. Due to time limitations, these studies were not 
performed during my PhD thesis. 
 
As there are very limited number of cell lines for the correlation of the 
polymorphism and CNR1 expression, I further investigated the 6bp 
polymorphisms in the CNR1 gene promoter for its involvement for prostate 
tumourigenesis in Chinese cases and controls, for which we have access 
to samples. The frequency of the longer alleles was slightly more common 
in Chinese normal than cancer samples. However, statistically, the longer 
allele (with insertion) was not associated with prostate cancer risk.  
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In conclusion, polymorphism tests for CNR1 gene (with long sequences) 
were not associated with prostate cancer incidence of the Chinese 
population, which discourages the further investigation of its role in UK 
samples, which we have not collected.  
 
3.4.2 EXPRESSION OF CNR1 GENE IN 
PROSTATE CANCER 
 
It is known that CNR1 is mainly distributed in the nervous system, however, 
this receptor has also been detected in various non-neuronal tissues 
including prostate (Miller and Devi 2011). I found CNR1 gene expression 
in both several human prostate tissues and cell lines, regardless of whether 
the samples were benign or malignant. 
 
A recent report demonstrated that CNR1 expression was silenced in 
human colorectal cancer due to methylation of the CNR1 promoter and that 
loss of CNR1 accelerated intestinal tumour growth in vivo (Wang, Wang et 
al. 2008). According to the findings in our group (Shan 2010), CNR1 is 
downregulated in prostate cancer cell lines and clinical samples compared 
to normal BPH samples. Therefore, I further investigated the expression of 
CNR1 in prostate cancer. 
 
According to my results, gene expression of CNR1 in LNCaP and 22RV1, 
DU145 but not PC3, are higher than immortalized epithelial prostate cells 
PNT1a and PNT2 at mRNA level. This finding is in slight contrast to the 
previous findings for the CNR1 by our group (Shan 2010) where under-
expression of CNR1 in prostate cancer cell lines LNCaP, 22RV1, DU145 
compared with BPH. The reason for the different findings is unclear, but 
maybe due the use of different control samples and also quantitative RNA 
detection method including Taqman probe/primers. Shan et al 2010 
performed RT-qPCR using probe/primers detecting the entire exon 4, 
which lied within a single exon which could be the reason for the low 
expression of CNR1 reported in prostate cancer cell lines (Shan 2010). I 
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used probe/primers span exon-exon junctions that bind the coding region 
of CNR1 to ensure that the primers cannot associate with gDNA.  
The discrepancy in results between these two methods may lie in the 
specificity of the primers. Another reason for this conflict in our results may 
also be due to using different controls that do express the CNR1 gene. In 
my RT-qPCR assay, I included two non-malignant control cells PNT1a and 
PNT2 to support the expression of CNR1 in prostate cancer cell lines, 
whereas in previous RT-qPCR study, BPH was used as a positive control. 
It was reported that CNR1 expression was found to be high in BPH, 
prostate cancer clinical samples and PrEC cells (ORELLANA-
SERRADELL, POBLETE et al. 2015). However, Other published papers 
showed that CNR1 was expressed in most prostate cancer cell lines 
including 22RV1, LNCaP, DU145 which supports my findings (Ruiz-
Llorente, Sanchez et al. 2003, Sanchez, Ruiz-Llorente et al. 2003, 
Sarfaraz, Afaq et al. 2006, Chung, Hammarsten et al. 2009).  
 
In addition I found that PC3 has low expression of CNR1 at mRNA and 
protein level, which is consistent with our previous findings (Shan 2010) 
and other published studies, where low expression of CNR1 at mRNA  
(Kamiyama, Fukasawa et al. 2013) and protein level (Christopher John 
Fowler 2009) were also detected at low level in PC3 cells. Moreover, this 
low expression was supported by the deletion of the CNR1 genomic region, 
which results in the low expression of CNR1. 
 
CNR1 protein expression assessment with a specific anti-CNR1 antibody 
would greatly improve the understanding of expression and the role of 
CNR1. However, recent studies have reported that a series of commercial 
CNR1 antibodies do not specifically detect CNR1 by western blot or IHC 
analysis (Grimsey, Goodfellow et al. 2008). Therefore the antibodies 
against CNR1 products were carefully tested and antibody-working 
conditions were optimised prior to use in further studies. First I evaluated 
a number of CNR1 antibodies in including C-terminal and N-terminal 
antibodies in prostate cancer cell lines as well as human brain tissues and 
found Abcam antibody works well but not the other antibodies reviewed in 
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the literature. I found that antibodies corresponding to C-terminal amino 
acids of the human CNR1 are more likely to detect CNR1 receptors in 
prostate cancer cell lines and brain tissues. However, Rabbit polyclonal 
Merck (209550) antibody, a recombinant protein consisting of the first 77 
amino acid of rat CNR1 receptor, failed to detect CNR1 receptors in 
prostate cancer cell lines and brain tissues.  
 
The anti-CNR1 antibodies ab23703 and L13 detected endogenously 
expressed CNR1 by western blot analysis giving bands at ~63 kDa 
(CNR1) and ~49 kDa (CNR1b) in the prostate cancer cell lines (LNCaP, 
22RV1, DU145, VCaP) which are consistent with previous published 
publications (Shire, Carillon et al. 1995, Ruiz, Miguel et al. 1999, Sarfaraz, 
Afaq et al. 2005, Czifra, Varga et al. 2009, Brown, Cascio et al. 2010). 
However, western blotting with both ab23703 and L13 antibodies are also 
associated with additional bands at other molecular weights.  A possible 
explanation is that these immunoreactive protein bands are in fact artefact 
of the isolation process.  
My western blot study supported my evidence for the poor specificity of 
the N-terminal antibodies for CNR1. One of the particular concerns was 
the detection of multiple proteins with different sizes to the CNR1 isoforms 
and failed to detect the positive control.  A possible explanation for the 
inefficiency of this antibody is that the protein conformation might change 
during the sample denaturation affecting the antibody recognition of the 
epitope by the antibody (Bass, Wilkinson et al. 2016). Also, although 
specific bands at ~45 kDa and ~35 kDa were identified by sc-10066, these 
molecular weights differ to the size commonly reported for this antibody at 
~49 to ~63 kDa.  
Previous studies have shown that CNR1 can be glycosylated at one or two 
sites in the N-terminal tail of the receptor generating a protein with a 
molecular mass of 63 kDa and 49 kDa (Song and Howlett 1995, Egertova 
and Elphick 2000, Porcella, Marchese et al. 2002). Alternative spliced 
isoforms have been reported in rat and human (Shire, Carillon et al. 1995) 
A possible explanation for the 49 kDa band is that this protein is an 
alternative spliced isoform of the glycosylated CNR1 receptor. I evaluated 
the Abcam and L13 antibodies for their ability to detect glycosylated CNR1 
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proteins and whether inhibition of glycosylation affects the size of CNR1 
protein detected by western blot using ab23703 and L13 antibodies. I 
found that the Inhibition of glycosylation by tunicamycin treatment in 
LNCaP cells induced the emergence of a prominent band at ~40 kDa when 
ab23703 antibody was used. Therefore, the 63 kDa and 49 kDa bands 
correspond in mass to the glycosylated CNR1 proteins, which were 
supported by previous studies (Shire, Carillon et al. 1995, Song and 
Howlett 1995, Egertova and Elphick 2000). In contrast, the use of L13 
antibody using the same approach did not show the low molecular weight 
band after treating LNCaP cells with tunicamycin and there was no 
apparent change of the density of ~63 kDa band. While it is difficult to 
explain the western blot results using L13, this experiment led to the 
selection of ab23703 antibodies for further application.  
 
Further validation of antibodies was carried out by targeting specific genes 
in mammalian cells for knockdown analysis, siRNA techniques have been 
widely adopted for functional gene studies (Elbashir, Harborth et al. 2001). 
The introduction of siRNA into target cells is critical for gene silencing. 
Thus, I further confirmed the specificity of the anti-CNR1 antibody 
ab23703 as I knocked-down CNR1 using double and reverse transfection 
of cells with siRNA. The idea of using two different approaches was to 
insure that both CNR1 and CNR1b were knocked down at the protein 
level. I found that both siRNA transfection protocols were efficient in 
decreasing CNR1 at protein levels in LNCaP cells using western blot 
analysis. My data demonstrate that the reverse transfection method is 
more effective than the standard siRNA gene knockdown and improved 
the knockdown of CNR1 expression at protein levels.    
 
Finally, to continue the story of confirming the specificity of the ab23703 
antibody, I used immunofluorescence (IF) microscopy, as it is also a 
broadly applicable method used to assess the expression levels of CNR1 
receptors (Pisanti, Picardi et al. 2011). The specificity of the antibody was 
confirmed. CNR1 is a cannabinoid receptor localised at the plasma 
membrane. Stably transfected 22RV1 cells, was used as a positive control, 
as it was demonstrated to have high CNR1 mRNA expression using RT-
 118 
qPCR analysis. In my studies, a decrease in CNR1 protein expression was 
observed in the stably transfected 22RV1 cells following siCNR1 treatment.  
Importantly, the protein expression of CNR1 was found to be under-
expressed in these 22Rv1 siCNR1 targeted cells after 24 h of treatment. 
The results were in agreement with previous IHC analysis that showed 
reduced receptor levels in the cell membrane (Shan 2010).  
My findings are also consistent with several other published studies 
showing that CNR1 was expressed in prostate cancer cell lines, including 
22RV1, LNCaP and DU145, and PC3 but at different levels using 
immunofluorescence imaging analysis (Sarfaraz, Afaq et al. 2005, Chung, 
Hammarsten et al. 2009, Czifra, Varga et al. 2009, Brown, Cascio et al. 
2010). The Abcam antibody applied here for IF analysis has been 
demonstrated to have high specificity in prostate tissue (Chung, 
Hammarsten et al. 2009). Chung et al had examined CNR1 expression 
using IHC analysis in 372 prostate cancer cases and 349 BPH samples 
(Chung, Hammarsten et al. 2009) and this study used the same CNR1 
antibody (Abcam). 
 
Overall, my results in this chapter confirmed the high expression of CNR1 
in prostate cancer cell lines with low expression in PC3 at mRNA and 
protein levels. Also, it showed that the expression of CNR1 at the mRNA 
level correlated with the protein levels in prostate cancer cell lines. The 
low expression of CNR1 at mRNA and protein level correlated with the 
presence of hetero-alleles in PC3 cells. Furthermore, the ab23703 
antibody proved to be specific for CNR1 receptors and can be used for 
further functional studies to investigate the role of CNR1 in prostate 
cancer. Although it is possible that the differences generated between the 
studies were caused by different cell linages or cell culture conditions, 
such as different media and growth factors, the misrecognition of a 
nonspecific band at the expected size of the CNR1 protein might have 
been the main reasons for these conflicting results. The conflict between 
a potential tumour suppressor role and reported high expression of CNR1 
may by due to the difficulty in accurate detection of CNR1 protein 
expression caused by the uncertainty of a specific and reliable antibody 
or/and a possible reason for the discrepancy between gene and protein 
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expression is that other post-transcription and/or post-translation 
mechanisms affect CNR1 expression. Moreover, as CNR1 is located at 
6q15, one of the most frequently deleted regions in prostate cancer; DNA 
mutation or methylation may reduce the receptor activity. Also, 
deregulation in downstream signalling pathways in some of the patient 
samples may have caused the reduction of receptor activity.   
 
Different observation supported the upregulation of CNR1 in prostatic 
adenocarcinoma tissues, and several cell lines including PC-3, DU-145, 
LNCaP, CWR22Rv1 and CA-HPV-10, as compared with normal prostate 
epithelial cells (Sarfaraz, Afaq et al. 2005, Chung, Hammarsten et al. 
2009, Czifra, Varga et al. 2009, Brown, Cascio et al. 2010, Sharma, 
Hudson et al. 2014). These observations agreed with my findings where 
CNR1 was upregulated in prostate cancer cell lines including DU145, 
LNCaP, and 22RV1. Furthermore, an extensive study of  human prostate 
cancer samples revealed the expression level of CNR1 was considerably 
higher in prostate cancer tissues than in normal prostate tissues (Chung, 
Hammarsten et al. 2009). Other cancer types including hepatocellular 
carcinoma (Xu, Liu et al. 2006) and pancreatic ductal adenocarcinoma 
showed an increased level of CNR1 expression in human pancreatic 
tumour cell lines as well as in biopsies of human pancreatic tumours, 
whereas in samples obtained from normal pancreatic tissue, mRNA levels 
for these receptors were very low or could not be detected (Carracedo, 
Gironella et al. 2006). 
 
Relatively large amount of data have accumulated during the last decade 
about the role of CNR1 receptors in tumour generation and progression. 
In many cases, these reports showed that levels of CNR1 are increased 
in cancers including prostate cancer, a situation that frequently correlates 
with tumour aggressiveness (Malfitano, Ciaglia et al. 2011). It was found 
that patients with a tumour with higher CNR1 expression had a 
significantly higher proportion of Gleason scores 8–10, and metastases at 
diagnosis (Chung, Hammarsten et al. 2009), indicating that a high tumour 
CNR1 score is associated with prostate cancer severity of the disease and 
poor prognosis (Chung, Hammarsten et al. 2009). In other types of cancer, 
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Fowler et al, reported that the level of CNR1 receptor expression in 
colorectal cancer is associated with the tumour grade in a manner 
dependent upon the degree of CpG hypermethylation. They found that the 
high CNR1 is indicative of a poorer prognosis in stage II microsatellite 
stable tumour patients (Gustafsson, Palmqvist et al. 2011).  Furthermore, 
CNR1 receptor levels are also increased and correlate with disease 
severity in human epithelial ovarian tumours (Messalli, Grauso et al. 2014) 
and have been proposed to be a factor of bad prognosis following surgery 
in stage VI colorectal cancer  (Jung, Kang et al. 2013, Velasco, 
Hernández-Tiedra et al. 2015).  
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     4    CHAPTER FOUR RESULTS 
 STUDY OF THE ROLE OF  CNR1 IN 
PROSTATE CANCER 
 
Recent studies have demonstrated that CNR1 regulates cell growth (Olea-
Herrero, Vara et al. 2009, Preet, Qamri et al. 2011), cell proliferation 
(Sarfaraz, Afaq et al. 2006, Sarfaraz, Adhami et al. 2008, Xian, Park et al. 
2010) and cell survival (Velasco, Hernández-Tiedra et al. 2015) (Pisanti, 
Picardi et al. 2011) in response to different stresses. The altered CNR1 
expression has been linked with the development and growth of various 
cancers (Bedoya, Meneu et al. 2009, Bedoya, Rubio et al. 2009, Larrinaga, 
Begoaa et al. 2010, Meneu-Diaz, Bedoya et al. 2011).  
 
It is well known that CNR1 signalling pathways control cell proliferation, 
differentiation and survival.  Deregulated CNR1 signalling pathways results 
in proliferation and contribute to the formation and progression of human 
cancers, including breast, pancreatic, lung and prostate cancers (Mimeault, 
Pommery et al. 2003, Sarfaraz, Afaq et al. 2005, Carracedo, Gironella et al. 
2006, Xu, Liu et al. 2006, Ramer and Hinz 2008, Chung, Hammarsten et al. 
2009, Zogopoulos 2015). Recently, the functional roles of CNR1 signalling 
in prostate cancer have been widely studied. Accumulated evidence suggest 
an active role for CNR1 involvement in the development and progression of 
prostate cancer (Pacher, BÅTkai et al. 2006). However, the exact role of 
CNR1 in prostate cancer is still unclear.  In this study, I investigated a 
potential role of CNR1 in the development and progression of prostate 
cancer.  
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4.1 EFFECT OF CNR1 KNOCKDOWN IN PROSTATE 
CANCER CELLS  
 
4.1.1 KNOCKDOWN OF CNR1 IN DU145 CELLS 
 
I previously examined the expression of CNR1 using qRT-PCR and 
western blotting, for mRNA and protein determination, respectively, in the 
prostate cancer cell lines 22RV1, LNCaP and DU145. However, the 
knockdown of CNR1 at the protein level in 22RV1 cells was difficult to 
detect using western blotting, therefore, I used DU145 cells as I found that 
CNR1 was expressed in DU145 cells both at mRNA and protein levels. 
CNR1 was knocked down in DU145 cells using the reverse transfection 
method as it was generally more effective than the standard transfection. 
To evaluate the functional significance of CNR1 in prostate cancer, I 
silenced CNR1 expression using siRNA in DU145 cells and then examined 
the expression of CNR1 in DU145 cell line by RT-PCR and western blot 
analysis. As shown in the Figure 4.1A,B & C, RT-PCR and western blot 
analysis showed that the mRNA and protein expression levels of CNR1 
were significantly decreased (P<0.001) by CNR1 siRNA with 80% 
reduction when compared with their expression in non-targeting siRNA. 
This demonstrates that CNR1 could be knocked-down in the prostate 
cancer cell line DU145, which supported further functional analysis of the 
gene in these cells. 
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Figure 4.1 Knockdown efficiency of CNR1 in DU145 cells. (A) Relative 
mRNA levels of CNR1 in DU145 cells quantified by qRT-PCR, showing a 
significant reduction after 48 hours of CNR1-siRNA (siCNR1) treatment 
compared to non-targeting siRNA (NT). CNR1 mRNA levels were 
quantified relative to the housekeeping gene GAPDH. (B) Bar chart 
representation of CNR1 protein expression in DU145 cells, showing a 
significant reduction of CNR1 protein levels after 48 hours of siCNR1 
treatment compared to Non-Targeting siRNA (NT). Protein levels of CNR1 
were quantified relative to the housekeeping protein β-actin. (C) Western 
blotting showing CNR1 expression levels after NT and siCNR1 treatment. 
(A-B) Mean ± SEM of triplicate determinations (***P<0.001; by two-tailed 
t-test). C) One Western blot image representative of three independent 
experiments.  
 
4.1.2 KNOCKDOWN OF CNR1 PROMOTES CELL 
PROLIFERATION IN THE DU145 PROSTATE 
CANCER CELLS  
 
4.1.2.1  Cell Viability analysis 
 
To evaluate the effect of CNR1 on cell proliferation, I analysed cell viability 
by the MTS cell proliferation assay. The results demonstrate a significant 
increase in DU145 cells proliferation/viability after down-regulation of CNR1 
(P<0.01) within 72h of siRNA transfection (Figure 4.2). This suggests that 
CNR1 knockdown caused a significant increase in prostate cancer cell 
viability.   
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Figure 4.2 Cell viability upon CNR1 knockdown in 
DU145 cells. Cell viability levels of DU145 cells after non-
targeting siRNA (NT) and CNR1 siRNA (siCNR1) for 48 and 
72 hours treatment. Data are presented as means ± 
standard deviations of 3 independent experiments SEM± 
(**P<0.01; by two-tailed t-test). 
 
 
4.1.2.2  Colony formation analysis 
 
Moreover, to confirm the inhibitory effect of CNR1 on cell growth of prostate 
cancer cells, I used a colony formation assay after transfecting DU145 cells 
with siCNR1 for 48 h (Figure 4.3A). The number of the colonies was 
observed in both CNR1 siRNA infected cells and the non-targeting siRNA 
cells. Clone formation rate of CNR1 siRNA transfected cells (362.5 ± 17.5, 
n=2) in DU145 cells was significantly higher (P<0.05) compared to non-
targeting siRNA cells (247.5 ± 17.50; n=2) (Figure 4.3B). The colonies in 
siRNA CNR1 knockdown cells were apparently bigger than non-targeting 
siRNA cells (Figure 4.3), but this was not measured. These data strongly 
support that with the decrease of CNR1, both the numbers and the sizes of 
the colonies are increased. Therefore, cell viability and colony formation 
assays indicate that CNR1 may act as a potential tumour growth suppressor 
gene in prostate cancer.  
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Figure 4.3 Colony formation assay in DU145 cell after CNR1 knockdown. (A) 
Image of colony formation assay of non-targeting siRNA (NT) and siCNR1 DU145 
cells. The cells were treated with siCNR1 for 48 h, then reseeded the cells for 
colony formation assay and were incubated for 7 days. Colony formation assay 
showing increased colony formation in numbers and sizes of colonies compared 
to non-targeting cells (NT). (B) Bar-chart of a number of colonies in non-targeting 
(NT) and siCNR1-targeting in DU145 cells treatment. Data are presented as 
means of 2 independent experiments ± SEM (*P<0.05; by two-tailed t-test). 
 
 
4.1.3 EFFECTS OF CNR1 SILENCING ON MIGRATION 
AND INVASION OF PROSTATE CANCER CELLS   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
The ability of tumour cells to migrate from the site of the primary tumour to 
invade surrounding tissues is a prerequisite for metastasis, which is the 
major cause of cancer-related mortality. Hence to evaluate the role of CNR1 
in prostate cancer, the effect of CNR1 knockdown on cell migration and 
invasion were investigated.  
  
 
 
4.1.3.1  Cell Migration 
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A scratch-wound assay was employed to study the effect of siCNR1 on 
DU145 cells. The scratch wound was induced by micropipette tips, and 
damaged cells were removed by changing of the culture media. As shown 
in Figure 4.4A and 4.4B, cells along the wound lines were viable after the 
scratch. The siCNR1 treated cells migrated rapidly to fill up the gap created 
by wounding and the gap was closed within 16h. The cells treated with non-
targeting cells siRNA migrated much slower than siCNR1 treated cells and 
closed the gap after 16h incubation. These results implicate the involvement 
of CNR1 in inhibiting cell migration.  
  
To further confirm the role of CNR1 in the progression of prostate cancer, 
Using the Transwell cell migration assay (Figure 4.5A), cells were seeded 
into the upper chamber with 1% fetal bovine serum (FBS) to promote 
migration to the lower chamber with 10% FBS levels. The number of 
migrating cells for non-targeting and CNR1 siRNA treated cells were 387.5 
± 26.5 and 719.5 ± 32.5 (averages ± SEM; n=2), respectively  (Figure 4.5). 
Compared with non-targeting control, the migrated number of cells in CNR1 
siRNA treated cells significantly increased (P<0.02). The results suggest 
that silencing of CNR1 promoted the migration of prostate cancr cells, 
indicating that CNR1 may act as tumour suppressor gene in prostate cancer.           
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Figure 4.4 Scratch-wound assay in DU145 cells after CNR1 knockdown. (A). 
Non-Targeting siRNA in DU145 cells. (B). siCNR1 targeting cells.  Cells were treated 
with siRNA-CNR1 (48h) migrated faster compared to Non-Targeting cells. Cells 
migration was evaluated 16 h after performing the scratch with 200 μl tips. Data are 
presented as one out of 3 independent experiments. 
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Figure 4.5 Transwell cell migration assay in DU145 cells after CNR1 
knockdown. (A) Image of transwell cell migration assay of non-targeting 
siRNA (NT) and siCNR1 treated DU145. (B) Bar-chart of a number of 
migrated DU145 cells upon NT and siCNR1 treatment. Data are 
presented as means ± SEM of 2 independent experiments (*P<0.02; by 
t-test). 
 
4.1.3.2  Cell invasion  
 
To further demonstrate the role of CNR1 in the invasion of prostate cancer 
cells, I employed the loss of function approach to knockdown CNR1 
expression in DU145 cells. I performed a Matrigel-coated Transwell invasion 
assay.  The invasion was determined as cells penetrating through the 
Matrigel-coated Transwell chambers and travel through 8 μm pores to the 
other side of the inserts (Figure 4.6A). The number of invading cells  in non-
targeting and CNR1 siRNA treated cells were 44.5 ± 1.5 and 77 ± 4 
(averages ± SEM; n=2) respectively (Figure 4.6B).  Compared with non-
targeting control treated cells, the invading number in CNR1 siRNA treated 
cells significantly increased (P<0.05; Figure 4.6B); confirmed by crystal 
violate staining of the cells in the upper chamber of the transwell inserts. The 
results suggest that silencing of CNR1, promotes the invasion of prostate 
cancer cells, indicating that CNR1 plays an important role in invasive 
prostate cancer.  
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Figure 4.6 The effect of CNR1 knock-down on cell invasion in DU145 cells 
examined by Matrigel invasion assay. (A) Schematic representation of 
Transwell chambers. Transwell chambers consist of a lower and an upper 
chamber coated with matrigel separated by a porous membrane. (B) Bar-chart 
showing that cells treated with siRNA-CNR1 (48 h) had increased migration to 
the lower chamber of the Boyden Chambers compared to cells treated with 
Non-Targeting siRNA (NT). Data are presented as means ± SEM of 2 
independent experiments (*P < 0.02). The invasion was measured by 
determining the number of cells that penetrated through Matrigel-coated 
Transwell chambers.  Cells were counted in five fields.  
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4.1.4 KNOCKDOWN OF CNR1 IN DU145 CELLS 
STIMULATED CELLS IN THE G1-PHASE TO 
PROGRESS THROUGH THE CELL CYCLE  
 
To continue investigating the effect of CNR1 knockdown in DU145 cells, I 
performed DNA cell cycle analysis to assess the distribution of cells in the cell 
cycle. Cells (1.2x104 cells/well) were seeded in 6-well plates and incubated with 
siCNR1 for 24 h. The siCNR1 treatment resulted in a significant decrease of the 
number of cells in G1-phase (P> 0.015) of the cell cycle in comparison to non-
targeting cells (Figure 4.7) after 24h. The decrease in the number of cells in the 
G1-phase was coupled with a significant increase in accumulation of cells in the 
G2/M phases compared to non-targeting cells (P> 0.015). These results 
suggested that siCNR1 causes cells in G1 to progress and enter the cell cycle 
promoting cell proliferation (Figure 4.8) by accelerating passage through the cell 
cycle. 
 
Figure 4.7 CNR1 knockdown effects on cell cycle distribution in DU145 
cells. Cells were transfected with siCNR1 and non-targeting reagents for 48 
h moved to method section. The siCNR1 treatment resulted in a significant 
decrease of DU145 cells in G1, increase in S phase (p > 0.05) and G2/M 
phases (P> 0.015) of the cell cycle in comparison to non-targeting cells. The 
percentages of cells in the sub-G1, G0/G1, S and G2/M phases were 
calculated using Waston Pragmatic integration with FlowJo 9.1 software.  
Data presented here are from two independent experiments.   
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 A Non-targeting DU145 cells 
      
 
 
B siCNR1 targeting DU145 cells 
      
Figure 4.8 Effect of CNR1 knock-down on cell cycle distribution in the 
DU145 prostate cancer cells. A) Cells were treated with non-targeting 
siRNA. B) Cells were treated with siRNA-CNR1 reagent.  Data shown here 
are representative of two independent experiments. M1 (sub-G1), R1 (G1), 
R2 (S), and R3 (G2/M) phases.   
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4.2 CNR1 ACTIVATION IN VITRO TO INVESTIGATE 
THERAPEUTIC POTENTIAL OF CANNABINOID 
ANALOGUES IN TREATING PROSTATE CANCER  
 
 
4.2.1 CNR1 ACTIVATION BY CANNABINOID AGONIST 
HU210 REDUCES PROSTATE CANCER CELL 
VIABILITY 
 
Although recent studies have shown that cannabinoids have an inhibitory 
effect on cell growth and migration of cancer cell (Carracedo, Gironella et al. 
2006, Ramer and Hinz 2008, Olea-Herrero, Vara et al. 2009, Guindon and 
Hohmann 2011, Velasco, Sanchez et al. 2012), not much is known about 
the effects of cannabinoid agonists on inhibiting prostate cancer growth and 
progression. I therefore, investigated the effects of the synthetic CNR1 
receptor agonist HU210 on prostate cancer cell proliferation, viability and 
migration.  
 
The HU210 [(−)-1,1-dimethylheptyl is a synthetic CNR1 agonist and an 
analogue of 11-hydroxy-Δ8–tetrahydrocannabinol. (THC). HU-210 also has 
affinities for CNR1 and CNR2 receptors that exceed other cannabinoids. 
Therefore, HU-210 is a particularly potent CNR1 agonist. Its pharmacological 
effects in vivo are also exceptionally long lasting (Pertwee, Howlett et al. 
2010). The enhanced affinity and relative intrinsic activity shown by HU-210 
at cannabinoid receptors can be largely attributed to the replacement of the 
pentyl side chain of 8-THC with a dimethylheptyl group, it is a potent CNR1 
synthetic agonist (Pertwee 2000, Gilgun-Sherki, Melamed et al. 2003). To 
my knowledge, the response to HU210 treatment has not been studied in 
depth in prostate cancer cells.  
 
I observed a dose-independent inhibitory effect of HU210 on the proliferation 
of all tested prostate cancer cell lines (Figure 4.9) the CNR1-positive LNCaP, 
22RV1 and DU145 cells and the low level of CNR1 in PC3 cells. Cells were 
treated with different concentrations of HU210 (1000, 500, 250, 125, 62.5, 
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31.25, 15.62, 7.8, 3.9, 1.95 µM) for 24 h and EC50-values were determined 
by the MTS viability assay (22RV1: 7.2±1.84 µM, LNCaP: 21.9± 5.98 µM, 
DU145: 29.7± 2.51 µM and PC3: 17.4± 5.88 µM, averages ± SEM; n=3). 
Cell exposure to HU210 caused dose-dependent cell death in all four 
prostate cancer cell lines (Figure 4.9A). Furthermore, the treatment with 
HU210 agonist showed that 22RV1 cells were more sensitive to the agonist 
compare to other cell lines. Surprisingly, HU210 treatment of PC3 cells 
resulted in similar EC50-value as in LNCaP cells despite the very low levels 
of CNR1 protein in PC3 cells (Figure 3.6), suggesting that this small amount 
of CNR1 receptors are sufficient in suppressing cell growth if activated. 
Therefore, this CNR1 agonist, such as HU210, can induce cell death in 
prostate cancer cells.  
 
(R)-SLV 319 also called Ibipinabant, a drug used in clinical research, acts 
as a potent CNR1 and highly selective CNR1 antagonist with lower 
lipophilicity. It has been used in scientific research as a drug called (SLV319) 
(Srivastava, Soni et al. 2008). The effect of (R)-SLV-319 on prostate cancer 
cell viability is shown in Figure 4.10. Cells were treated with different 
concentrations of (R)-SLV-319 or DMSO and analysed by the MTS viability 
assay 24h later. The highest dose of (R)-SLV-319 at 100µM killed <20% of 
22RV1, LNCaP and PC3 cells while 60% of DU145 cells were killed at this 
dose (Figure 4.10). These results demonstrate that the antagonist had no 
significant effect on cell viability at low doses (<30µM) in any PCa cell line 
after 24h treatment.  
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Figure 4.9 Effect of HU210 on prostate cancer cell viability. (A) Cell viability was assessed after 24h treatments 
using the MTS assay to quantify live cells as an indirect measurement of cell death. Cells were treated with different 
concentrations of HU210 (µM) or DMSO for 24 h (B) EC50-values of CNR1 agonist HU210 in µM, see text for 
values. The percentage of viable cells was determined as the ratio of treated cells to untreated controls (basal or 
DMSO control). Results are representative of triplicate experiments.  
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Figure 4.10 Effect of (R)-SLV-319 on prostate cancer cell viability. Cells were treated with different concentrations 
of (R)-SLV-319 or DMSO for 24 h. Cell viability was assessed using the MTS assay to quantify live cells as an indirect 
measurement of cell death. Results are representative of triplicate experiments.  
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4.2.2 HU210-INDUCED CELL KILLING IS MEDIATED 
THROUGH A CNR1- DEPENDENT MECHANISM 
 
One of the important aspects of an effective anti-tumour drug is its ability to 
inhibit proliferation of cancer cells. Cancer cells proliferate rapidly and 
uncontrolled. Also, cancer cells escape death mechanisms which a normal 
cell undergoes including apoptosis (Chakravarti, Ravi et al. 2014).  
Cannabinoids have been demonstrated to be anti-proliferative and induce 
apoptotic death in cancer cells. 
 
To verify whether the cell death induced in the four prostate cancer cell 
lines was mediated through specific CNR1 activation, I treated LNCaP, 
22RV1, DU145 and PC3 cells for 24 h with a combination of the CNR1 
agonist HU210 (25, 10, 30 and 25 µM respectively) based on the EC50-
values obtained previously for HU210. The doses of the antagonist (R)-
SLV-319 were selected, based on the MTS viability assay (Figure 4.10), at 
a concentration killing <20% of cells (LNCaP; 25 µM, 22RV!; 15 µM, 
DU145; 25 µM and PC3; 25 µM). The reduction in cell viability induced by 
the cannabinoid HU210 was significantly prevented by (R)-SLV-319 in all 
evaluated cell lines (P <0.01; Figure 4.11). These results indicate that the 
inhibiting effects of the agonist on cell viability are mediated by CNR1 
activation. Furthermore, no significant reduction in cell viability was noted 
when cells were treated with antagonist alone. The reduction of HU210-
induced cell death by (R)-SLV-319 blockage of CNR1 in PC3 cells, which 
is similar to the value observed in LNCaP cells further confirms that there 
are low level receptors present in PC3 cells and that this small amount of 
CNR1 are very active in suppressing cell growth if activated.  
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Figure 4.11 HU210 reduces cell viability of 22RV1, LNCaP, DU145 and PC3 cells by activation of the CNR1. 22RV1, LNCaP, 
DU145 and PC3 cells cultured in serum-free medium in the presence of a combination of CNR1 agonist (HU210) and antagonist 
(R)-SLV-319) 10/15, 25/25, ,30/25 and 25/25 µM respectively for 24 h. Cell viability decreased in the presence of HU210 that was 
significantly reversed by addition of (R)-SLV-319. A significant effect on cell viability was not seen in cells treated by the vehicle 
alone. Cell viability was expressed as a percentage compared to non-treated controls (Ctl). Data are presented as means ± SD 
of 3 independent experiments (**P < 0.01, ***P < 0.001) 
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4.2.3 EVALUATION OF THE INDUCTION OF APOPTOSIS 
UPON HU210-ACTIVATED CNR1 
 
Since treatment of prostate cancer cells lines with HU210 decreased cell 
viability (section 4.2.1), I therefore, evaluated whether CNR1 activation by 
HU210 induced apoptosis. Cell cycle analysis was performed by FACS in 
LNCaP, 22RV1, DU145 and PC3 cells treated with 25, 10, 30 and 25 µM of 
HU210 for 24 h. DNA content was assessed according to the detection of 
Propidium Iodide. For all evaluated cell lines, cell cycle histograms showed 
that HU210 treatment increased the number of cells distributed in the sub-G1 
phase in comparison to the untreated cells (Figure 4.12 & 4.13). In PC3 cells, 
where CNR1 expression is low, HU210 treatment also caused accumulation 
of 10% of PC3 cells in the sub-G1 phase. These results suggest that HU210 
may cause cell death through induction of apoptosis.      
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Figure 4.12 The effect of HU210 agonist on cell cycle distribution and sub-
G1 population. The chart indicates the cell cycle phases sub-G1 (apoptosis), 
G1, S, and G2/M, measured by fluorescence emission at 617 nm (FL-2) after 
treating with RNase A and staining with PI. The cells treated with HU210 or 
DMSO for 24 h. The percentage of cells in the sub-G1, G1, S, and G2-M phases 
was calculated using Waston Pragmatic integration with FlowJo9.1 software. 
The data shown here are from three independent experiments. The effect of 
HU210 on inducing apoptosis in prostate cancer cell lines, 22RV1, LNCaP,, 
DU145 and PC3 was determined by the accumulation of cells in sub-G1 phase.  
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Figure 4.13 HU210 agonist affects cell cycle distribution and the sub-G1 
phase.  Representative cell cycle profiles from flow cytometry of 22RV1, 
LNCaP, DU145 and PC3 cells treated with HU210 or DMSO for 24 h. Data 
shown here are representative of three independent experiments. The 
histogram indicates the phases of the cell cycle: sub-G1, G1, S and G2/M. 
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To further investigate whether apoptosis played a role in the HU210-
mediated cell death, I explored the levels of caspase-3 activation and PARP 
cleavage by western blot. Cells were treated with 4 µM HU210 for 1 h and 
cell lysates analysed for cleavage of PARP and pro-caspase-3 after 24h. I 
found that HU210 treatment decreased the levels of procaspase-3 in all 
prostate cancer cell lines. the downstream signals during apoptosis are 
transmitted via caspases, which upon conversion from inactive to active 
cleaved forms mediate the cleavage of PARP. I found HU210 treatment 
caused increased cleavage of the 116 kDa PARP protein to the 89 kDa form 
that is characteristic for apoptosis (Figure 4.14) in all prostate cancer cell 
lines except in 22RV1 cells. Protein intensity revealed a decrease in the 
protein expression of PARP protein (116 kDa) with a concomitant increase 
in its cleaved product (89 kDa).   
 
   
 
Figure 4.14 Effect of HU210 treatment on pro-caspase-3 and PARP protein 
expression. The protein expression of procaspase-3, PARP and cleavage of 
PARP in prostate cancer cell lines. As detailed in methods, the cells were treated 
with HU210 or DMSO alone for 1h and total cell lysates were prepared for western 
blot analysis. β-actin was used as a loading control with expected size at 43 kDa.  
The data shown here are from a representative experiment repeated two times with 
similar results.  
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4.3 DISCUSSION 
4.3.1 EFFECT OF CNR1 KNOCKDOWN IN PROSTATE 
CANCER CELLS  
  
Cancer cells carry the tumour suppressor and oncogene mutations that 
define cancer as a genetic disease (Hanahan and Weinberg). TSGs 
function by one of the following mechanisms: DNA repair, inhibition of 
regulated progression through cell cycle, induction of apoptosis and 
inhibition of cellular migration and metastasis.  
The altered CNR1 expression has been linked with various cancers 
(Bedoya, Meneu et al. 2009, Bedoya, Rubio et al. 2009, Larrinaga, Begoaa 
et al. 2010, Meneu-Diaz, Bedoya et al. 2011). However, the exact role of 
CNR1 in prostate cancer proliferation has not been clarified. To my 
knowledge, the response to CNR1 knockdown had not been previously 
investigated in prostate cancer. Therefore, I investigated the role of CNR1 
in prostate cancer by knocking-down the receptor in the prostate cancer 
cell line DU145, and examined whether the knockdown would increase 
cell viability. I found that depletion of CNR1 led to a significant increases 
in cell proliferation and colony formation. Similar results have been 
reported in colorectal cancer where the inhibition of CNR1 accelerated 
intestinal adenoma growth in ApcMin/+ mice whereas activation of CNR1 
attenuated intestinal tumour growth by inducing cell death via down-
regulation of anti-apoptotic factor survivin  (Wang, Wang et al. 2008). 
These results suggest that activation of the CNR1 gene may inhibit cell 
proliferation in prostate cancer cells. It would be interesting to further 
investigate if survivin may also play a role in mediating CNR1 mediated 
prostate cancer cell growth inhibition. 
 
Metastasis is a multifactorial process that includes the acquisition of a 
motile and invasive phenotype. During progression to a metastatic 
phenotype, tumour cells undergo a series of changes that begin with loss 
of contact inhibition and increased motility, allowing them to migrate from 
the primary tumour site, invade distant organs, and induce neo-
vascularization resulting in metastasis (Laezza, Pisanti et al. 2008). 
Several models of tumour invasion and metastasis have been 
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proposed, although different mechanisms will be used in different cancers 
(Weigelt, Peterse et al. 2005, Phay and Ringel 2013). In my study I found 
that knocking down CNR1 increased the ability of DU145 cells to invade a 
Matri-gel matrix. It has been reported that CNR1 receptor mediates 
inhibition of transmigration in MDA-MB-231, a highly invasive human 
breast cancer cell line (Laezza, Pisanti et al. 2008). My study 
demonstrates that CNR1 can inhibit the growth and invasion of prostate 
cancer cells and further support the involvement of CNR1 inactivation in 
the malignant progression of prostate cancer. Therefore, the above results 
provided evidence to suggest that CNR1 may play a potential tumour 
suppressor role in prostate cancer.   
 
It is well recognised that uncontrolled cellular growth, a consequence of 
defects in the cell cycle, is responsible for the development of most 
cancers including prostate cancer (Sarfaraz, Afaq et al. 2006). I therefore, 
further investigate the effect of CNR1 as a TSG on the cell cycle 
distribution in prostate cancer cell lines. In this part of my research, I found 
that CNR1 knockdown resulted in significant decrease of DU145 cells in 
the G1-phase of the cell cycle in comparison to non-targeting cells. The 
knockdown of CNR1 stimulates the cells from G1 to enter the cell cycle 
resulting in cell proliferation. It would be interesting to further investigate 
cell migration and invasion in the presence of agonist and antagonist to 
prove the activation of CNR1 may suppress tumour progression by 
inhibiting cancer cell migration and invasion .  
 
4.3.2 CNR1 ACTIVATION IN VITRO TO INVESTIGATE 
THERAPEUTIC POTENTIAL OF CANNABINOID 
ANALOGUES IN TREATING PROSTATE CANCER  
 
Endocannabinoids and other CNR1 agonists are drawing renewed 
attention because of their diverse pharmacological activities such as cell 
growth inhibition, anti-inflammatory effects, and tumour regression in many 
cancers (Freimuth, Ramer et al. 2010, Ramos and Bianco 2012). Data 
from in vitro and in vivo experiments suggest that cannabinoid receptor 
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agonists can reduce tumour growth and induce apoptosis in several 
tumour types, including melanoma, breast and prostate cancer, colon 
cancer, leukemia, and glioma (Joseph, Niggemann et al. 2004, Grimaldi, 
Pisanti et al. 2006, Chakravarti, Ravi et al. 2014, Javid, Phillips et al. 2016). 
Hu210 inhibit the proliferation of EFM-19 breast cancer cells (De 
Petrocellis, Melck et al. 1998, Melck, De Petrocellis et al. 2000). In 
addition, Cannabinoids have been shown to prevent cell proliferation and 
induce apoptosis in prostate cancer (Carracedo, Gironella et al. 2006, 
Sarfaraz, Afaq et al. 2006, Preet, Qamri et al. 2011, Ellert-Miklaszewska, 
Ciechomska et al. 2013, Pellerito, Notaro et al. 2014, Orellana-Serradell, 
Poblete et al. 2015). However, the response to HU210 cannabinoid 
treatment and its role in the control of tumour proliferation has not been 
studied in depth in prostate cancer. In this part of my study, I investigated 
the effects of cannabinoid receptor agonists (HU210) in the prostate 
cancer cell lines and demonstrated that the cannabinoid receptor agonist 
HU210 exerted an antiproliferative and proapoptotic action on prostate 
cancer cell lines through activation of the CNR1 receptor. I found that 
treatment with the CNR1 agonist HU210 of the prostate cancer cells 
(22RV1, LNCaP, DU145 and PC3) resulted in dose-dependent decreases 
of cell viability as determined by MTS assay. The specificity of this effect 
for CNR1 was supported by the CNR1-specific antagonist (R)-SLV-319, 
which was able to significantly restore cell viability in HU210 treated cells.  
Surprisingly, HU210 treatment also reduced cell viability of the PC3 cells, 
despite the low levels of CNR1 protein in PC3 cells, suggesting that there 
are low level receptors present and that this small amount of CNR1 is 
sufficient in suppressing cell growth if activated. It has been reported in 
one study where HU210 rapidly blocked PC3 cell viability and halted cell 
mobility (Christopher John Fowler 2009). Therefore, the use of the specific 
CNR1 receptor blocker (R)-SLV-319 confirmed that this effect was 
produced primarily from the activation of the CB1 receptor. Although there 
may be other pathways causing HU210 induced anti-proliferative effects 
in PC3 cells, the inhibition of HU210 induced anti-proliferative effects by 
(R)-SLV-319 confirms that HU210 induced anti-proliferative effects is 
mediated by activation of this small amount of CNR1 in PC3. It would be 
interesting to investigate further other pathways that may trigger the 
activation of CNR1 in PC3 cells, which may have the potential to decrease 
cancer development, growth, and metastasis. 
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As cancer cells not only proliferate rapidly and uncontrollably but also 
escape apoptosis, a programmed cell death mechanism that involves the 
activation of caspase dependent and independent pathways (Hanahan 
and Weinberg). When the balance between proliferation and apoptosis is 
lost tumour progression may occur. Consistent with this concept, there is 
a need to identify novel targets and mechanism-based apoptosis-inducing 
agents for the management of prostate cancer. It is generally recognised 
that apoptosis is a pivotal cellular mechanism to eliminate cancer cells. I 
therefore, evaluated whether the treatment with the cannabinoid receptor 
agonist HU210 lowers the viability of the prostate cancer cells (22RV1, 
LNCaP, DU145 and PC3) through the induction of apoptosis. Using 
western blot analysis, I observed that HU210 treatment caused a 
significant decrease in the inactive procaspase-3, suggesting cleavage to 
active caspase-3. In agreement with caspase-3 activation the 116 kDa 
PARP protein was cleaved into its apoptosis-related 89 kDa product, 
which is consistent with the effect of HU210 treatment on the 
accumulation of cells in the sub-G1 phase in all tested cell lines. This is 
interesting and may be useful for designing strategies for the management 
of human prostate cancer because CNR1 agonists could reactivate 
apoptosis. Surprisingly, I did not observe cleaved caspase-3; the antibody 
that I used should detect both pro-caspase (35 kDa) and cleaved 
caspase-3 (17 kDa & 12 kDa). I checked if there were low molecular 
weight proteins in the membranes after staining with Ponceu. 
Unfortunately, no weak signal for the cleaved caspase-3. It is possible that 
there is a technical issue to sensitively detect cleaved caspase-3. 
Based on all these data, there is a potential to target CNR1 for prostate 
cancer therapy. It is may be feasible to develop a cannabinoid receptor 
agonists such as HU210 into a novel therapeutic agent for the treatment 
of prostate cancer. 
 
5 CONCLUDING REMARKS 
 
More research is necessary to substantiate the suppressor role of CNR1 
in the management of prostate cancer. One potential strategy to progress 
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the state of knowledge and expertise in the area of prostate cancer 
treatment is presented by the current investigation that demonstrated the 
potential role of the CNR1 gene in prostate cancer. The results of this 
thesis provide additional evidence that CNR1 gene may have a tumour-
suppressing role in prostate cells.  
 
In order to study the tumour-suppressor role of this gene in prostate 
cancer, I investigated the potential mutations in the coding and promoter 
regions of the CNR1 gene in several prostate cancer and non-malignant 
prostate cell lines and 73 prostate cancer samples with combined fluidigm 
amplification and next generation sequencing and found the absence of 
CNR1 mutation. This means that although CNR1 mutation can be a 
genetic mechanism for its inactivation in other cancer development (Wang, 
Wang et al. 2008, Bedoya, Meneu et al. 2009, Bedoya, Rubio et al. 2009), 
it did not appear to contribute to CNR1 inactivation in the tested prostate 
cancer samples. Therefore. 6q15 region genomic deletion, which occurs 
in nearly half of prostate cancer, may be the main mechanism that leads 
to the loss of function of CNR1 in prostate cancer. Recently, epigenetic 
modification, in particular DNA methylation, has been shown playing an 
important role in cancer development and progression. It should be further 
investigated if and to what extend DNA methylation contributes to loss of 
CNR1 function. 
 
I found a high frequency of the longer CNR1 allele of the 6 bp 
polymorphism in the promoter region in prostate cancer cell lines, with the 
potential to bind additional transcription factor proteins. However, our 
further investigation of the polymorphism in a Chinese prostate cancer 
case control study did not support a role in prostate carcinogenesis in the 
Chinese population. As the polymorphism in the CNR1 promoter has a 
trend to correlate to CNR1 expression levels in the limited number of 
prostate cancer cell lines that were available, further studies will be 
required to investigate if this polymorphism disrupts the transcription 
activity of CNR1 and contributes to prostate carcinogenesis in the 
European population.  
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Moving from genomic studies to transcript and protein expression 
analysis, CNR1 has been shown to be expressed at the mRNA and protein 
levels in the prostate cancer cell lines 22RV1, LNCaP, DU145 and PC3 by 
using qRT-PCR and Western blotting, respectively. Moreover, in order to 
confirm and clarify its tumour-suppressing role, CNR1 was further studied 
at the cellular level by diverse functional assays and cell cycle analysis 
in CNR1 knocked-down DU145 cells. I observed that abrogation of CNR1 
activity in these cells resulted in increased cell viability, migration and 
invasion. These cellular studies suggested that CNR1 might act as a 
tumour suppressor gene in prostate cancer.  
 
Another interesting finding is that CNR1 knockdown causes cell 
proliferation via cell cycle progression. This is the first reported study on 
knockdown of CNR1 in prostate cancer suggesting that CNR1 may act as 
a tumour suppressor gene in prostate cells. Our findings provide another 
new evidence that CNR1 plays an essential role in cell growth and may be 
a potent therapeutic target in human prostate cancer, based on which we 
could develop more effective therapeutic approaches to prolong patient 
survival.  
 
Therefore, I determined the effectiveness of using cannabinoid agonists 
for the treatment of prostate cancer by using the CNR1 agonist HU210 in 
22RV1, LNCaP, DU145 and PC3 cells. Treatment of 22RV1, LNCaP, 
DU145, and PC3 cells with HU210 significantly decreased cell viability, 
indicating the anti-proliferative effects of HU210 via activation of the 
cannabinoid receptors. Furthermore, the CNR1-specific antagonist (R)-
SLV-319 was able to significantly restore cell viability suggesting that 
inhibiting effects of the agonist on cell viability are mediated by CNR1 
activation. Moreover, caspase-3 protein expression evaluated by Western 
blotting revealed that treatment with HU120 activated the apoptotic 
pathways in prostate cancer cell lines. Our findings thus demonstrate that 
HU210 is a promising CNR1 agonist agent to use to inhibit prostate cancer 
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cell growth via CNR1 receptors for potential anti-cancer treatment in 
patients.  
 
While the anti-tumourigenic effects of the CNR1 ligands such as 
endocannabinoids and CNR1 agonists may be used for the treatment of 
prostate cancer patients by affecting cancer cell growth, apoptosis, 
angiogenesis, migration, invasion, adhesion, and formation of metastasis 
(Freimuth, Ramer et al. 2010), the tumour suppressor role of CNR1 as 
demonstrated by the current study also suggests the potential use of 
exogenous CNR1 gene in gene therapy. CNR1 gene therapy may be 
especially applicable in patients with tumours expressing low or no CNR1. 
Other research streams could target the down-stream gene(s) of CNR1 
pathway(s) (Freimuth, Ramer et al. 2010, Fowler, Josefsson et al. 2013). 
 
All together, these results demonstrate the foremost tumour-suppressing 
role of CNR1 gene by influencing the proliferation, migration and invasion 
of prostate cancer. Nonetheless these results could encourage further 
investigation of the role of the CNR1 gene in prostate cancer, and lead to 
novel promising treatment strategies in prostate cancer.  
 
 
 
 
 
 
 
6 FUTURE PLANS 
 
 149 
6.1 CHARACTERISATION OF CNR1 STATUS IN 
PROSTATE CANCER 
 
6.1.1 The effect of the polymorphism in CNR1 promoter 
regions in gene transcription activity 
 
We have confirmed that the CNR1 gene has a variant, rs147446147 
insertion located within the upstream promoter region. Given that this 
variant is located in the promoter region, it may affect gene activity and 
transcription.  The effect of the variants on CNR1 gene expression will be 
investigated with relation to prostate cancer.  Both the longer and shorter 
allele DNA fragment of the upstream region of the CNR1 gene will be 
subcloned into the promoter region of a luciferase reporter system for 
analysing the promoter activity with or without the rs147446147 6 bp 
sequence.   
 
 
   6.1.2 DNA methylation in CNR1 in prostate cancer 
 
Inactivation of tumour suppressor genes in cancer cells resulting from 
epigenetic silencing, such as DNA methylation, is as important as genomic 
inactivation.  Therefore, whether DNA methylation of CNR1 contributes to 
the low levels of transcription will be examined in PC3 cells. These cells 
will be treated with the demethylating agent 5-aza-dC and then CNR1 
mRNA and protein expression will be analysed. The methylation of the 
CNR1 upstream promoter sequence will be analysed (1kbp) in prostate 
cancer samples using Bisulfate genomic sequencing.   
 
 
 
 
6.2  STUDY OF THE ROLE OF  CNR1 IN PROSTATE 
CANCER 
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Since CNR1 agonist HU210 triggers apoptosis in LNCaP cells, this same 
effect will be determined in other prostate cancer cell lines, and whether 
this effect correlates with the endogenous levels of CNR1 expression. It 
will also be investigated whether increasing the CNR1 expression affects 
responses to agonist treatment in prostate cancer cell lines with low 
endogenous levels of CNR1 expression (e.g. PC3 cells).  Finally, it will be 
investigated whether this effect is specific to this CNR1 agonist and the 
effect of CNR1 antagonists, (which could inhibit apoptosis). 
 
The collected data show that CNR1 agonist (HU210) can induce growth 
inhibition and cell death. Classical caspase-dependent pathway will be 
analysed for its involvment in inducing apoptosis in prostate cancer cell 
line using apoptosis assays such as FITC annexin V apoptosis detection 
kits and detection of caspase activation (cleavage).  Also, most cancer 
treatments consist of multiple drugs working together to eliminate the 
malignant cells. It would be interesting to study combinations of 
cannabinoids (HU210 agonist) with therapeutic drugs.   
 
Most of the drugs that inhibit the growth of cancer cells in vitro turn out to 
be ineffective when tested in animals. However, there is now evidence 
that few cannabinoids activate cannabinoid receptors may act as 
apoptotic drugs in vivo. For example, THC administration can effectively 
reduce the growth of gliomas in mice by inducing apoptosis of the tumour 
cells (Galve-Roperh, Sanchez et al. 2000). Moreover, previous studies 
showed that HU210 is capable of reducing rhabdomyosarcoma (aRMS) 
xenograft growth through induction of apoptosis in vivo where proliferation 
of tumour cells remained unaffected. It would be interesting to investigate 
the role of CNR1 in PCa tumour growth xenograft studies in vivo and 
determine efficacy and toxicity after administration of HU210. 
 
To further investigate the role of CNR1 in cell survival and proliferation, 
CNR1 will be overexpressed in different prostate cell lines, and a series 
 151 
of functional assays will be performed, including cell viability (MTS), 
apoptosis and cell cycle assays. Also invasion and migration assays will 
be performed to determine whether CNR1 affects cell motility.  Soft agar 
colony formation assay will be performed to investigate whether CNR1 
expression affects cell anchor-independent growth.   
 
It has been reported that treatment of gliomas with cannabinoids led to the 
activation of ERK1/2 signalling pathway and AKT inhibition (Ellert-
Miklaszewska, Ciechomska et al. 2013). This continued ERK1/2 activation 
could mediate cell-cycle arrest and apoptosis.  I will investigate the effect 
of CNR1 agonists on the activation of ERK and the inhibition of PI3K/AKT 
in prostate cancer, in order to understand the mechanism by which 
apoptosis is triggered in response to CNR1 receptor activation.  
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